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"And voices in me said, If you were a man 
You would take a stick and break him now, and finish 
him off.
But must I confess how I liked him,
How glad I was he had come like a guest in quiet, to 
drink at my water-trough 
And depart peaceful, pacified, and thankless.
Into the burning bowels of this earth?"
from "Snake". D.H.Lawrence
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PREFACE
The work which forms the basis of this thesis was carried 
out at Port Moresby General Hospital, Papua New Guinea 
between May 1991 and October 1993. During that period, all 
patients bitten by snakes were entered into a prospective 
clinical study begun by Dr David Lalloo in 1990. I held the 
post of visiting clinical lecturer in the Department of 
Medicine, funded by the Wellcome Trust of Great Britain. 
Between August 1992 and October 1993, I was clinical team 
leader of the University of Papua New Guinea-Oxford 
University medical research team based in Port Moresby, 
under the joint auspices of Professor Sirus Naraqi and 
Professor David Warrell. During the first year of the 
studies reported here, Dr David Lalloo and I worked together 
with the snakebite patients. In the second year of the 
studies, I was assisted by a research registrar, Dr Nneka 
Nwokolo and other Papua New Guinean registrars who worked 
under my supervision. Throughout the study, the nursing 
staff provided excellent skilled help in the management of 
patients. The immunoassays were done by Dr David Theakston 
and his staff in the Venom Unit at the Liverpool School of 
Tropical Medicine. Mark O ’Shea, herpetologist, kindly 
permitted me to use his photographs, Plates 1.1 and 1.2 and 
figure 1.2. To all of these people I owe a considerable debt 
and I express my gratitude.
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SUMMARY
The purpose of the work described in this thesis was 
to further knowledge about the circumstances and 
effects of envenoming by the Papuan taipan {Oxyuranus 
scutellatus canni) and to determine how morbidity and 
mortality can be reduced. My specific aims have 
included analysis of the epidemiology of taipan bite, 
of first aid treatment and of the efficacy of current 
antivenom treatment. I have also determined the in vivo 
electrophysiological effects of the neurotoxins in 
taipan venom and applied these observations to assess 
drugs of potential benefit in the treatment of 
envenomed patients.
Each year, approximately 160 patients are seen 
at Port Moresby General Hospital (PMGH), Papua New 
Guinea after having been bitten by a snake. Between 90 
and 100 of these are significantly envenomed and up to 
50% require intubation and ventilation despite 
treatment with antivenom. Snakebite is the commonest 
indication for admission to the intensive care unit at 
PMGH. In the two years of the study, a total of 169 
snakebite patients were admitted to the intensive care 
unit for a total of 831 days, 28.5% of available ITU 
bed days. During the period of the study, at least 20 
patients bitten in remote parts of the Province died 
before reaching hospital. In each of the last three 
years, the Papua New Guinea Department of Health has 
spent over £100,000 on antivenom, the majority of which 
is used in Central Province. Frequently however, rural 
health centres either run out of antivenom or have a 
type inappropriate to the snake species biting in their 
area.
The development of enzyme linked immunoassays 
(EIA) for the detection of snake venom antigen has 
enabled retrospective identification of biting species,
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has provided the opportunity to make reliable species 
specific observations and has helped to define the 
epidemiology of snakebite. In this study, EIAs were 
used to identify definitive taipan bites from a 
prospective series of all snakebite victims admitted to 
PMGH between May 1991 and May 1993. All patients with 
signs of systemic envenoming were managed according to 
treatment guidelines contained in standard treatment 
books published by the Papua New Guinea Department of 
Health. The circumstances of the bite and all clinical 
details were recorded on a proforma.
Electrophysiological studies were done on selected 
patients with neurotoxicity who were believed on 
clinical grounds to have been bitten by a taipan. The 
results of these studies were compared with similar 
studies done in a group of volunteer Melanesian 
controls. A subset of the envenomed patients with 
established neurotoxicity was included in studies 
looking at the effects of edrophonium and 3,4- 
diaminopyridine. Patients were included in this study 
if taipan venom antigen was detected at a significant 
level in one or more of: an admission serum sample, a 
bite site aspirate or a swab of the bite site. One 
hundred and seventeen patients were included in the 
epidemiological analysis, 106 in the clinical study and 
smaller numbers in each of the electrophysiological 
studies.
The taipan was confirmed to be the species 
accounting for the majority of cases of significant 
envenoming in Central Province. Between 1991 and 1993, 
89% of envenomed patients admitted to PMGH in whom a 
definitive identification of biting species was made, 
were bitten by a taipan. The Papuan black snake 
(Pseudechis papuanus), which is widely feared and 
believed by most lay people and many medical staff to
12
be the most numerous and dangerous species in Central 
Province, accounted for less than 1% of bites.
This suggests a change in the herpetofauna of the 
Province over the past 30 years and has significant 
implications for the use of monovalent antivenoms.
There is little role for the continued use of 
monovalent black snake antivenom in Papua New Guinea, 
polyvalent antivenom is a better option if a black 
snake bite is considered a possibility.
Virtually all taipan bites occurred during 
daylight hours in low lying coastal parts of the 
Province, predominantly in Eucalyptus savannah. Few 
patients were able to describe distinguishing features 
of the snake that bit them. The majority of patients 
envenomed by a taipan had non-clotting blood by the 
time they reached a medical facility and this sign has 
a predictive value of over 95% for taipan bite in 
Central Province. Despite the majority receiving 
antivenom,46.7% of patients progressed to require 
intubation and ventilation. Antivenom was of maximal 
value if given within 4 hours of envenoming but even 
early antivenom did not prevent progression of 
neurotoxicity in a high proportion of patients. 
Antivenom appeared to hasten the resolution of 
coagulopathy in envenomed patients but there was little 
evidence that this produced a significant clinical 
advantage.
Envenomed patients had normal sensory and motor 
conduction velocities but showed markedly reduced 
evoked compound muscle action potentials and slightly 
reduced sensory nerve action potentials. There was a 
décrémentai response on repetitive nerve stimulation 
testing, enhanced by exercise or tetanic stimulation. 
These findings are consistent with neuromuscular block 
localised to the synapse. The decline and recovery of 
Compound Muscle Action Potential (CMAP) amplitudes
1 3
closely mirrored recordings of peripheral grip 
strength. The rate of recovery suggests that 
reinnervâtion may be occurring. Motor unit architecture 
appeared relatively normal on electromyographic studies 
during the recovery phase suggesting that toxin damage 
is predominantly localised to the nerve terminal. Both 
edrophonium and 3,4-diaminopyridine produced an 
electrophysiological response in envenomed patients, 
maximal when the two drugs were used in combination. 
There was a minor increase in peripheral grip strength 
but insufficient improvement to be clinically useful.
The majority of deaths which occured from 
snakebite in Central Province during the study were 
attributable to delay in the patient reaching hospital. 
Amongst patients who reached PMGH, most morbidity and 
mortality was associated with complications of 
intubation and the management of ventilated patients, 
some of which were avoidable. Current antivenom 
treatment is expensive and appears to be of limited 
benefit. Patients who received antivenom within 4 hours 
of the bite fared significantly better. There is 
realisable potential for a far higher proportion of 
patients to be treated within this time. The use of 
pressure bandages as first aid treatment to delay 
absorption of venom may prolong the period in which 
existing antivenom produces maximum benefit. There is a 
however, a need for the development of better 
antivenoms for the treatment of snakebite victims in 
PNG. Possibilities include the development of species 
specific or subunit antivenoms directed against 
specific toxins. Electrophysiological studies provide 
an objective basis for studying the effects of 
pharmacological interventions in snakebite patients 
with neurotoxicity, but neither edrophonium or 3,4- 
diaminopyridine can be recommended for the treatment of 
patients envenomed by the Papuan taipan.
Plate 1.1 and 1.2 The Papuan Taipan {Oxyuranus
scutellatus canni)
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CHAPTER 1 - BACKGROUND
i . Background and aims
Snakebite is a problem predominantly of 
rural populations in the tropics. The effects of 
envenoming are often exacerbated by fear, ignorance, 
inappropriate first aid and by the inaccessibility of 
medical care. Papua New Guinea is no exception. It is 
impossible to be precise about the true incidence of 
snakebite in Papua New Guinea because of the remoteness 
of the terrain but an average of 160 patients a year 
presented to Port Moresby General Hospital (PMGH) 
between 1990 and 1993 reporting a bite, of whom 
approximately 60% had signs of envenoming and 30% 
required mechanical ventilation because of respiratory 
paralysis caused by venom neurotoxins. The majority of 
victims of snakebite are young, previously well adults, 
and children. The mortality rate is not known but there 
were at least 10 deaths from snakebite in Central 
Province in both 1991 and 1992, the majority occurring 
outside hospital. This is likely to be an 
underestimate. The majority of envenomed patients are 
treated with antivenom, either at a health centre or at 
PMGH. This is manufactured by Commonwealth Serum 
Laboratories in Melbourne, Australia and is 
prohibitively expensive. A single vial of polyvalent 
antivenom costs £594, a vial of monovalent taipan 
antivenom £545. Between January 1991 and March 1993, 
the Department of Health spent £394,000 on antivenom. 
Despite this, there were occasions during the course of 
this study when the rural health centres, and even 
PMGH, had no antivenom supplies with which to treat 
envenomed patients.
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This study focuses on the Papuan taipan 
{Oxyuranus scutellatus canni). 87% of envenomed 
patients admitted to PMGH in the past three years in 
whom the biting species could be reliably identified 
were bitten by taipans. Taipan victims showed little 
response to antivenom and the majority of management 
problems and deaths were in patients bitten by this 
species. This study set out to determine how to reduce 
the morbidity and mortality resulting from taipan bite 
in Papua New Guinea. It involved analysing existing 
treatment in the community,in the hospital and the 
potential for developing new therapeutic approaches.
The clinical features of envenoming by the 
Papuan taipan have been recently described by Gurriei 
and Lalloo^ and clinical description is not the main 
focus of this thesis. Clinical details of the patients 
in this series are included where directly relevant or 
where original but I have attempted to avoid repetition 
of existing work. The specific aims of this study 
were : -
1. to define the epidemiology of taipan bite in 
Central Province.
2. to assess current pre-hospital treatment of taipan
bite.
3. to describe the clinical features of envenoming by 
the Papuan taipan.
4. to assess the use and efficacy of antivenom in the 
management of envenoming following a taipan bite.
5. to determine the in vivo electrophysiological 
effects of envenoming by the Papuan taipan.
6. to use clinical and electrophysiological parameters 
to assess drugs of potential value in the 
treatment of neurotoxicity due to taipan venom.
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7. to make recommendations which might improve the 
management of patients and diminish morbidity and 
mortality from snakebite in Central Province, Papua 
New Guinea.
PAPUA NEW GUINEA
i. Topography and geography
The island of Papua New Guinea sits at 
the junction of two global crust plates, the movement 
of which has created its dramatic topography. The 
interior of both Papua New Guinea and Irian Jaya is 
dominated by high mountains which rise to over 4000 
metres in places and form a spine extending along the 
length of the island. To both north and south of the 
mountain ranges, huge river systems flow out to the sea 
forming extensive deltas and swampy floodplains, most 
notably the Fly, Sepik and Ramu rivers. Two arcs of 
islands fringe the mainland to the east, many of which 
have active or dormant volcanoes^. The tectonic 
activity of the last 100 million years continues today 
and much of the country is still prone to earthquakes 
and volcanic eruptions.
The geographic barriers which have influenced the 
migration of both man and animals have not remained 
constant. Within the past 50,000 years there have been 
extensive changes in sea level^. At times, Papua New 
Guinea has been linked by a landbridge to what is now 
Australia forming a more extensive southern land mass 
called Sahul. This land mass remained separate from the 
archipelagoes of Sunda (now Indonesia) to the west due 
to the depth of the oceans surrounding them, the so- 
called Wallace line. The mammalian fauna of Papua New 
Guinea is dominated by marsupials and the herpetofauna 
of the island today reflects that of the Australian
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subcontinent. The venomous land snakes of Papua New 
Guinea are all elapids and are all related to similar 
Australian species. The distribution of venomous snakes 
within PNG is not uniform; the mountains appear to form 
a demarcation line with some species peculiar to either 
the north or the south. Even during the times of 
Sahul, there was very little low lying land connection 
between what are now the northern and southern halves 
of the island. The average temperatures were 
considerably lower than they are today, by perhaps 3- 
6°G. As the temperatures increased, the glaciers began 
to melt and the sea level rose until Papua New Guinea 
became a separate island.
The distribution and composition of the 
herpetofauna in Papua New Guinea today may be explained 
by earlier land connections and by the physical 
barriers of the mountains and rivers which have 
prevented free migration internally. Climatic 
differences within the land mass of Papua New Guinea 
and Irian Jaya may also have limited the distribution 
of species. In Australia, the taipan {Oxyuranus 
scutellatus scutellatus) is not found where the average 
maximum winter temperature is less than 18°C^. Much of 
the high ground in Papua New Guinea and Irian Jaya is 
uninhabitable. There is extensive local variation in 
rainfall ranging from an average of less than 
1OOOmm/year along the southern Papuan coast to greater 
than 8000mm/year in the Star mountains of Western 
Province^. This produces wide variation in both flora 
and fauna and may well influence the distribution of 
snakes. There are also seasonal variations in rainfall 
throughout the country with distinct wet seasons which 
are usually, but not solely, in the months of January 
to April,
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ii. History
The prehistory of Papua New Guinea is not 
well understood but it is believed that the country was 
first inhabited by seafaring migrants travelling from 
the east7. The first documented European contact with 
the land mass of New Guinea was in 1526 when a 
Portugese explorer, Jorge de Menenses landed on the 
north coast. The island was named New Guinea in 1545 by 
the Spaniard Ortiz Retes, the appearance of the 
Melanesian people reminded him of the people of the 
Guinea coast of Africa. "Papua" is believed to derive 
from the Malay word papuwah, meaning frizzy-haired. 
There was increasing European contact over the next 
three centuries resulting in the colonisation of the 
western half of the island by the Dutch in 1828.
Germany and Britain divided the eastern half of the 
country, administering New Guinea in the north and the 
territory of Papua respectively. In 1906, Australia 
took over the administration of Papua from the British.
New Guinea was invaded by Australian forces 
during the first world war. In the 1920’s, although 
significant German economic interests remained, it 
became a League of Nations mandated territory under 
Australian administration. In January 1942, the 
Japanese invaded Rabaul on the island of East New 
Britain and subsequently went on to occupy New Guinea 
and parts of Papua. Following the conclusion of the 
war, the administration of New Guinea and Papua was 
combined and the first legislative council for the 
combined territory was convened in 1951. The 
parliamentary system was gradually developed over the 
following 20 years with the establishment of a 
democratically elected House of Assembly which had the 
function of preparing the country for self government. 
Full independence was declared on September 16th, 1975
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and Papua New Guinea is now a sovereign state within 
the British Commonwealth.
The new government of Papua New Guinea inherited 
an economy which was largely dependent on Australian 
aid. The small monetary sector was almost exclusively 
foreign owned. The major commodities which were sold 
abroad were coffee, copra, cocoa, rubber and palm oil, 
all of which were subject to wild fluctuations in price 
on the world market. The development of the country’s 
extensive mineral resources has subsequently formed an 
increasingly important part of the economy. The aims of 
the new government in 1975, based on a report by the 
Overseas Development Group of the Institute of 
Development Studies at Sussex®, involved increasing 
equity of income and services, increased economic 
independence and an emphasis on small scale 
enterprises. Unfortunately, geographic barriers, 
political instability and social unrest have all 
inhibited the achievement of these laudable aims. In 
1975, over 80% of the population were rural dwelling 
subsistence farmers. By the late 1970’s urban 
population numbers were increasing by around 12% each 
year. Although urban drift has continued, the rate has 
slowed considerably in most areas except Port Moresby®. 
Most of the larger cities have squatter settlements.
The presence of a large, unemployed, landless 
population and the absence of a welfare net has 
resulted in an increase in crime, which, in turn, has 
discouraged investment and tourism.
iii. Central Province and National Capital District
The capital of Papua New Guinea is Port 
Moresby, named after Captain John Moresby, a British 
naval captain. The large urban area surrounding the
20
city had an estimated population of 195,197 in the 1990 
national census^. National Capital District (NCD) is 
surrounded by Central Province which covers an area of 
29,500km2 and has a population of 141,197. The coastal 
belt of Central Province is relatively flat and 
consists typically of mangrove swamps and palm trees. 
Further inland, dry eucalyptus and grass savannahs 
stretch up to the rainforest covered foothills of the 
Owen Stanley mountain ranges which reach to a height of 
over 4000 metres (see Plate 1.3). The mean daytime 
temperatures in the coastal areas range from 27.8°C to 
32.1°C throughout the year. The staple diet in the 
coastal areas is predominantly banana, yams and fish.
In inland areas of the Province, sweet potato and taro 
are the main staple foods. In NCD, imported and 
processed foods such as rice and tinned fish now make 
up a significant part of the diet of the majority of 
the population. In Central Province however, only 
around 10% of the population were wage earning at the 
time of the 1980 census and traditional staples remain 
extremely important.
iv. Language
There are over 750 languages described in 
Papua New Guinea. Most are localised Austronesian 
languages which are peculiar to small, often 
geographically isolated, areas. The main linguae 
francae in coastal Papua are Hiri Motu and English. A 
form of pidgin English tok pisin, is spoken widely 
throughout much of the rest of the country including 
the is lands.
Plate 1.3 Eucalyptus savannah outside Port Moresby
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V. Health
The majority of the population of Papua New 
Guinea are rural dwellers. Their first point of contact 
with health services is usually at a village health 
centre, staffed by a Health Extension Officer or 
qualified staff nurse, or at a village aid post. None 
of the 17 health centres in Central Province has a 
doctor. There is a small mission hospital at Veifa'a in 
the west of the Province which does not have a doctor 
at present. Health centre staff prescribe and manage 
the majority of non-surgical cases. Patients can be 
referred for out-patient appointments or for admission 
to Port Moresby General Hospital (PMGH) but it is often 
a long and arduous journey. PMGH is a teaching hospital 
with 600 beds, which receives patients from throughout 
the Province and is a tertiary referral centre for the 
whole country. It is staffed by a variety of national 
and expatriate doctors. All of the nursing staff in the 
hospital are Papua New Guinean. The hospital has a six 
bedded intensive care unit with facilities to ventilate 
patients. It also has laboratory and X-ray facilities.
The infant mortality rates in Central 
Province and National Capital District are below the 
national average of 7 2 / 1 0 0 0 io but still remain high. 
Hospital admissions due to diseases common in the 
western world such as ischaemic heart disease, 
hypertension and diabetes are all increasing, but the 
major causes of morbidity and mortality in both adults 
and children are infectious diseases.
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SNAKES AND SNAKEBITE IN PAPUA NEW GUINEA
i. The venomous snakes of Papua New Guinea
Papua New Guinea has a rich herpetofauna which 
shares many similarities with that found in northern 
Australia. There are five families of land snakes, the 
Typhlopidae, Boidae, Acrochordidae, Colubridae and 
Elapidae. There are seven dangerous venomous land 
snakes which all belong to the family Elapidae. In 
Papua, the species responsible for the vast majority of 
bites is the Papuan taipan {Oxyuranus scutellatus 
canni). The other significantly venomous species are: 
death adders {Acanthopis sp.), Papuan whipsnakes 
(Demansia sp.), the Papuan black (Pseudechis papuanus), 
the small-eyed snake (Micropechis ikaheka), the eastern 
brown snake {Pseudonaja textilis) and the king brown 
snake (Pseudechis australis). Although the eastern 
brown snake has been found in a small area of Northern 
Province, the only venomous snakes found in most of 
northern Papua New Guinea and northern Irian Jaya are 
the death adder and small eyed snake.
ii. The Papuan Taipan
The Papuan Taipan, Oxyuranus scutellatus canni 
is a separate subspecies from the Australian 
taipan,(Oxyuranus scutellatus scutellatus) which is 
found in northern Queensland and the Northern 
Territory. The name "taipan" is said to derive from the 
aboriginal vernacular of the Cape York peninsular, 
where the Australian sub-species is common'' ' . The 
distinguishing features of the Papuan species, 
described by Slater'%, include more pronounced scale 
keels, a distinctive dorsal red stripe and perhaps 
greater average size than its Australian counterpart.
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The distribution of the snake in Papua New Guinea 
appears to be exclusively within what used to be Papua, 
south of the main mountain ranges which divide the 
island. It is found mainly in the coastal belt, in the 
dry arid savannah scrub land, but also in wetter areas 
to the west. Taipans are present on the edge of the 
Sogeri plateau at a height of about 400 metres, but it 
is unlikely that they inhabit areas at a much greater 
altitude. Taipans are common in Central Province, 
Western Province and the western edge of Milne Bay 
provinces. They are also known to occur around Malalaua 
and may have been responsible for two recent snakebite 
deaths in Kerema, also in Gulf Province. Taipans are 
also common in the southern plains of Irian Jaya 
extending at least as far west as Senggo. The species 
is particularly well documented in Central Province and 
it is clear that it is prevalent throughout the whole 
of the low lying coastal belt from Cape Rodney in the 
east to Bereina in the west. Figure 1.2 shows sites 
where live specimens have been collected in Papua New 
Guinea,
The Papuan taipan, is a long, slender, fast 
moving snake. Adult specimens vary from 1.5-3.5 metres 
in length. The head of the snake is long and coffin 
shaped, with a distinct neck. The eye is round and 
relatively large, with a red iris. The tail is thin and 
whip like. The fangs are sited anteriorly and average 
around 10mm in length. The colouring of the snake 
varies considerably. The dorsum may be olive, dark 
brown or grey with probable seasonal variation. The 
ventral surface is usually cream or off-white and may 
have orange red stippling. The most distinctive feature 
of the snake from a distance is a copper coloured 
stripe on the dorsum due to colouration of the 
interstitial skin of the vertebral scale rows. This 
colouration may become more evident as the snake
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prepares to strike, as more of the interstitial skin is 
exposed. The snake does not have a loreal or subocular 
scale, a morphological feature common to elapids. The 
supraocular scale shelves sharply giving the snake a 
frowning expression. At mid-body, there are 21 or 23 
scale rows, with a total of between 220 and 250 ventral 
scales. The anal plate is single and there are 45-80 
subcaudal scales  ^  ^.
The taipan is regarded as a shy snake. 
It has acute eyesight and sense of smell and generally 
avoids contact with man. If startled however, it 
becomes aggressive and commonly strikes repeatedly. The 
average venom yield from a single milking of an 
Australian taipan is 100-200mg with as much as 400mg 
recorded^?. At the time of the strike, the snake 
flattens its head and lunges forwards and upwards. 
Because of the tendency to strike repeatedly, a large 
volume of venom may be injected. The length and 
position of the fangs allow the snake to inject venom 
even through relatively protective coverings such as 
canvas boots although by far the majority of bites are 
on exposed skin. The snake is oviparous, diurnal and 
crepuscular. It may be more active nocturnally during 
especially warm weather.
The snake usually feeds on small mammals, 
rats, bandicoots and possibly ground nesting birds. 
Taipans do not feed on amphibians. It appears that 
since the introduction of the cane toad Bufo marinus, 
to Central Province in the 1940's, the numbers of 
taipans have increased whilst the numbers of other 
elapids, notably the Papuan black snake Pseudechis 
papuanus, have declined. It has been suggested that the 
amphibian eating elapids have suffered as a result of 
eating the toxin containing cane toads creating an 
expanded ecological niche for the taipan. A similar
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scenario may explain changes in the herpetofauna of 
Queensland over the past 50 years'!®.
Papuan taipan venom contains multiple toxins some 
of which are discussed at greater length below. In 
animal experiments it has been shown to be extremely 
toxic with LD50's of between 2 and 64ug/kg in guinea 
pig and mouse respectively when given 
intravenously^^>20. When the venom was given 
subcutaneously to mice, Trethewie found an LD50 of 
120ug/kg21.
iii. Snakebite in Papua New Guinea
The credit for the pioneering work on snake 
envenoming in Papua New Guinea goes almost entirely to 
C.H.Campbell who worked at Port Moresby General 
Hospital from 1960. He published extensively on 
snakebite and collated much of his work in an 
M.D.thesisi9. He published detailed descriptions of the 
patterns of envenoming seen with different species, the 
effect and side effects of antivenom and on other 
aspects of treatment. Campbell was hindered in his 
conclusions by difficulty in the definitive 
identification of the biting species. A few patients 
brought a dead snake in with them, but the majority did 
not. In some cases, Campbell felt confident enough to 
ascribe a bite to a particular species on the basis of 
the patient's description of the snake. The majority of 
snakebite victims in Papua New Guinea however, are 
bitten by a fast moving snake in long grass and, as 
Campbell recognized, patients' descriptions were often 
scanty and unreliable.
The development of enzyme immunoassays to 
identify species specific venom antigen, has been a 
major step forward in the study of envenoming22. We are 
now able to identify with certainty the snake species 
responsible for many cases of envenoming. This allows
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reliable distinction of the clinical syndromes of 
envenoming and offers a new insight into the 
epidemiology of snakebite in the area. At present this 
technology remains a research tool in Papua New Guinea 
but there is scope for the diagnostic application of 
rapid venom detection assays to indicate the 
appropriate antivenom to use. This is discussed in 
chapter 7. At a population level, assessment of biting 
species in different areas may help to direct the 
appropriate allocation of antivenom supplies and 
relevant ancillary pharmacological treatments such as 
anticholinesterases which are of value in the 
management of patients envenomed by death adders 23.
Campbell first published on Papuan elapid 
bites in 1961 when he described 15 patients, all of 
whom developed some form of neurotoxicity, ranging from 
slight ptosis to respiratory paralysis which required 
tracheotomy and ventilation2 4. All but one of the 
patients were bitten during daylight hours and all were 
bitten on the foot or the leg. Six patients were noted 
to have a bleeding tendency including one who had 
haematuria and two who had "haemoglobinuria". Antivenom 
was given to all patients, a combination of tiger snake 
and taipan antivenom to the majority. In addition, 
death adder antivenom was given if a patient described 
being bitten by a short snake and black snake antivenom 
if there was an excessive bleeding tendency. One 
patient who was given tiger snake and taipan antivenom 
had a rapid reversal of his ptosis and Campbell 
suggested that this patient had probably been bitten by 
a death adder. Fourteen of the 15 patients in the 
series survived and Campbell made the point that with 
adequate care of the airway and ventilatory support 
elapine snakebite victims reaching hospital should 
survive.
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Campbell published further observations on 
envenomed patients seen in Port Moresby throughout the 
1960's. In 1964, he described a series of 52 envenomed 
patients^®. Of 52 bites, 50 occurred during the hours 
of daylight, the other two at dusk. 51 patients were 
bitten on the lower leg or foot. The age range of the 
patients was 3-45 years. 44 patients were male, 8 
female. Five patients brought dead snakes with them, 3 
death adders, 1 taipan and 1 Papuan black snake. Fang 
marks were only seen in 8 cases. Many patients had 
received local treatment before admission to hospital. 
This usually took the form of local incisions. An 
unspecified number had tourniquets applied. The 
earliest sign of envenoming was the appearance of local 
tender lymph nodes. Neurotoxicity initially manifested 
as ptosis, followed by external ophthalmoplegia, bulbar 
and respiratory paralysis. 39 of the 52 patients 
described (75%) developed ptosis, 21 of these developed 
complete ophthalmoplegia and 15 required tracheotomy 
and ventilation. Two patients in the series died(4%) 
although, as Campbell pointed out, it is probable that 
15 would have died had advanced respiratory support not 
been available. There was evidence of bleeding in 11 
patients with haematemesis or haemoptysis; 3 had 
haemoglobinuria.
In 1966 and 1967, Campbell published three 
further papers delineating the syndromes of envenoming 
by death adders, Papuan black snakes and 
taipans2 6,1 7,2 7  ^ He described a series of 6 taipan 
bites of which two patients brought a dead snake to the 
hospital. The other four were identified on the basis 
of the victim's description of a bite from a black 
snake with a red back. Three patients developed signs 
of neurotoxicity of which two required tracheotomy and 
ventilation, one of whom had coexisting coagulopathy. 
One patient had coagulopathy in isolation. Of the two
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patients who brought snakes to the hospital, one had 
local lymphadenopathy alone and one complained of 
abdominal pain but did not develop any signs of 
envenoming.
In the 5 years between 1967 and 1971, there 
were a further 192 admissions to Port Moresby General 
Hospital with snakebite due to a venomous snake, on the 
basis of either clinical signs of envenoming and/or a 
dead specimen. Price and Campbell suggest that of these 
admissions, all were unidentified except 22 death 
adders although they do not state how the death adder 
bites were identified définitively2s. The case fatality 
rate during this period was 3.1%. Brian and Vince 
described 54 cases of children bitten between August 
1981 and October 198429. Forty nine of these had signs 
of neurotoxicity of which 38 (73%) also had 
coagulopathy. Two patients had coagulopathy alone. 
Sixteen patients required intubation including 11 who 
had already received antivenom. The case fatality rate 
was 7.7%. Currie et al. in their paper collated Papua 
New Guinea snake bite data from a variety of sources®o. 
This included a prospective study over a period of 30 
months at Port Moresby General Hospital in which 208 
patients were seen and data from 48 patients admitted 
to Madang hospital during the same period. Fifty six of 
the patients seen in PMGH required ventilation. The 
mortality rate was 6.3%. Serum, urine and bite site 
swabs were taken from a total of 262 patients between 
December 1986 and June 1989. Taipan venom antigen was 
detected in 174 serum samples (73%), death adder venom 
antigen in 11 serum samples (5%) and eastern brown 
snake in 2 (1%). Unfortunately it was not possible to 
assay for Papuan black snake venom antigen due to 
difficulty in obtaining venom to raise the test 
antiserum against.
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ENVENOMING BY THE TAIPAN
i. The effects of a bite by the Australian taipan
The Papuan taipan (Oxyuranus scutellatus canni) 
was identified as a separate subspecies from the 
Australian taipan (Oxyuranus scutellatus scutellatus) 
by Slater in the early 1 950's'* 2 . The snakes are however 
closely related and it appears that there are many 
similarities between the clinical features of 
envenoming by the two subspecies. Bites by the 
Australian taipan are relatively rare. The snake is 
found predominantly in the Cape York peninsula, the 
Gulf of Carpentaria and in North West Australia which 
are all relatively sparsely populated areas. It is also 
found in eastern Queensland. The first definitive 
reports of taipan bite 3 1 - 3 3  and earlier reports of 
suspected c a s e s ® *  describe a variety of clinical 
features including vomiting, headache, abdominal pain, 
a bleeding tendency, ophthalmoplegia and peripheral 
paralysis resulting in death from respiratory failure 
in two of four cases. The first description of the use 
of the newly developed taipan antivenom to treat an 
envenomed patient was in 1957 although definitive 
identification of the snake was not made®®. This 
patient, who had both coagulopathy and neurotoxicity, 
made a clear and distinct improvement within two hours 
of being given 9000 units of taipan antivenom. In 1980, 
there was a report of the rapid death of a 4 year old 
boy after a bite subsequently shown by immunoassay to 
be from a taipan, presumably due to a respiratory 
arrest®®. In 1981, Brigden and Sutherland reported a 
case of a patient bitten by a taipan who had 
rhabdomyolysis and myoglobinuria®®. Jamieson and Pearn 
found one definite taipan bite amongst 218 children 
admitted to hospital in south-east Queensland following 
snakebite between 1978 and 1987®?. Morphological
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changes in red blood cells were described in a patient 
envenomed by an Australian taipan and were 
demonstrated after exposing red cells to taipan venom 
in vitro®®. In the same year, King and Smith reported 
the cases of a cane farmer from Mount Molloy admitted 
with coagulopathy and neurotoxicity following the bite 
of a snake later identified as a taipan by the use of a 
venom detection kit®^. The venom detection kits do not 
however distinguish between the taipan and the inland 
taipan (Oxyuranus microlepidotus) which may also be 
present in the Mount Molloy area.
The difficulty in making a definitive diagnosis, 
the wealth of venomous snakes and the geographical and 
temporal spread of a relatively small number of taipan 
bites demands the collation of work from several 
observers to describe the clinical effects. It appears 
that the features of envenoming are similar to those 
produced by the bite of the Papuan taipan described by 
Campbell but there are important differences. Several 
of the features listed by Mirtschin et al. such as 
fixed dilated pupils, hypotension, convulsions, 
oliguria and local bite site swelling and necrosis are 
not typical of Papuan taipan bite®. Campbell and 
subsequent workers in Port Moresby did not observe the 
clear improvement seen by Lester in any patients 
following treatment with antivenom®®. The clinical 
relevance of Broad's unpublished observation that the 
LD50 of O.S.canni (0.0505mg/kg) is significantly lower 
than that of 0.s .scutellatus (0.099mg/kg) is unknown*® 
as is the observation that there are some differences 
between the protein composition of the two venoms.
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ii. Taipan venom
The mean venom yield at a single milking from 
an Australian taipan (Oxyuranus scutellatus 
scutellatus) has been estimated at 120 mg dry weight 
(maximum 400mg)'’?. The LD50 of whole venom in mice has 
been estimated at 0.064mg/kg with a certain lethal dose 
of 0.17mg/kg 2 0,41  ^ The combination of the high venom 
yield and toxicity of the venom makes the taipan one of 
the most dangerous venomous snakes in the world.
When dried crude Oxyuranus scutellatus 
scutellatus venom is separated on a Sephadex column, 
four protein and one non-protein fractions are seen. If 
the individual fractions are tested for LD50 in mice, 
the most toxic, with an LD50 of 2ug/kg, is fraction 
two. Its action is paralytic. Fraction four also causes 
respiratory paralysis but at a lower LD50 of 100ug/kg. 
Fohlman et al, proposed that this fraction contained a 
post synaptic curarimimetic toxin, similar to those 
which have been found in other elapid and hydrophid 
v e n o m s * 2, Fraction one appears to contain the 
prothrombin activator whilst fraction five, which is 
predominantly non-protein, contains the pigment which 
gives the crude venom its yellow colour. Fraction three 
contains phospholipases which appear to be related to, 
but distinct from, the phospholipases of fraction two 
discussed below.
Taipoxln
Fraction two, which is the most lethal of 
the individual fractions and more lethal than the crude 
venom (LD50 12ug/kg) consists of four components when 
separated electrophoretically. Fohlman et al. isolated 
the major component of the fraction, and christened the 
toxin "Taipoxin"* 2. Taipoxin is a phospholipase A z . It
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has a molecular weight of 46,700 and consists of three 
distinct components, the alpha, beta and gamma 
fractions. There are two isoforms of the beta subunit. 
The stoichiometry of the taipoxin complex is not 
completely understood although the subunits are clearly 
present in a ratio of 1:1:1. Amino acid analysis of the 
terminal sequences shows considerable homology with the 
terminal sequences of notexin, from the Australian 
tiger snake (Notechis scutatus), with a basic 
phospholipase isolated from the venom of the black­
necked spitting cobra (Naja nigricollis) and with 
porcine pancreatic phospholipase A z .
Kamenskaya and Thesleff demonstrated that the 
major effect of taipoxin was to inhibit transmitter 
release from presynaptic cholinergic nerve terminals*®. 
Both spontaneous and evoked transmitter release was 
affected. The rate of onset of inhibition of 
transmission in a nerve diaphragm preparation was 
increased by stimulation of the nerve and by increased 
temperature*®'**. Removal of the nerve-diaphragm 
preparation to a toxin free bath failed to prevent 
progression of toxicity. Gull-Gandy demonstrated 
similar findings and estimated the LD50 of the isolated 
toxin at 2ug/kg body weight*®. He also demonstrated 
that the toxin produced ultrastructural abnormalities 
at the pre-junctional terminal, most notably a 
depletion in synaptic vesicles, omega shaped 
indentations on the presynaptic membrane and the 
presence of granular material in affected terminals.
Taipoxin hydrolyses phospholipids, predominantly at 
the presynaptic membrane and it is probable that it 
produces its effect through the destruction of 
molecules integral to normal neuromuscular 
transmission. The in vitro action of phospholipases is 
typically triphasic. There is an initial inhibition of 
transmitter release followed by a short period of
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enhanced transmission, in turn followed by a further 
period of declining transmission and ultimately 
failure. The initial phase is unaffected by conditions 
which alter enzymatic activity (eg. temperature, 
concentration of calcium ions) and may be related to 
the binding of the toxin at a site distinct from the 
catalytic site*®. The second phase may be due to 
hydrolysis of membrane lipids and subsequent 
depolarisation*? although other workers have suggested 
that the inhibition of slow activating potassium 
channels and subsequent prolongation of opening of 
voltage sensitive Ga++ channels might be the mechanism 
of increasing transmitter release*®. Galcium appears to 
be an essential cofactor for enzymatic activity. Most 
other divalent cations inhibit enzyme activity. It has 
been noted in vitro that even if the preparation is 
washed during stage 2 of the triphasic process, 
neuromuscular paralysis will progress, suggesting that 
the toxin is already tightly and irreversibly bound to 
the presynaptic membrane*^. The structural changes 
which were described by Gull-Gandy, are believed to be 
due to a failure in vesicular cycling*®. It appears 
therefore that there are two stages of action of the 
toxin, the initial biphasic stage, which may correlate 
with binding, and the subsequent irreversible failure 
of transmission which may result from the catalytic 
action of the toxin on the membrane structure either at 
or close to the binding site.
The exact nature of the binding sites has not 
been elucidated. It appears that the effects of 
crotoxin, B-bungarotoxin and taipoxin, although similar 
in end result, do not involve binding at the same 
receptor site. Mutual potentiation has been observed in 
vitro when the toxins are given together, as has a lack 
of competition between them*9. However, Degn and 
Seebart have shown that taipoxin inhibits the specific
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binding of crotoxin to guinea pig synaptosomes®®. 
Whatever the nature of the binding sites, it appears 
that they are highly specific and the authors suggest 
that this may be due to the toxin’s affinity to protein 
rather than lipid domains. Binding is poorly 
reversible. It appears that the action of the toxin 
does not involve internalisation but may involve a 
conformational change following binding®i. Other 
investigators have found that neurotoxic phospholipases 
bind and hydrolyse negatively charged phospholipids 
with a high degree of specificity®®.
A number of investigators have attempted to 
solve the questions of mechanism of block by looking at 
cell free systems such as synaptosomes and 
mitochondria. Harris discussed the problems of 
extrapolating these findings, highlighting the wide 
variability in uptake seen at different temperatures, 
toxin concentrations, sources of preparation and 
duration of incubation®®. The reliability of 
extrapolating from observations in cell free systems is 
therefore open to doubt. Unfortunately the same 
problems recur in subcellular systems in which attempts 
have been made to look at transmitter release. There is 
little doubt, however, that the ultimate effect of 
taipoxin is to destroy nerve terminals. It may be that 
the omega shaped indentations and mitochondrial damage 
seen reflect the early stages of this destruction 
rather than a halt in endo or exocytosis.
Taipoxin is known to be myotoxic when injected 
subcutaneously into the hind limb of laboratory rats®*. 
Only the alpha subunit is myotoxic in isolation but the 
effect is augmented by the presence of the other 
subunits. Ultrastructural changes occurred in the 
muscle as early as one hour after injection in both 
innervated and deinnervated muscle. There was rapid 
loss of membrane potential from the damaged myofibrils
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with gradual recovery from around the third day to 
complete recovery around 20 days. Harris suggested that 
the myotoxicity of taipoxin was probably due to 
hydrolysis of the membrane lipids resulting in a non­
specific increase in membrane permeability and a loss 
of cross membrane ionic gradients®®.
Other phospholipases
Taipan venom is known to contain a 
variety of other phospholipases, three of which have 
been purified and characterised®®. The clinical 
significance of these single chain phospholipases is 
not known. The binding of one of them, iodine labelled 
"OS2" was inhibited by other toxic phospholipases and 
also by potassium channel blockers, an observation 
raising the possibility of specific interaction with a 
family of potassium channels.
Post synaptic neurotoxins
Fohlman postulated the presence of a 
curarimimetic neurotoxin in fraction 4 of the crude 
venom*®. Mebs confirmed the presence of a post synaptic 
neurotoxin®?. The clinical significance of this toxin 
is believed to be minor.
Taicatoxin
Possani and coworkers have recently identified a 
further toxin in the venom of 0.s .scutellatus acting 
specifically on calcium channels®®'®®. This toxin, 
which they have christened "Taicatoxin" blocks the high 
threshold calcium channel current of excitable 
membranes in the mouse heart. It appears to act at an 
extracellular site with a high degree of specificity
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and does not affect the low threshold calcium currents. 
The toxin consists of three molecules, an alpha- 
neurotoxin, a phospholipase enzyme and a hydrolytic 
enzyme inhibitor. The specificity of the toxin suggests 
that the mechanism of action of the toxin does not 
involve extensive hydrolysis of the membrane and also a 
recognition of the structural differences of the 
different calcium channels. It also appears that the 
effects of the toxin are not restricted to cardiac 
muscle, high threshold calcium channels in some muscle 
and neurosecretory cells were also affected. The 
clinical significance of taicatoxin is at present 
unknown.
Prothrombin activator
Kellaway and Williams demonstrated that crude 
taipan venom from Oxyuranus scutellatus scutellatus 
caused citrated plasma to coagulate®®. Denson 
demonstrated the presence of a prothrombin activator in 
the venom with a very pronounced procoagulant action® 
The prothrombin activator is a complex of a catalytic 
factor similar to factor Xa with a molecular weight of 
57,000, and a co-factor similar to factor Va with a 
molecular weight of 220,000. The prothrombin activator 
has also recently been shown to activate factor VII®®.
Other venom components
Taipan venom is known to cause degranulation 
and agglutination of platelets in vitro®®. It is also 
believed to have some thrombin like activity in vitro 
and weak fibrinolytic activity. The venom also has weak 
haemolytic activity although this is much less marked 
than that associated with many other Australasian 
elapid venoms®*. The presence of a weak, heat stable
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anticoagulant in taipan venom has been suggested®® but 
no haemorrhagin activity has been demonstrated®®.
BACKGROUND TO INTERVENTION STUDIES
The potential therapeutic role for 
pharmacological agents in established neurotoxicity is 
to improve the clinical state of a patient by enhancing 
neuromuscular transmission once the toxin has bound and 
has inhibited transmitter release. There is no obvious 
mechanism whereby any existing drug would prevent the 
action of a circulating toxin more effectively than 
antivenom. The potential is therefore that of an 
adjunct to, rather than a replacement for, antivenom. 
Once neurotoxicity is established in taipan bite, 
presumably once the toxin has bound to the membrane, 
antivenom has little or no effect (discussed below).
The clinical impression is that this situation is 
frequently reached before a patient receives antivenom. 
In these circumstances a drug that delayed or prevented 
the need for intubation and ventilation, would 
substantially reduce the risk of the most hazardous 
phase of envenoming.
The in vitro studies of taipan venom suggest 
that the predominant effect is presynaptic. The ability 
of the post synaptic receptors to respond to 
acetylcholine appears largely unaffected. A drug which 
increases the synaptic concentration of acetylcholine 
may have therapeutic value. There are two groups of 
drugs which appear to be possible candidates, drugs 
which inhibit acetylcholinesterase, slowing the 
degradation of released transmitter, and drugs which 
act presynaptically to increase transmitter release. In 
order for a drug to be useful in the management of 
patients with neurotoxicity, it must be safe, 
preferably available in both oral and intravenous 
preparations and produce a sustained increase in
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peripheral muscle strength, most importantly in the 
respiratory and bulbar muscles. Anticholinesterases 
have filled all of these roles in the treatment of 
neurotoxicity due to post synaptic neurotoxins 
following envenoming by the Philippine cobra {Naja naja 
philippensis)^^, the Malayan krait (Bungarus 
candidus)^^ and the death adder (Acanthopis app.j®®»®®.
A second group of drugs which could produce a 
beneficial response in presynaptic neurotoxicity are 
the aminopyridines. These agents act by blocking 
voltage dependent potassium channels in the region of 
the nerve terminal?®. Delay in the opening of potassium 
channels in this region in turn prolongs the opening of 
calcium channels through which calcium enters the 
presynaptic terminal. The release of acetylcholine is 
augmented by a high concentration of calcium in the 
pre-synaptic terminal. Aminopyridines appear to have 
little effect on miniature end plate potentials (mepps) 
but significantly increase the quantal content of the 
end plate potential (epp). Aminopyridines have been 
used in a variety of clinical situations?i including 
reversal of non-depolarising neuro-muscular blockade?®, 
myasthenia gravis?®"?®, congenital myasthenic 
syndrome?®, botulism??"®® and Eaton-Lambert syndrome® 
®®. Watt et al showed some evidence of an improvement 
in the respiratory function of rabbits poisoned by both 
B-bungarotoxin and whole krait venom after 
administration of 3,4-diaminopyridine®*>®®. In the 
clinical situations in which aminopyridines have been 
used, their action has been found to be significantly 
augmented by co-administration of an anticholinesterase 
and the drugs appear to have a synergistic effect®®.
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CHAPTER 2 - METHODS
1. Introduction
Epidemiological, demographic and clinical 
details of both envenomed and non-envenomed patients 
were recorded on standard proformas, examples of which 
are shown in appendices 1 and 2. All patients were 
examined in the casualty department of Port Moresby 
General Hospital (PMGH) on admission and managed 
according to the recommended treatment regimens 
detailed in the standard treatment books published by 
the Papua New Guinea Department of Health®?-®®. All 
envenomed patients were examined at a minimum of six 
hourly intervals for the first 36 hours after admission 
and at regular intervals thereafter until discharge. 
Patients were reviewed between one and two weeks after 
discharge. Selected patients, who gave informed 
consent, had a series of electrophysiological tests 
performed during their admission and some received 
pharmacological interventions. All of the studies which 
were carried out had the full approval of the National 
Ethics Committee of Papua New Guinea.
2. Criteria for inclusion
Patients were included in the study if they 
were admitted between May 1991 and May 1993, had 
clinical signs consistent with envenoming and if the 
biting species was definitively identified as a Papuan 
taipan by one or more of the following means:
i. Dead snake brought and identified as a taipan 
from an identification keyi® and subsequently 
confirmed by visiting herpetologist.
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ii. Taipan venom antigen detected in at least one 
of serum, bite site swab, bite site aspirate 
or admission urine sample at a level of more 
than 18ng/ml*.
iii. Taipan venom antigen detected at level of less 
than 18ng/ml in at least one specimen, but with 
corroborative evidence that biting species was 
a taipan, either:
- Spontaneous unsolicited description of dark 
snake with red back by patient at admission,
or
- Positive CSL venom detection kit immunoassay
for taipan venom from swab of bite site at
admission.
*A level of 18ng/ml was taken as the cut-off for 
significance in the assay for venom antigen. This is 
explained below.
A total of 117 patients met these criteria. In 
addition, a prospective series of 100 patients claiming 
to have been bitten by a snake, but without clinical
signs of envenoming, was collected from May 1991. These
patients were included in order to compare the results 
of EIA venom antigen assays with those taken from 
envenomed patients.
3. Epidemiology of taipan bite
Information was sought to elucidate the 
epidemiology of taipan bite in Papua. The answers to a 
variety of questions concerning the circumstances and 
specific details of the bite were recorded on a 
proforma (see appendix 2). The proformas of all 
patients admitted to PMGH between May 1991 and May 
1993, who were later confirmed to have been bitten by a 
taipan, were included in the analysis, a total of 117
41
patients. This included 11 patients who were admitted 
when the author was not in Port Moresby but who met the 
other diagnostic criteria. These patients were seen and 
managed by either Dr David Lalloo or Dr Nneka Nwokolo 
using the same protocol.
4. Clinical studies
i. Admission criteria
The clinical records of 106 confirmed envenomed 
taipan bites, seen and managed by the author between 
May 1991 and May 1993, form the basis of the clinical 
analysis.
Clinical signs of envenoming were regarded as 
unequivocal if they included one or more of the 
following : tender local lymphadenopathy in the bitten 
limb, incoagulable blood, spontaneous bleeding and 
evidence of neurotoxicity.
ii. Clinical management
All patients were examined at admission in the 
casualty department and managed according to approved 
regimens®?'®®. Envenomed patients were given one vial 
of antivenom, either polyvalent or monovalent taipan 
antivenom (Commonwealth Serum Laboratories, Melbourne), 
depending on whether the species was known, given as an 
infusion in 100ml of dextrose, over 20 minutes. 12.5mg 
or 25mg of promethazine was given intravenously as 
premedication according to body weight. One ml of 
tetanus toxoid, given subcutaneously and a single dose 
of 1 MU penicillin given intramuscularly or 
intravenously depending on the presence or absence of 
coagulopathy, were also administered at admission. 
Penicillin was then given for a further five days.
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Envenomed patients were admitted to the high dependency 
ward. Further management depended on the clinical 
course. Fresh frozen plasma was given to a small number 
of patients in whom bleeding persisted. Patients with 
pooling of secretions were nursed on their side and 
pharyngeal suction was used as required.
Electrocardiograms were done at admission, 24 hours and 
at other times in some patients. All significantly 
envenomed patients had a urinary catheter inserted to 
monitor urine output.
Any additional unrelated pathology identified or 
developing during the course of admission was managed 
as considered appropriate.
iii. Intubation and ventilation
Patients were intubated if they had obvious 
pharyngeal pooling of secretions and were considered at 
risk of aspirating. They were ventilated, using a Bird 
Mark 7 pressure cycled ventilator, if respiratory 
function became inadequate. This usually manifested as 
diminishing chest expansion, falling tidal volume and 
minute ventilation and increasing respiratory rate. 
Unfortunately it was not possible to measure blood 
gases at PMGH during the course of the study. Patients 
were sedated using intravenous boluses of diazepam and 
morphine as required. A local pharyngeal anaesthetic 
spray was used prior to intubation. Neuromuscular 
blocking agents were not used. Patients were weaned 
from the ventilator when they were able to maintain an 
adequate tidal volume, had a respiratory rate of less 
than 25/minute, were able to cough effectively and 
could sustain hand grip and head lift for at least 5 
seconds. They were subsequently extubated when adequate 
respiratory function was maintained. All patients who 
were intubated had a portable chest X-ray to check the
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position of the endotracheal tube. Other patients were 
X-rayed if clinically indicated.
iv. Clinical progression and effect of antivenom
All patients were examined at regular 
intervals. For the first 36 hours they were examined at 
least once every six hours and subsequently a minimum 
of once every 12 hours until discharge. In order to 
compare the clinical course in different patients, 
specific stages of progression or resolution of 
neurotoxicity were identified. These included the onset 
and resolution of ptosis and ophthalmoplegia, times to 
intubation, ventilation, weaning and extubation, length 
of intubation and ventilation and time to discharge.
The time taken after envenoming for complete resolution 
of ophthalmoplegia was estimated as the midpoint 
between the time of the last observation at which eye 
signs were definitely present and the first observation 
at which they were definitely absent. The time taken to 
initial improvement in ophthalmoplegia was estimated 
similarly. Successive grip strength measurements were 
recorded using a hand held dynamometer. A simple 
classification of neurotoxicity was used for 
comparative purposes (see appendix 3). The ability to
discriminate the taste of sugar, salt, quinine (bitter)
and vinegar was tested in 10 patients both during
hospital admission and at follow up.
Patients were requested to attend for review 14 
days after the day of their admission or one week after 
their discharge. Bus fares were given to those needing 
them to encourage attendance. At follow up, a clinical 
examination was performed, any necessary blood tests 
done (if abnormalities were present at discharge) and 
the patient’s weight was measured.
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V. Autonomic function
Full testing of autonomic function in 
significantly envenomed patients proved impossible.
There was no tilt table for measuring responses to 60% 
tilt and testing of responses to sustained grip and 
Valsalva procedure did not prove possible. The 
following tests were done on 9 patients, all of whom 
were tested when at stage 3 neurotoxicity (see appendix 
3)
1. Ciliospinal reflex - pupillary repense to swift 
downward
scratch with orange stick on skin overlying 
sternocleidomastoid muscle.
2. Heart rate response to intravenous atropine
3. Blood pressure and heart rate response to 30 degree
tilt, from head up to head down (maximum 
attainable
with available beds).
4. Variation in RR interval during carotid sinus 
massage.
Direct and consensual pupillary reflexes, were 
tested in
all patients.
vi . Non-envenomed
Patients who gave a history of snakebite but who 
appeared to be non-envenomed were managed in short stay 
beds attached to the casualty department. They were 
examined at presentation and at regular intervals 
thereafter. All patients who were suspected to be non- 
envenomed, were observed in the department for a 
minimum of 12 hours before being discharged.
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5. Laboratory studies
i. Identification of biting species
The following samples were tested for the
presence of
venom antigen :
1 . Bite site swab
2. Bite site aspirate
3 . Serum
4. Urine
The basis for inclusion in the study was the 
detection of significant levels of taipan venom antigen 
either at the bite site, in serum or in urine. Blood 
samples were taken from all patients at admission and 
the serum separated. This was then frozen at -70°G and 
stored. No antivenom was given at PMGH until a blood 
sample had been taken but 20 patients had already 
received antivenom at a health centre before transfer. 
When a bite site could be identified and had not been 
obscured by topical traditional medications, it was 
swabbed with a cotton wool swab previously damped with 
sterile water. This swab was stored at -70°C. In some 
patients, the swab was tested for the presence of venom 
antigen using bedside venom detection kits (VDKs, CSL 
Diagnostics, Melbourne) prior to freezing. When fang 
marks could be identified unequivocally, 0.5ml of 1% 
lignocaine was infiltrated locally. A 25 gauge needle 
was then inserted perpendicularly to the skin along the 
estimated direction of the fang incisions. Tissue fluid 
was aspirated, The syringe was then flushed with 0.5ml 
of sterile water and the sample frozen at -70°C. A 2ml 
urine sample was collected as soon as possible after 
admission and stored.
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Swab, aspirate, serum and urine samples were 
stored and later analysed by Dr David Theakston and his 
staff at the venom unit at the Liverpool School of 
Tropical Medicine, Swabs were eluted in 1 ml normal 
saline and these together with the serum, aspirate and 
urine samples were tested for the presence of venom 
antigen against : Oxyuranus scutellatus canni, 
Acanthopis sp., Pseudechis papuanus, Pseudonaja 
textilis and Micropechis ikaheka venom2 2,89, Microsorp 
F96 microtitre plates (Nunc Gibco Ltd, UK) were coated 
with 100ug/ml rabbit anti-whole venom IgG (protein A- 
derived) in coating buffer at 4°C overnight. At all 
stages 1OOul volumes were used in each well.Following 
washing, plates were post-coated with 1% bovine serum 
albumin (Sigma Chemical Co.UK) for 1 hour as a blocking 
step, and subsequently rewashed. Test samples, together 
with a series of venom standards (0.1-500ng/ml) and 
appropriate positive and negative controls diluted 1:10 
in incubation buffer were then added in duplicate to 
the wells. To each of these 1% normal rabbit serum 
(lOul/ml) incubation buffer was added to prevent non­
specific reactions. Following incubation at room 
temperature for 4 hours, plates were rewashed. A 1:500 
dilution of rabbit anti-venom IgG alkaline phosphatase 
conjugate (Sigma Ltd,UK) in incubation buffer was added 
and the plates were incubated at 4°C overnight. They 
were subsequently rewashed and the substrate (p- 
nitrophenyl phosphate disodium. Sigma Ltd.UK, Img/ml in 
diethanolamine buffer) was added. Following generation 
of colour, the optical densities were read on a 
Titertek Mulitskan ELISA "through the plate" reader 
(Flow Laboratories,UK) after 30 minutes substrate 
incubation.
Venom levels in the test samples were estimated by 
reference to a standard curve. The baseline for the 
venom assay was established by assaying control samples
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from 102 patients who had never been bitten by a snake. 
The mean OD and SEM was calculated for these controls 
and this mean + 2SEM was subtracted from the venom 
levels measured in patients.
Based on immunoassays in controls (n=102).
.Q.E.t.i.ca l Dens i t y Venom Ag . L eve l s (,ng/ml )
mean SD median mean cutoff
0.35 0.73 0.00 3.48 18.16
The cutoff was derived from the standard curve (mean 
+2SD of optical density). Venom antigen levels of less 
than 18ng/ml were not accepted as definitive evidence 
that the biting species was a taipan except in 4 
patients in whom there was strong corroborative 
evidence (detailed above).
ii. Venom Detection Kits
Commonwealth Serum Laboratories (CSL), Melbourne, 
produce bedside rapid diagnostic kits for the detection 
of the venom of the major Australasian elapids, with 
the aim of indicating appropriate antivenom to use. The 
kits are designed to be used with either bite site 
swab, urine or serum sample with the first recommended. 
The test is based on an enzyme linked immunoassay and 
can detect levels of antigen as low as 10ng/ml9o-93. 
Bite site swabs from 42 patients were tested 
immediately on admission. The swab was then frozen at 
-70°C and stored for later analysis using the 
laboratory method described above. When the VDK gave an
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unequivocal positive result, monovalent antivenom was 
used.
iii. Biochemistry and routine haematology
The following investigations were carried out on 
patients during their admission. Additional samples 
were analysed in individual cases if deemed clinically 
appropriate.
1. Urea and electrolytes - Admission, days 2,3 and 
discharge.
2. Liver function tests - Admission and discharge.
3. Creatinine kinase - Admission, days 2,3 and 
discharge.
4. Full blood count and platelet count. - Admission, 
days
2,3 and discharge.
5. Blood slide for red cell morphology and 
differential
white count - Admission.
6. Urine sample for urinalysis and microscopy - 
Admission.
The biochemistry was done in the hospital 
laboratory using Technicon RA-1000 and Technicon RA-XT 
autoanalysers. Hospital standard ranges were used. 
Routine haematology was done by Mrs Julie Black and Mr 
Asi Matuka using a Coulter counter model M450 (Coulter 
Electronics Ltd, Australia). Differential white cell 
counts were determined manually from slides fixed in 
methanol and stained with 50% Giemsa for 10 minutes. 
Platelet counts were determined manually in a modified 
Neubauer counting chamber. Ammonium oxalate was used as 
a diluent. Normal ranges for the white cell count and 
platelet count were determined from 100 Melanesian
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controls by determining the mean +/- two standard 
deviations. Unspun urine samples were examined for 
casts, cells and crystals in the research laboratory. 
Urinalysis was done using Multistix (Boehringer 
Mannheim).
iv. Haemostasis
1. Tube clotting test - Admission and six hourly 
until clotting (some patients only).
T h e  p r e s e n c e  o r  a b s e n c e  o f  c o a g u l o p a t h y  w a s  
d e t e r m i n e d  u s i n g  t h e  2 0  m i n u t e  w h o l e  b l o o d  c l o t t i n g  
t e s t  ( 2 0 W B G T ) 9 4 .  2 m l s  o f  b l o o d  w a s  p u t  i n  a  c l e a n ,  
u n u s e d  g l a s s  t u b e  a n d  a l l o w e d  t o  s t a n d  u n d i s t u r b e d .  
W h e n  a  c l o t  h a d  f a i l e d  t o  f o r m  a f t e r  2 0  m i n u t e s ,  t h e  
t e s t  w a s  c o n s i d e r e d  p o s i t i v e  i n d i c a t i n g  s i g n i f i c a n t  
d e f i b r i n a t i o n .  In s o m e  p a t i e n t s ,  s e q u e n t i a l  6 h o u r l y  
c l o t t i n g  t e s t s  w e r e  d o n e  t o  d e t e r m i n e  t h e  t i m e  t a k e n  
f o r  t h e  b l o o d  t o  c l o t  a f t e r  a n t i v e n o m .
Analysis of the mechanism of the disturbances of 
haemostasis was not included as part of this study. 
Several patients included in this series did, however, 
have coagulation factor and fibrin(ogen) degradation 
product assays performed as part of a separate study 
and will be reported elsewhere.
V. Clinically non-envenomed
All patients who appeared to be non-envenomed 
had admission serum samples taken for venom antigen 
detection. When a bite site could be identified swabs 
and aspirates were also taken. 2ml of whole blood was 
taken for the whole blood clotting test^^.
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6. Electrophysiological studies
i. Conduction studies
As a prelude to studies using 
pharmacological interventions, and to look in detail at 
the course of envenoming at the bedside, a series of 
baseline studies were performed on adult patients with 
suspected taipan bites and also on a number of healthy 
Melanesian controls, all of whom gave informed consent. 
Only patients who were later confirmed by immunoassay 
as taipan bites were included in the analysis of 
envenomed patients. All studies were done using a 
Medelec Neurostar MS92B EMG machine. All patients were 
studied either in the intensive care unit or the high 
dependency ward. Air temperatures varied from 25°C - 
28°G. Control studies were done in the laboratory in 
the clinical sciences department, with air temperatures 
varying from 23°C - 27°C. Skin temperatures were 
recorded using a Temp/SC 200T thermistor 
(Lafayette,Indiana). No corrections were made for 
variations in skin temperature between individuals or 
between recordings in the same individual but patients 
with significant peripheral hypoperfusion were excluded 
from the analysis.
Sequential studies were performed on envenomed 
patients during the course of their hospital admission 
and when possible at follow up appointments after 
discharge. The position of recording electrodes was 
marked at each examination so that electrode positions 
were, as far as possible, consistent. The times of 
study varied between patients and for purposes of 
comparison, stages of clinical neurotoxicity (see 
Appendix 3) were used in addition to time elapsed post 
envenoming. This system was used because of the wide 
variation in severity and time course of neurotoxicity
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between patients. A single study was performed in the 
control patients except for a small number in which 
repeat studies were done to check the reproducibility 
of results.
The following studies were done at rest:
1. Motor nerve conduction studies in ulnar and median
nerves including:
i. measurement of GMAP amplitude
ii. measurement of F-wave latencies (minimum of
10 responses)
iii. calculation of Motor conduction velocities
2. Sensory nerve conduction studies in ulnar and 
median nerves including:
i. measurement of sensory nerve action potential
amplitudes.
ii. calculation of sensory nerve conduction 
velocities
Compound muscle action potentials (CMAPs) were 
recorded from abductor digiti minimi and abductor 
pollicis muscles after stimulation of the ulnar and 
median nerves respectively at the wrist. Ulnar and 
median nerves were chosen for the majority of studies 
because of their accessibility and the ease of 
performing consistent studies. In addition, the 
majority of patients admitted to PMGH are bitten on the 
lower limb and many have had emergency treatment with a 
tourniquet and local incisions which may cause 
transient or permanent nerve damage. A bipolar 
stimulator was used and a bipolar 3cm surface recording 
electrode positioned over the belly and tendon of the 
muscle. A wrap around ground electrode was placed
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between the stimulating and recording electrodes. The 
threshold stimulus was determined and recorded as the 
stimulus intensity at which a maximal amplitude CMAP 
was obtained. A supramaximal stimulus intensity of 125% 
threshold was used for recording. For motor studies the 
stimulus duration was 0.1msec. The filter settings 
were: 2Hz-10kHz for motor studies, 20Hz-2kHz for 
sensory studies and 20Hz-10kHz for concentric needle 
EMG.
CMAP amplitudes were measured from the 
baseline to the peak of the negative deflection. 
Latencies were measured from the stimulus artefact to 
the onset of the negative deflection and duration was 
measured from the onset of the CMAP to the return to 
the baseline. Both were calculated using the machine’s 
automated callipers. Motor nerve conduction velocities 
(MNCV) were calculated by using two stimulation points 
along the course of the appropriate nerve. For the 
median nerve, stimulation sites used were at the wrist 
and cubital fossa. For the ulnar nerve, the sites were 
the wrist and the medial aspect of the proximal third 
of the forearm. Surface distances were measured using a 
hand held tape marked in millimetres. F waves were 
recorded by supramaximally stimulating the ulnar nerve 
at the wrist and recording the shortest latency of 10 
responses recorded over abductor digiti minimi.
Sensory amplitudes were measured by 
stimulating the digital branches of median and ulnar 
nerves in the palm at a distance of 8cm from recording 
electrodes placed over the mixed nerves at the wrist. 
Latencies were determined and conduction velocities 
calculated.
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ii. Repetitive nerve stimulation studies
Repetitive nerve stimulation studies were 
performed by stimulating the ulnar nerve at the wrist 
and recording over abductor digiti minimi with surface 
pad electrodes. Stimulation intensities of 125% 
threshold were used and a train of nine stimuli given 
at a frequency of 3 Hz. The percentage change in CMAP 
amplitude was recorded between responses 1 and 4 and 1 
and 9, using the automated callipers. Five second 
bursts of stimuli at 50 Hz were given to some patients 
and controls, followed by subsequent low frequency 
(3Hz) trains of nine stimuli at 5 seconds. Changes in 
the size of the first CMAP in the train and in the 
ratio of 1-4 and 1-9 were recorded.
iii. Electromyography
The majority of patients studied in this series 
had a coagulopathy which precluded extensive concentric 
needle EMG studies. A small number of patients with 
unusual clinical abnormalities were examined, notably 
patients with clinically evident fasciculation and 
three with pronounced difficulty with jaw opening. In 
all cases studies were not done until the 20WBCT was 
normal.
iv. Controls
Control studies were done on 26 people 
including relatives of envenomed patients and some 
members of staff at the hospital. All were fit 
Melanesians with no clinical evidence of neurological 
abnormality. Values were recorded from both right and 
left arms except in one patient with a previous wrist 
injury. F wave values were obtained in 23 patients and
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compared both as a group with envenomed patients and as 
far as possible, height and age matched. Repetitive 
nerve stimulation studies were performed in 15 control 
subj ects.
iv. Single fibre studies
Single fibre studies were done on four 
patients subsequent to the series reported here. The 
findings in these patients will be published 
separately. These studies were done with Dr Sean 
Connolly from the Regional Neurosciences Centre, 
Newcastle upon Tyne.
7. Intervention studies
i. Patient selection
Patients were included in one arm of the study if 
they filled the following criteria:
1. proven taipan bite - by wound swab venom
detection kit or dead snake identification and 
subsequent comfirmation by ELISA.
2. adult (>14 years)
3. with significant neurotoxicity, minimum stage 
2 and either static or progressing.
4. with a known and significant reduction in CMAP
estimated as at least 50%.
5. having given informed consent.
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Exclusion criteria:
1. pregnancy
2. past history of epilepsy.
3. inability to co-operate with testing eg.,
inability to tolerate electrophysiological 
testing or grip strength measurements, 
vomiting, agitation, unstable clinical state.
Patients were included at various times after 
envenoming and at various stages of neurotoxicity 
(stages 2-5) but only included once the presence of 
neurotoxicity was clearly established as both present 
and static or deteriorating.
ii. Interventions
Three intervention groups were selected:-
Group 1. Edrophonium 1Omg intravenously or placebo.
Group 2. 3,4-diaminopyridine 1Omg intravenously or 
placebo.
Group 3. 3,4-diaminopyridine 1Omg followed by
edrophonium 1Omg at 7 minutes, both given 
intravenously.
A solution of 3,4-DAP was prepared by dissolving 1Omg 
of powder (Small Scale Pharmaceuticals,Brighton) in 10 
mis of sterile water under aseptic conditions. The 
solution was then filtered through a sterile millipore 
filter. The solution was administered by slow 
intravenous push over 1 minute into a peripheral vein. 
Each administration was preceded by injection of 0.6mg 
atropine 5 minutes before and followed by infusion of 
lOOmls of either 5% Dextrose or N.Saline solution. 
Patients in groups 1 and 2 were given either active 
drug or a saline placebo. In group 1, given the short 
half life of edrophonium, this was conducted in a
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double blind crossover fashion with a 30 minute 
recovery period between the two injections. No 
crossover procedure was attempted with 3,4- DAP due to 
the longer half life of the drug. Both active drug and 
placebo were drawn up into syringes labelled A and B by 
an assistant who recorded the code. This procedure was 
not carried out in Group 3 where only active drugs were 
given. 10 mg of edrophonium was given 7 minutes after 
the injection of 3,4-DAP. This time period was chosen 
to allow time to observe the initial effect of DAP and 
to fit in with the observations which were taken each 5 
minutes.
iii. Assessment
The following tests were done in each patient:
1. CMAP amplitude in abductor digiti minimi at
rest following 125% supramaximal threshold 
stimulus to ulnar nerve at the wrist.
2. muscle grip strength readings (MGS)
3. eye movements recorded as degrees of abduction.
4. grade of ptosis.
5. mouth opening recorded in millimetres interincisor
distance.
6. sequential repetitive nerve stimulation response at
3 Hz. (some patients only)
Recordings were done using a Medelec Neurostar MS92B 
EMG machine. A 3cm bipolar stimulator was used fixed 
over the ulnar nerve and taped in place throughout the 
readings. Disc surface recording electrodes were taped 
over the abductor digiti minimi. The stimulus threshold 
was determined and a stimulus of 125% threshold used 
for baseline readings. This stimulus intensity was used 
throughout subsequent recordings. Three readings were
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taken at each assessment and the maximum amplitude 
recorded from baseline to peak using the cursors and 
automated calculator. Repetitive nerve stimulation 
tests done in some patients were done using the 
electrodes and results were recorded as the percentage 
increment or decrement between 1 and 4 in a train of 9. 
A dynamometer was used to record maximal muscle grip 
strength. Three readings were taken at each assessment 
with the arm fully extended and the readings averaged. 
In all cases any electrophysiological recordings were 
made prior to grip strength readings to avoid any 
potential post exercise effects. Eye movements were 
assessed on the maximum lateral movement of the 
abducting eye ranging from zero to normal. Ptosis was 
assessed using the MRC scale and the extent (in mm) of 
iris uncovered on upward gaze with the head held facing 
horizontally. In non-intubated patients, the maximum 
inter-incisor distance was recorded using a hand held 
ruler.
Objective assessment of respiratory 
function proved difficult. Recording of maximal 
inspiratory pressure tidal volume and peak flow were 
initially attempted but proved highly variable and were 
abandoned from the analysis.
8. Data analysis
The epidemiological and clinical data were 
analysed using the "Epi Info" statistics package 
(USD,Inc.Georgia). Numerical data were stored using the 
Lotus R123 spreadsheet programme and analysed using the 
Instat biostatistics programme (GraphPad Software 
Inc.). Continuous variables which were not normally 
distributed were compared using the Kruskal-Wallis 
test. Continuous variables which were normally 
distributed were compared using the two tailed t test,
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assuming equal or unequal variance as appropriate. 
Categorical data were compared using the Chi squared 
test with Yates correction or Fisher exact test if the 
expected value was less than 5.
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CHAPTER 3 - THE EPIDEMIOLOGY OF TAIPAN BITE
1. Incidence and mortality rates
Table 3.1 shows the numbers of proven taipan bites 
and the total numbers of envenomed patients admitted to 
PMGH in the period May 1991 - May 1993. Estimated 
incidence and mortality rates for National Capital 
District (NCD) and for Central Province are shown based 
on a calculation from PMGH admissions and the national 
Papua New Guinea census of 199Q9. The figures do not 
include envenomed patients who were not referred to, or 
did not arrive at PMGH.
Tab,l,e 3.1 Taipan bi tes : incidence and morta,l,i,ty
NCD Central Province
Proven Taipan Bites 24 93
Incidence/1 00,000/yr 6 . 2 33
Mortality/100,000/yr 0 1 .8
All envenomed patients 38 156
Incidence/100,000/yr 9.8 55
Mortality/100,000/yr 0.5 3.2
Between May 1991 and May 1992, 74 patients were 
seen in the casualty department at PMGH who reported 
having been bitten by a snake but who did not show any 
clinical signs of envenoming. 45 of these were bitten 
in National Capital District, which would give an 
estimated incidence of snake bite of 32.8/100,000 for 
the urban area and 75.8/100,000 for Central Province.
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2. Biting species
There were a total of 194 patients with 
signs of systemic envenoming admitted to PMGH between 
the beginning of May 1991 and the beginning of May 
1993. Definitive diagnoses of biting species were made 
on 130 of these on the basis of venom detection at a 
level >18ng/ml from serum, bite site swab or aspirate. 
Venom antigen was detected in 161 of the 194 patients 
and this distribution is also shown in Table 3.2.
Table 3.2; Biting speci es
SPECIES Definitive Venom detected
Oxyuranus scutellatus canni 1 1 7 90% 143 88 ,.8%
Acanthopis Spp. 1 1 8.5% 1 5 9,.3%
Pseudonaj a textilis 2 1 .5% 2 1 ,. 2%
Pseudechis papuanus - - 1 0,. 6%
3. The demography of taipan bites
i. Geographical location of bite
The geographical locations of the 117 confirmed taipan 
bites are plotted on the map Figure 3.1.
ii. Age and sex of victims
Figure 3.2 shows the number, age and sex of 
patients bitten by taipans during the period May 1991- 
May 1993.
Many patients did not know their date of birth and 
estimations of age had to be calculated from memorable 
events, such as the age of the patient at the
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Figure 3:2 Age and sex distribution of patients envenomed 
following taipan bites between May 1991 and May 1993.
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Figure 3:3 The time of the bite in cases of proven 
taipan envenoming between May 1991 and M a y l993.
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declaration of independence in 1975. The data must be 
interpreted with this inherent inaccuracy borne in 
mind. Seventy seven of the envenomed patients were male 
(66%), 40 female (34%). The estimated mean age of males 
and females was 27.9 and 25.8 years respectively.
iii. Time of the bite
Figure 3.3 shows the distribution of confirmed 
taipan bites by time of bite. The bite time is based on 
the patient's estimate. Each division begins on the 
hour such that a bite at 1000 hours is included in the 
1000-1100 group but not in the 0900-1000 hours group.
iv. Month of the bite
Figure 3.4 shows the number of confirmed taipan 
bites admitted to PMGH during each month of the study. 
Rainfall figures are shown which are calculated from 
the monthly rainfall averages from 3 centres, Port 
Moresby (Lat:09° 27', Long:147° 12', elevation 35 
metres). Ou Ou Greek (Lat:08° 55', Long:146° 34') and 
Moreguina (Lat:10° 20', Long 148° 28'). Three centres 
were chosen in an attempt to compensate for the 
significant variations which occur between different 
areas of the Province from which the patients came. All 
are low altitude weather stations at less than 200 
metres above sea level. Rainfall data from the four 
other weather stations in Central Province were not 
used, Kilakila and Loloata Island because they are 
geographically very close to the Port Moresby weather 
station and have almost identical monthly totals. The 
rainfall data from Fane were not used because the 
station is at high altitude (>1000 metres) in the Owen 
Stanley ranges, has a high rainfall all year round 
which is unrepresentative of Central Province and is
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Figure 3:4 The number of patients admitted to PMGH envenomed 
following a taipan bite each month between May 1991 and May 1993. 
Averaged rainfall data shown as line.
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Figure 3:5 The number of envenomed patients admitted to PMGH 
each month between May 1991 and May 1993 (all snake species). 
Averaged rainfall from three centres shown as line.
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not an area in which taipan bites occur. The rainfall 
data from the other station, Bereina, in the west of 
Central Province, was incomplete.
Figure 3.5 shows the total number of envenomed 
patients admitted to PMGH during each month including 
many who were suspected to have been bitten by taipans 
but who did not meet the criteria for definitive 
diagnosis (see chapter 2).
V. Circumstances of the bite
Table 3.3 shows the circumstances in which the 117 
patients in the study were bitten. A distinction is 
made between those who were bitten on cleared bush 
tracks and those who were bitten in rough bush or kunai 
grass. The 52 patients who were bitten in overgrown 
areas were participating in a variety of activities at 
the time of being bitten, including hunting, collecting 
firewood, on route to a garden, playing and urinating.
Table 3.3: Circums  of the bite
Activity when bitten Number
Working in garden 32
On bush track 1 7
On road 3
Around house surrounds 3
In bush/kunai grass 52
Unknown 10
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vi. Site of the bite wound
Table 3.4 shows the site of the bite wound in the 
116 patients in whom it could be identified.
Table 3.4,,: Site of the bite wound
Site Number
Foot 65
Ankle 17
Calf/shin 29
Thigh 3
Hand 2
Of the two patients who were bitten on the hand, the 
first attempted to pick up a live snake. The second was 
taking wood from a wood pile in which the snake was 
concealed. Of the patients bitten on the thigh, one was 
sitting beside the road when he was bitten, one was 
walking in long grass. The third patient was found 
lying in the road and was unable to give any 
explanation of the sequence of events.
vii. Victims' description of the snake
Very few patients could reliably identify the 
snake that bit them. Most described a black or dark 
snake but could not describe other identifying 
features. Several patients gave descriptions which gave 
no clue to the identity of the biting species. The 
majority of victims were also unable to estimate the 
length of the snake that bit them. Details are shown in 
Table 3.5 and Table 3.6
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T a b l e 3 . 5 V i c t i m s o f t h e s n a k e c o l o u r
Description given Number of patients
"Taipan" 1
Black 44
Black/red back 12
Black/brown back 5
Black/yellow, black/green , black/grey 4
Brown 7
Other 4
Unseen 40
.6: Victims' description of the snake length
Length of snake Number of patients
1 metre or more 44
<1 metre 1 2
Unseen/unsure 61
4. Pre-hospital treatment
i. First aid
Table 3.7 shows the first aid treatment 
instituted by patients or their companions prior to 
reaching either a health centre or hospital.
Table 3.7: First aid treatment
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First aid treatment Number of patients
Tourniquets 
Tourniquet + cuts 
Razor cuts 
Pressure bandage 
None
Limb immobilisation
40 
8 
1 1 
1
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0
Tourniquets were made from a variety of materials 
including grass, cloth, a strip of rubber and rope. In 
general they were not tied sufficiently tightly to 
cause significant ischaemia although one patient, not 
included in this series, was seen who lost the use of 
his leg after prolonged use of a tight tourniquet?5. 
Nineteen patients had razor cuts made around the site 
of the bite. Typically, these were in the pattern of 
multiple small,shallow, vertical incisions (Plates 
3.1,3.2). No attempt was made to excise the bite site 
itself in any patient.
ii. First point of contact with medical help
Table 3.8 shows the first point of contact 
with medical help for the 117 patients in the series. 
Mean and median times of arrival after envenoming are 
shown for patients arriving at a health centre first, 
for those self-referring immediately to hospital and 
for those who were referred to hospital after being 
seen first at a health centre. The patients who 
presented initially at a health centre were 
predominantly those who were bitten in the geographical 
locations furthest from Port Moresby. 85% of this group
Plate 3.1 Scarification around bite site
Plate 3.2 The consequences of a tight tourniquet
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were referred from 4 health centres, Bereina, Vaifa'a, 
Kwikila and Kupiano (see map).
Table 3.8: First point of contact with help
Health Centre Hospital Referred
Number of patients 55 62
Median arrival(hrs) 2.0 2.75 7.5
Range (hrs) 0.5-24 0.5-74 1.25-48
Twenty of the 55 patients who were referred 
from a health centre to Port Moresby were given 
antivenom prior to transfer. Eleven were given 
polyvalent antivenom, 6 were given taipan monovalent 
antivenom and 3 were given black snake antivenom. 
Despite a perceived need, 35 patients were not given 
antivenom at the health centre prior to referral. The 
usual reason for this was lack of stock of antivenom at 
the health centre. Seven patients had pressure bandages 
applied to the bitten limb by health centre staff prior 
to referral, 6 of these were treated by the same 
person. Only one patient who was given antivenom, also 
had a pressure bandage applied.
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CHAPTER 4 - CLINICAL STUDIES : RESULTS 
1. Basis for inclusion
i. Envenomed patients
A total of 106 patients with signs of 
systemic envenoming were included in the clinical 
series. The basis for inclusion was the presence of 
unequivocal signs of systemic envenoming together with 
subsequent detection by laboratory EIA of significant 
levels of taipan venom antigen Table 4.1.
Table 4.1: The source of venom antigen
Patients with venom antigen 
level >18ng/ml
Serum alone 33
Swab alone 8
Aspirate alone 1 1
Serum and swab 1 9
Serum and aspirate 7
Aspirate and swab 9
Serum, swab and aspirate 1 5
Total 1 02
Four other patients with clinical signs of 
envenoming were included in the series. These were: 
three patients who gave spontaneous descriptions of 
having been bitten by a red backed, dark coloured 
snake, who also had detectable levels of taipan venom 
antigen at <18ng/ml in at least one of swab, aspirate
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or admission serum sample. The fourth patient had a 
serum antigen level of 17ng/ml with a positive bedside 
VDK ELISA for taipan venom antigen from a bite site 
swab. Unfortunately this patient's wound swab was 
misplaced and a confirmatory laboratory EIA antigen 
test was not done. A bite wound is shown in Plate 4.1.
In several patients, the exact location of the bite 
site was not clear. In others, a variety of local 
topical traditional medications had been placed over 
the site, so swabs and aspirates were not done. The 
table does not give an indication of the sensitivity of 
each test. All but three patients had serum samples 
analysed. Taipan venom antigen was detected in a high 
proportion of admission urine samples of envenomed 
patients (21 of 39 in this series) but at levels 
<18ng/ml in all cases.
ii. Clinically non-envenomed patients
Patients were defined as clinically non-envenomed 
if they did not have any of:- tender lymphadenopathy, 
prolonged clotting, spontaneous bleeding or signs of 
neurotoxicity. One hundred consecutive patients 
reporting a snakebite, but not clinically envenomed, 
were studied from May 1991. Serum samples were analysed 
on all of these and aspirates and swabs were done when 
the bite site could be identified. Taipan venom antigen 
was detected in 23 patients and at levels greater than 
18ng/ml in 15. Death adder venom antigen was detected 
in 6 patients and eastern brown snake venom antigen in 
one. Eighteen of the 100 patients in the series 
reported nausea and abdominal discomfort, symptoms 
consistent with envenoming. Eight of the 18 patients 
with symptoms did not have detectable venom antigen and 
5 were shown to have levels of taipan venom antigen
Plate 4.1 Fang marks at bite site
Plate 4.2 Non-clotting blood at admission and subsequent samples taken at 6 hourly intervals
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greater than 18ng/ml. None of the patients with 
symptoms, developed any signs of envenoming.
2. Clinical course of envenoming
i. Early symptoms
Table 4.2. shows the symptoms occurring at or 
before admission in patients envenomed following a 
taipan bite, 89% of patients complained of pain in 
groups of lymph nodes draining the site of the bite, 
most commonly inguinal nodes. Abdominal pain was a 
feature in 67% of patients all of whom were bitten 
somewhere on the lower limb. The two patients in the 
series who were bitten on an upper limb did not 
complain of this symptom. Vomiting was common (64.1%) 
and occurred within minutes of the bite in all patients 
who were to experience this. 58% of patients complained 
of "heavy eyes" at the time of admission, including 
some patients who did not have clinical evidence of 
ptosis at the time but who subsequently developed the 
sign unequivocally. Headache was a common feature 
(57.6%) and developed within 1-2 hours of the bite and 
usually resolved within 10 hours. Typically the 
headache was frontal, bilateral and continous. 51.9% of 
patients complained of bleeding which was from a 
variety of sites, most commonly from gums and mouth, 
but including local incisions made at the site of the 
bite and less commonly in vomitus, from the nose or per 
rectum. All of the patients in this series who were to 
have bleeding manifestations had evidence of active 
bleeding at the time of admission to hospital. 
Drowsiness was reported by 44.3% of patients and this 
preceded the administration of antivenom and 
promethazine in the majority of these (77%). Dysphonia, 
dysphagia and diplopia were complained of by
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approximately one third of patients at the time of 
admission. All three symptoms became much more common 
during the progression of the neurotoxicity. 17.6% of 
patients reported, or were witnessed, collapsing within 
minutes of the bite. One of them was subsequently 
witnessed to have a grand mal seizure, one was admitted 
with conjugate deviation of the eyes and appeared post 
ictal, one had fundal haemorrhages and one was admitted 
with apparent diffuse hypoxic brain damage. 15.5% of 
patients complained of dyspnoea at admission. A higher 
proportion had clinical evidence of impaired 
respiratory function (most commonly tachypnoea and 
reduced respiratory excursion) but it appeared that 
patients were not immediately aware of this. Seven 
patients complained of general myalgia although none of 
these had muscle tenderness on palpation or visible 
myoglobinuria.
ii. Early signs
Table 4.3 shows a summary of the clinical signs 
present at admission in envenomed patients and those 
developing during the course of the hospital stay. 
Tender lymphadenopathy localised to the nodes draining 
the bite site was the most common early sign of 
envenoming. All patients who had tender lymph nodes at 
admission either had, or developed prolonged clotting 
and/or neurotoxicity. Six patients did not have tender 
nodes but had other signs of systemic envenoming. 77.9% 
of envenomed patients had a coagulopathy on admission, 
defined as blood that did not clot in a clean, new 
glass tube after 20 minutes (see plate 4.2)94,
Abdominal tenderness (57.8%) and evidence of 
spontaneous bleeding (51.9%) were the next most common 
early signs of envenoming (see Plate 4.3). Persistent 
bleeding from venepuncture sites was common amongst
SYMPTOM N % SYMPTOM N %
Lymph node pain 89/100 89 Dysphonia 35/97 36.1
Abdominal pain 67/99 67.7 Dysphagia 34/97 35.1
Vomiting 66/103 64.1 Diplopia 33/97 34
Ptosis 58/100 58 Collapse 18/1 02 17.6
Headache 57/99 57.6 Dyspnoea 15/98 15.3
Bleeding 54/104 51.9 Myalgia 7/98 7.1
Drowsiness 43/97 44,3
Table 4.2 showing symptoms present at or before admission in 106 patients 
envenomed foilow ing taipan bite, Incomplete data on some.
SIGN ! ADMISSION 1 (N) ; % : PRESENT DURING HOSPITAL STAY %
Tender lymph nodes j 98/104 i 94.2 ■i ! 98/104 94.2
Abdominal tenderness 59/1021
1 1 57,8 ; 59/102 57.8
Bleeding 1 54/105 51,4 '1 i 54/105 51.4
Ptosis i1 50/99 : 50.5 ; 95/105 90.5
Restricted eye movements ! 45/98 ; i45,9 89/105 85.0
Restricted jaw opening 34/91 37,4 : 67/86 77.9
Dysarthria 34/92 41.3 59/93 63.4
Hypotension (Systolic<80mmHg) 3/102 2,9 ■ 3/102 2.9
Non-clotting blood 1 81/104 77.9 81/104 77.9
Table 4.3 showing signs present at admission and developing during hospital stay 
in patients envenomed follow ing taipan bite N==106, incomplete data m some.
Plate 4.3 Gum bleeding
Plate 4.4 Ptosis and ophthalmoplegia
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patients with a coagulopathy. The major sites of 
spontaneous bleeding are shown below in Table 4.4.
Table 4.4: Sites of bleeding
Site of bleeding N
Gingival sulci 45
Guts around bite site 14
Fang marks 8
Haematemesis 8
Grazes 6
Epistaxis 2
50.5% of envenomed patients had 
unequivocal ptosis at admission, and 90.5% had ptosis 
at some time during their hospital stay (Plate 4.4). 
Only half of the patients who eventually developed 
restriction of eye movements or jaw opening showed 
these signs on admission. Dysarthria was a common sign 
which typically appeared along with other features of 
neurotoxicity. It was not always easy to discern 
dysarthria objectively, particularly when the patient’s 
first language was not pidgin English. Three patients 
were found to be hypotensive at admission before the 
administration of antivenom. None of these was in the 
group reporting collapse at the time of the bite. In 
all three cases, the blood pressure returned to normal 
following administration of intravenous fluids. Thirty 
five patients had a bradycardia of less than 60/minute 
during their admission, usually occurring at the same 
time as maximum neurotoxicity. Electrocardiograms which 
were done on some of these patients showed a sinus 
bradycardia often with septal T wave changes.
Fasciculation or vermicular movement was seen in 20 
patients (19%), most commonly visible in the skin
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overlying gastrocnemius but also overlying deltoids and 
pectoral muscles in some patients. This usually became 
evident around 10-20 hours after envenoming and lasted 
for up to 72 hours. Fasciculation always occurred in 
association with other signs of significant 
neurotoxicity, of sufficient severity in the majority 
of cases, for intubation and ventilation to be 
required.
H i .  Duration of admission and outcome
Table 4.5 shows a summary of major clinical events 
and outcomes of the patients in the study.
Table 4.5 : Summa,ry of clinical outcome
Survived 102/106 96 . 2%
Bled 54/105 51 .4%
Developed neurotoxicity 95/105 90.4%
Required intubation 60/105 57.1%
Required ventilation 49/105 46.7%
The mean duration of admission was 6.49 days, (SD 
3.53), median 6 days. Two patients, who were kept in 
hospital for treatment of previously undiagnosed 
pulmonary tuberculosis, were excluded from this 
analysis.
iv. Progression of neurotoxicity
The initial signs of neuromuscular paralysis were 
ptosis followed by external ophthalmoplegia, 
progressive peripheral weakness and involvement of 
bulbar muscles. The mean time of onset of signs of 
neurotoxicity was 8.2 hours (SD 6.6), range 0,5 to 22
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hours, with a median time of onset of 6.5 hours. In 60 
patients (57.1%), involvement of the bulbar musculature 
was sufficiently severe for them to require intubation. 
The median time of intubation amongst those requiring 
it, was 17 hours with a range of 5.3 to 55 hours. The 
median duration of intubation required was 88 hours 
with a range of 2 to 500 hours. Paralysis of 
respiratory musculature was sufficiently severe for 49 
patients (46.7%) to require mechanical ventilation. The 
median duration of ventilation required was 62 hours 
with a range of 6 to 500 hours. The prolonged 
intubation and ventilation in one patient is detailed 
below in conjunction with details of antivenom 
treatment. No association was seen between the 
patient’s weight and the severity of neurotoxicity.
Sequential grip strength readings showed a 
decline beginning around 10 hours and typically 
reaching nadir values at around 20-25 hours after 
envenoming. The rate of recovery was fastest in those 
with least severe clinical neurotoxicity. In patients 
who required intubation and ventilation, grip strength 
readings began to increase on the 4th or 5th day after 
envenoming and reached maximal attainable values for 
each individual between 2 to 3 weeks after envenoming.
A typical trace is shown in figure 5.6 together with 
CMAP amplitude readings taken at the same time.
V. Autonomic function
All 105 patients in the series who were tested, had 
normal direct and consensual light reflexes and normal 
accommodation. All 9 tested had normal ciliospinal 
reflexes. Seven patients who received intravenous 
atropine had an increase in heart rate with a mean 
maximum increase of 28 beats per minute, range 6-46. 
Eight out of 9 patients showed an increase in systolic
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blood pressure in response to head down tilt of 30 
degrees with a mean increase of 8.8mmHg, range 4- 
1OmmHg. The 9th patient showed a decrease in systolic 
blood pressure of 15mmHg. Eight out of nine patients 
showed a mean increase in diastolic blood pressure in 
response to head down tilt, with a mean increase of 
8mmHg, range 3-1OmmHg. One patient, whose systolic 
pressure had increased following head down tilt, showed 
a fall in diastolic blood pressure of 6mmHg. Changes in 
RR intervals were variable. RR intervals decreased in 5 
patients after tilting with a mean decrease of 0.11 
seconds. RR intervals increased in 4 patients with a 
mean increase of 0.05 seconds. Responses to carotid 
sinus massage were also variable. 3 patients showed an 
increase in RR interval varying from 0.04 to 1.28, 3 
patients showed no change and 3 patients showed a 
decrease in RR interval ranging from 0.03 to 0.12 
seconds.
vi. Complications and deaths
Six of the 60 patients who required intubation 
developed pneumonia during the course of their hospital 
stay. In two of these there were signs suggesting 
aspiration before admission. In all cases, signs 
resolved after treatment with antibiotics. Four 
patients had prolonged stridor after extubation. One of 
these patients required reintubation and later 
developed tracheal stenosis requiring a tracheostomy. 
This patient had been intubated with a rubber 
endotracheal tube at a time when no plastic tubes were 
available in the hospital. Two patients developed 
marked periorbital oedema. In one patient (see Plate 
4.6) this appeared to be part of an antivenom reaction. 
Conjunctival oedema was relatively common in ventilated 
patients but did not produce lasting problems. One
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patient developed thrombophlebitis from a drip site 
infection. This responded to antibiotic therapy.
Four patients died in this series of 106 
patients (3.8%). A three year old boy died after a 
respiratory arrest during a difficult intubation. A 17 
year old girl was moribund on arrival at the hospital 
after a respiratory arrest and could not be 
resuscitated. An elderly man with concomitant pulmonary 
tuberculosis, died suddenly in the ward after an 
apparent recovery from neurotoxicity requiring 
intubation and ventilation. The fourth patient, a 15 
year old girl who did not receive antivenom because 
none was available at the time, could not be weaned 
from the ventilator, developed pneumonia and died 21 
days after admission.
vii. Sequelae
Forty eight patients (47% of survivors) attended 
follow up appointments which were between 2 and 3 weeks 
after the time of the bite. Seventeen of them had 
clearly defined loss of sensation around the bite site, 
usually extending in all directions over an area of up 
to 100 square centimetres (see Plate 4.5). All 
modalities were affected. There was gradual recovery of 
sensation in the few patients who were followed up for 
longer intervals over the following weeks. No sensory 
abnormalities were detected distant to the bite site. 
Two patients had marked persistent muscle weakness at 
follow up and were unable to squat. Maximal grip 
strength was regained between 12 and 20 days in the 
majority of patients who had significant neurotoxicity 
(see Figure 5.5). Two patients had persistent minor 
swelling at the bite site. No patients were seen with 
serum sickness. No patients reported noticing any 
change in their sense of taste or smell following
Plate 4.5 Local sensory loss around bite site. (Site of fang marks indicated)
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envenoming. Taste was specifically tested in 10 
patients both during their admission and at follow up 
and all could discriminate between sweet (sugar), salt, 
bitter (quinine) and sour (vinegar).
3. Laboratory results
i. Biochemistry
The mean maximum creatinine recorded in 
91 patients was 150umol/l with a median of 120 and a 
range of 80-999umol/l (normal range 50-120umol/l).
Renal function returned to normal during the course of 
admission with conservative management in all patients. 
Sixty five patients had urinalysis performed on a 
sample of urine at admission. Fifty five of these had 
proteinuria (85%), Haematuria or haemoglobinuria was 
detected in 47 (72%). Microscopy was performed on 19 
admission urine samples and 10 of these contained 
granular casts and white cells.
The mean creatinine kinase level recorded in 70 
patients was 724 IU/1 with a median of 369 and a range 
of 33-4330 IU/1 (normal range 0-243IÜ/1). Lactate 
dehydrogenase levels were measured on 17 patients. The 
mean maximum recorded was 345IÜ/1, median 360, range 
51-513IU/1, (normal range 120-230IU/1). Aspartate 
transaminase levels were measured on 83 patients. Mean 
levels were 69 U/1, median 49 U/1,range 11-433 U/1 
(normal range 5-50U/1).
ii. Haematology
The results of haematological 
investigations from 87 patients are shown below in 
Table 4.6
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Tabl,e 4.6 : Routine haematgl  in enyengmed patients
Median Mean Range
Admission Hb (g/dl) 13.0 13.0 7.2-17.8
Nadir Hb (g/dl) 11.7 11.7 5.4-16.4
Admission WCC(109/1) 11.4 12.5 4.5-27.1
Admission Platelets(10^/1) 1 69 1 78 47-466
Nadir Platelets (10^/1) 149 1 60 71-272
iii. Coagulation studies
The twenty minute whole blood clotting test was 
abnormal in 81 of 104 clinically envenomed patients 
(77.9%). The test was normal in all 100 clinically non­
envenomed patients.
Detailed coagulation studies were not carried out 
specifically as part of this study although some of the 
patients included in this series did have assays of 
clotting factors performed. The results of studies of 
mechanisms of coagulopathy in Papuan taipan bite, which 
include these patients, are presented elsewhere^.
iv. Venom detection kits (VDKs)
VDK tests were done on a total of 42 patients from 
this series. The results are shown in Table 4.7 and 
refer to taipan venom unless specified.
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Table 4.7 : Venom detection kit results
LABORATORY VENOM ANTIGEN ASSAY 
Negative <18ng/ml >18ng/ml
VDK Positive 4 2 31
VDK Negative 4 1 0
VDK Positive for
different species 0 0 0
4. Antivenom treatment
i. Type of antivenom
Twenty patients were given antivenom at a health 
centre prior to referral to PMGH, of whom 17 received 
appropriate antivenom. Ten patients were given a second 
vial of antivenom at the hospital, either because the 
initial antivenom was considered inappropriate (1) or 
because signs of envenoming were progressing and 
adequate supplies were available to give a second vial 
(8). One patient was given a vial of death adder 
antivenom at the hospital because he had neurotoxic 
signs without coagulopathy and envenoming by a death 
adder was considered a clinical possibility which had 
not been covered by the initial treatment of taipan 
antivenom. No polyvalent antivenom was available in 
PMGH at the time. There were occasions during the study 
when no antivenom was available in the hospital, or 
when the clinically most appropriate antivenom was not 
available. The median time of administration of the 
first vial of antivenom at either hospital or health 
centre was 5.5 hours, range 0.75 to 76 hours. Table 4.8 
shows the antivenom treatment given to the 106 patients 
in the series.
Table 4.8 : Type of antivenom given
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First AV Second AV No. Patients
Polyvalent 
Polyvalent 
Polyvalent 
Taipan 
Taipan 
Taipan 
Black snake 
Black snake 
Death Adder 
No antivenom given
Polyvalent
Taipan
Taipan 
Death Adder 
Polyvalent
53
4
1
26
3 
1 
1
4 
1
12
ii. Antivenom - adverse reactions and prophylaxis
The majority of patients receiving antivenom 
were given prophylaxis to minimise the risk of 
antivenom reactions. The regimes given varied and are 
detailed below. Minor early antivenom reactions 
occurred in 10 patients, 10.8% of those given 
antivenom. Seven of these patients had received 
polyvalent antivenom, 3 had been given taipan 
antivenom. Eight of the patients with antivenom 
reactions had urticaria and pruritus, one of whom 
developed facial and periorbital swelling (Plate 4.6). 
Two patients became agitated and developed a 
tachycardia during administration of antivenom but did 
not complain of pruritus. No severe anaphylactic 
reactions occurred. All patients with minor reactions 
were given intravenous hydrocortisone and all except 
one were able to complete antivenom treatment. No 
patients required adrenaline.
Plate 4.6 Conjunctival and periorbital oedema in early antivenom reaction
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Table 4.9 shows the prophylaxis given to the 93 
patients who were given antivenom, either at the health 
centre or at the hospital. The number of patients who 
had a minor antivenom reaction (AYR) is shown.
Table 4.9 : Antivenom reaction prophylaxis
Prophylaxis N o ,. Patients AYR
Promethazine alone 74 8
Promethazine + hydrocorti sone 1 0 1
Promethazine + adrenaline 1 0
Hydrocortiso ne alone 3 0
No prophylax is 4 1
Unknown 1 0
5.The efficacy of antivenom
The following section analyses various measures of 
efficacy and the time post envenoming at which 
appropriate antivenom was given. It is assumed that the 
effect of one vial of polyvalent antivenom is 
equivalent to one vial of taipan antivenom, both 
contain 12,000 units of taipan antivenom.
i. Antivenom, survival and outcome
Table 4.10 shows the proportion of patients who 
survived, the proportion who required intubation and 
mechanical ventilation and the mean length of admission 
for patients receiving antivenom (AV) and those who 
received either no antivenom, or inappropriate 
antivenom (4).
81
Table 4.10 : Antivenom and outcome
AV No AV
Survival 88/89 (99%) 14/16(88%)
Intubated 54/89 (61%) 6/16(38%)
Ventilated 44/89 (49%) 5/16(31%)
Mean (median) length admission 6.6(6.0) 5.5(5.0)
Figure 4.1 shows plots of progressive grip 
strength recordings from 10 typical patients with 
advanced neurotoxicity, 5 of whom received antivenom 
and 5 of whom did not. Each point indicates the 
percentage of the maximum grip strength recorded in 
each patient, whether at admission or following 
recovery.
ii. Antivenom, coagulopathy and bleeding
Table 4.11 shows the proportion of patients in each 
group who had coagulopathy and bleeding manifestations 
at admission. It also shows the time after antivenom 
(or admission in those who did not receive antivenom) 
at which samples from patients with incoagulable blood 
at admission was noted to clot. Seven patients in the 
AV group were given fresh frozen plasma, in three cases 
this was due to persistent bleeding after admission, in 
the other four as a precaution because of significant 
bleeding which had occurred prior to admission. Two 
patients who had not received antivenom were given FFP. 
No patient in the group who did not receive antivenom 
had significant bleeding after admission.
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Fig.4.1 showing the recovery in peripheral grip strength in patients who did 
and did not (broken line) receive antivenom. All patients had neurotoxicity
of stage IV or V.
LENGTH OF ADMISSION (DAYS)
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Fig. 4.2 Mean length of admission in patients grouped according to the time after envenoming at which antivenom was given. Two groupings are shown for comparison.Figures within columns indicate number of patients. Mean time of first AV in 2AV group 7.0 hours.
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Table 4.11 Antivenom and cpagulppath^
AV No AV
Non-clotting at adm. 76/88 (86%) 5/16 (31%)
Bleeding at or after adm. 51/89 (57%) 3/16(19%)
Clotting by 6 hours 17/29 (58.6%) 0/2
Clotting by 12 hours 26/29 (89.7%) 0/2
iii. Time of antivenom and outcome.
Figure 4.2 shows the number of patients 
receiving appropriate antivenom at different times 
after envenoming and the mean length of hospital 
admission.
Figure 4.3 shows the proportion of patients 
requiring intubation compared with the time after the 
bite at which they received antivenom. Two groupings of 
time of receiving antivenom are shown for comparison. 
Figures are also included for the small number of 
patients who received two vials of appropriate 
antivenom. In this group, the mean time of receiving 
the first of the two vials of antivenom was 7 hours.
The median length of intubation is shown for those 
patients who required it. Of 16 patients who did not 
receive antivenom, 6 required intubation.
Table 4.12 shows the relationship between the time of 
receiving antivenom and either developing neurotoxicity 
for the first time or having signs of neurotoxicity 
which progressed after treatment. The proportion of
NO.OF PATIENTS MEDIAN LENGTH OF INTUBATION (HRS)
No. PATIENTS
No.IN TUBATED 
L L N U IH  INTUB
< 3 3-6 6-9 >9 2 AV 0-2 2-4 4-6 6-8 >8
TIME OF ANTIVENOM (HOURS)
Fig 4.3 The proportion of patients requiring intubation in groups of patients 
receiving antivenom at different times post envenoming,
Two separate groupings shown for comparison,
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Fig.4.4 Scatter plot of time of receiving antivenom and the length of intubation required in those patients who progressed to stage IV or stage V neurotoxicity.
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Fig. 4.5 Scatter plot showing time of receiving antivenom and the length of time after envenoming to complete resolution of eye signs of neurotoxicity.
TIME OF i AV NUMBER OF I PATIENTS I DEVELOPING NEUROTOXICITY AFTER AV DETERIORATING POST AV ; NO ' PROGRESSION
0-2 11 0 7 (64%) 4 (36%)
2-4 21 ; 11 (52%) 6 (29%) 4 (19%)
4-6 16 7 (44%) 6 (38%) 3 (18%)
6-6 ; 13 , 5 (39%) 7 (64%) 1 ( 7%)8-10 ; 10 3 (30%) 5 (50%) ' 2 (20%)
>10 ; 15 0 11 (73%) 4 (27%)
Table 4,12 showing the time of receiving antivenom and the proportion of 
patients who developed neurotoxic signs or showed a deterioration 
of existing neurotoxicity.
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patients receiving antivenom in each time group who did 
not deteriorate is shown.
Figure 4.4 is a scatter plot showing the time of 
receiving antivenom and the length of intubation 
required.
Figure 4.5 is a scatter plot showing the time of 
receiving antivenom and the time to complete recovery 
of ophthalmoplegia.
Tables 4.13 and 4.14 shows the relationship between 
the time of receiving antivenom and the time to start 
recovery and to complete resolution of neurotoxic eye 
signs. For comparison, two groupings of time of 
receiving antivenom are shown.
TIME OFANTIVENOM (HRS) NUMBER OF | PATIENTS ! HOURS TO COMMENCE NEURORESOLUTION HOURS TO COMPLETE NEURORESOLUTION 10-2 4 ! 34.0 (31) 95.4 (94.5) j2-4 14 ! 41.0 (44) 74.3 (70) 14-6 15 46.9 (48.3) 120.7(116.8) i6-8 11 47.0 (43.9) 124.5(116.9)8-10 8 46.9 (41) 118.3 (116)>10 14 51,8 (51) 122,9 (119)
NO ANTIVENOM 9 41.1 (37) 106 (102)2 VIALS AV 9 49.9 (49) 103.2 (98.5)
Table 4.13 showing the time from envenoming to the onset of recovery and complete resolution of neurotoxicity in groups of patients given antivenom at different times. Only patients in whom accurate estimates could be made are Included. Median times shown in brackets.
TIME OFANTIVENOM (HRS) NUMBER OF PATIENTS HOURS TO COMMENCE NEURORESOLUTION HOURS TO COMPLETE NEURORESOLUTION
0-3 12 37,3 (39) 71.6 (68)
3-6 20 46.4 (48) 106.6 (108)
6-9 17 46.6 (45) 116.2 (110)
9-12 5 56.1 (45) 115.2 (110)
>12 11 49.1 (42) 124.4 (118)
Table 4.14 showing similar data to Table 4.13 with time of antivenom divided into 3 hour brackets.
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CHAPTER 5 - RESULTS OF ELECTROPHYSIOLOGIGAL STUDIES.
The results of the electrophysiological studies in 
both control and clinically envenomed patients are 
shown in the form of tables and figures.
i. Control studies
Figure 5.1 shows the results of median and 
ulnar nerve conduction studies in fit Melanesian 
controls.
ii. Motor and sensory studies in envenomed patients
Figure 5.2 shows the results of median and 
ulnar nerve conduction studies from envenomed patients. 
All had obvious neurotoxicity, all were intubated and 
the majority were also ventilated. Sequential studies 
were done throughout the clinical course in all 
patients; the values used in this table are taken from 
studies performed at the stage of maximal clinical 
neurotoxicity.
ill. Sequential studies in envenomed patients
Figure 5.3 shows sequential compound muscle action 
potential (CMAP) amplitudes from six patients recorded 
after stimulation of the ulnar nerve at the wrist and 
recording over abductor digiti minimi. These are 
typical of the shapes of curve seen in all the 
envenomed patients studied.
Figure 5.4 shows sequential CMAP values from the 
same six patients in Fig 5.3 after stimulation of the 
median nerve at the wrist and recording over abductor 
pollicis. These traces are also typical of those seen 
in the rest of the patients studied.
Median Nerve 
Ulnar Nerve 
Median Nerve (S) 
Ulnar Nerve (S)
F Wave (Ulnar)
N:
51
51
50
50
46
MEAN 
CV (M/S)
60.0
63.8
58.2 
56.0
26.2
2SEM
MEAN CMAP/ 
SNAP 2SEM
1.0 9.8mV 0.7
1.3 8.7mV 0.8
1.6 43.0uV 1.6
2.3 23.4uV 4.5
0.9
Fig 5,1 showing values of motor and sensory nerve conduction velocities 
and amplitudes of Compound Muscle Action Potentials (CMAP) and Sensory 
Nerve Action Potentials (SNAP) in Melanesian controls (age range 14-60),
N - MEAN CV (M/S) 2SEM
MEAN CMAP 
or SNAP 2SEM
Median Nerve 24 59.0 2.2 2.1mV 0.6
Ulnar Nerve 24 58,8 2.4 2.5mV 0.7
Median Nerve (S) 16 55.4 3.1 30.7uV 4.7
Ulnar Nerve (S) 16 55.4 3.1 13.1uV 3.4
F Wave (Ulnar) 16 26.1 0.9
Fig 5.2 Motor and sensory nerve conduction velocities and CMAP and SNAP 
amplitudes in envenomed patients with stage 4 or 5 neurotoxicity.
(Age range 16-55)
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Fig 5.3 Sequential CMAP amplitudes recorded in abductor digiti minimi 
after stimulation of the ulnar nerve. All 5 patients required ventilation.
CMAP (mV)
0 100 200 300 400 600 600 700
HOURS POST ENVENOMING
Fig 5.4 Sequential CMAP amplitudes recorded in abductor pollicis after 
stimulation of the median nerve. Studies from same patients as figure 5.3.
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Figure 5.5 shows sequential grip strength readings 
from the same six patients. Each value is the mean of 
three measurements using a hand held dynamometer.
Figure 5.6 shows sequential studies of CMAP 
amplitudes recorded after stimulation of ulnar and 
median nerves from a single envenomed patient (S4193). 
Grip strength recordings are plotted on the same graph 
to show the correlation between the two.
Figure 5.7 shows the first section of Figure 5.6 
in more detail with clinical events marked. At the time 
of discharge, the patient still had marked peripheral 
weakness and reduced GMAPs, both of which gradually 
improved over the following weeks.
iv. Repetitive nerve stimulation studies
Figure 5.8 shows the results of repetitive nerve 
stimulation tests in controls and envenomed patients 
with grade 4 or 5 neurotoxicity (ie. intubated +/- 
ventilated). Incremental or décrémentai changes are 
calculated by dividing the amplitude of the 4th or 9th 
CMAP in a chain of 9 by the amplitude of the first.
This is expressed as a percentage and the table shows 
the mean values for control and envenomed groups. The 
significance of the observed differences between the 
two groups was calculated using the unpaired t-test.
Figure 5.9 shows the results of repetitive nerve 
stimulation studies performed after a high frequency 
stimulus of 50Hz for 5 seconds. Differences are shown 
between the calculated increment or decrement between 
the 1st and 9th CMAP in a train. In addition, the 
difference in the amplitudes of the 1st CMAP in the 
pre-tetanic train and the 1st CMAP in the post tetanic 
train are shown.
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Fig 5.5 Sequential grip strength readings from patients 
shown in Fig.5.3 and Fig.5.4
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Fig 5.6 The relationship between CMAP amplitudes and 
grip strength readings in patient S4193 throughout clinical course.
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Fig 5.7 Sequential CMAP and grip strength readings in patient 84193. 
Patient admitted and antivenom given 6 hours after envenoming.
Clinical events marked,
CONTROLS
N=22
ENVENOMED PATIENTS 
N=1G (STAGE IV/V)
MEAN CHANGE 
CMAP 9/1
104.2%
92.5%
p<0.0001
95% Confidence limits 
for mean
102,5-105,9%
88.5-96,5%
Fig.5.8 Changes in CMAP amplitude during a train of 9 stimuli at 3 Hz 
in control patients and in envenomed patients with significant neurotoxicity.
POST-TETANIC CMAP 9th/1st 95% Confidence limits for mean POST TETANIC. 1st/ PRE-TETANIC.1stCONTROLS 106.5% 104.6-108.4% 103 %N=15
ENVENOMED PATIENTS 66.7% 51.9-81.4% 174 %N-9 (STAGE 4/5) 1
p<0.0001 p<0.0001
Fig.5.9 The effect of 5 seconds stimulation at 50hz on a subsequent train of 9 stimuli 
at 3Hz. and the relationship between the amplitude of the first post tetanic CMAP and
the initial pre-tetanic CMAP
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Figure 5.10 shows a typical décrémentai response 
at rest in abductor digiti minimi after repetitive 
stimulation of the ulnar nerve at 3 Hz. Subsequent 
recordings show the response following repetitive 
stimulation after sustained exercise of the muscle.
V. Needle electromyography
Insertional activity was normal in all patients 
studied. Recruitment was markedly reduced, maximally in 
patients at peak neurotoxicity with gradual improvement 
thereafter. Patients studied at follow up 10-14 days 
after envenoming still had reduced recruitment patterns 
but the morphology of the motor unit action potentials 
appeared normal. Spontaneous activity was seen in 
several muscle groups during the first 12-72 hours 
after envenoming. The most frequent abnormalities were 
fibrillation potentials and positive sharp waves and 
occasional fasciculation potentials were also seen. 
These abnormalities were most pronounced in association 
with clinically evident fasciculation which was seen in 
20 patients, most commonly in gastocnemii but also 
occasionally in deltoids and pectoral muscles. 
Limitation of jaw opening was a common early sign seen 
in 37% of patients. Needle studies in the masseter 
muscles of 3 of these patients showed fibrillation 
potentials and positive sharp waves but no evidence of 
complex repetitive discharges.
INTERVENTIONS IN THE MANAGEMENT OF NEUROTOXICITY.
1. The effect of edrophonium in envenomed patients
Table 5.1 shows the mean and median percentage 
changes in CMAP amplitudes recorded in 11 patients 
following an intravenous dose of edrophonium or saline.
At Rest:
After Exercise:
5 secs
30 secs
5 mins
30 mins
1 mV
Fig. 5.10 showing CMAPs recorded in abductor digiti minimi aftei 
repetitive stimulation of the ulnar nerve at 3 Hz.
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The probability values that the observed differences 
occurred by chance are shown. Table 5.2 shows similar 
data for grip strength recordings from the same 
patients. Figures 5.11 and 5.12. show the change in 
CMAP amplitude recorded after intravenous edrophonium 
and placebo. Figures 5.13 and 5.14 show the results of 
sequential grip strength measurements after edrophonium 
and placebo respectively.
Table 5.1 : Mean and median changes in CMAP amplitudes
after edrophonium
Median values in brackets, n=11.
TIME (mins) EDROPHONIUM PLACEBO p value*
T4 9.0% (8) -0.5% (0) 0.001
T9 17.7% (15) -0.5% (0) 0.001
T1 4 12,1% (5) -0.5% (0) 0.004
T1 9 10.7% (8) -0.4% (0) 0.001
T24 7.7% (4) -1.0% (0) 0.005
Table 5.2 : Mean and median changes in grip §..trength
after edrpphon
TIME EDROPHONIUM PLACEBO p value*
T4 5% (0) 0.1% (0) 0.8
T9 2.8% (0) -1.6% (0) 0.94
T1 4 6.9% (4) -5.8% (0) 0.04
T1 9 2% (0) -6.4% (0) 0 . 26
T24 2.2% (0) -6.4% (0) 0.22
* p value calculated using paired t-test.
In the majority of patients edrophonium produced a 
small but measurable increase in the amplitude of the
THE EFFECT OF EDROPHONIUM IN TAIPAN ENVENOMING
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Fig 5.11 The effect of lOmg edrophonium on CMAP amplitudes recorded 
from abductor digiti minimi after stimulation of the ulnar nerve (n -11 ).
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Fig 5.12 Sequential CMAP amplitudes after placebo.
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Fig 6.13 Grip strength follow ing intravenous edrophonium (10mg).
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Fig 5.14 Grip strength after placebo.
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CMAP measured over abductor digiti minimi. This was 
maximal around 9 minutes after the injection of the 
drug and was typically of the order of 15% (range -4% 
to 56%). Increases in CMAP amplitude were not generally 
seen in the placebo group. The difference between the 
active drug and placebo groups was significant up to 
and including T24. The majority of patients also showed 
a marginal increase in grip strength after edrophonium, 
mean increases are shown in Tables 5.2. Increases were 
also seen in some patients after receiving placebo and 
the difference between the two groups was not 
significant except at T14. In 3 patients there was a 
small increase in the range of eye movements after 
edrophonium. No change was seen in any patients after 
placebo. No improvement in the degree of ptosis or in 
the maximal extent of mouth opening was recorded in any 
of the 11 patients after either active drug or placebo.
Side effects
No side effects were observed or reported.
2. The effect of 3,4-diaminopyridine
Table 5.3 shows the mean and median changes in 
CMAP amplitude recorded after 10 mg 3,4-DAP and after 
placebo. Table 5.4 shows the mean and median changes in 
grip strength after active drug and placebo.
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Table 5 .3: Mean and median changes in CMAP amplitude
after 3,4-DAP (n= 12/6)
TIME 3,4-DAP PLACEBO p value*
T5 2.8% (3.5) -0.8% (0) 0.28
T1 0 5.4% (4.8) -3.7% (-4) 0.008
T1 5 6.5% (5) -3.3% (-3.5) 0.005
T20£ 6.4% -3.6%
T30 6.0% (9) -4.7% (-5.5) 0.07
T45 2.0% (4) -4.4% (-4) 0.04
£ only 6 and 5 readings respectively at T20.
Table 5.4 : Changes in grip strength after 3,4-DAP
TIME 3,4-DAP PLACEBO p value*
T5 5.5% (3) 3.0% (0) 0.58
T10 10.6% (0) 4.6% (0) 0.43
T1 5 12.1% (8) 4.6% (0) 0.09
T30 13.1% (6) 5.4% (0) 0.44
T45 10.6% (2) -0.8% (0) 0.31
* p values calculated using unpaired t-test.
Figure 5.15 shows the percentage changes in CMAP 
amplitude after 10 mg of 3,4-diaminopyridine. Figure 
5.16 shows the responses in the same patients after 
placebo. Figure 5.17 and Figure 5.18 show the results 
of sequential grip strength measurements.
The results of both CMAPs recorded in abductor digiti 
minimi and muscle grip strength after both 3,4-DAP and 
placebo were variable. The general trend was a small 
increase in amplitude recorded after active drug and 
also a small increase in grip strength. Neither was
THE EFFECT OF 3,4 DAP IN TAIPAN ENVENOMING
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Fig 5.15 The effect of lOmg 3,4-diaminopyridine on CMAP 
amplitudes recorded from abductor digiti minimi.
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Fig 5.16 Sequential CMAP amplitudes after placebo
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Fig 5.17 Grip strength after lOmg 3,4-DAR
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Fig 5.18 Grip strength after placebo.
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impressive or uniform and the variation of the 
responses recorded was high. There was a difference in 
the amplitude response between the active drug and the 
placebo groups reaching significance between TIG and 
T30. There were patients in both groups whose grip 
strength improved and ranking of the responses showed 
no evidence of a significant difference between the two 
groups. In general, patients given placebo showed 
little change in either variable although one patient 
showed some improvement in grip strength in successive 
readings raising the suspicion of a learned response.
It was noticeable however that those patients with 
initial unrecordable grip strength (ie. reading 0 
dynes) did not show any improvement after either active 
drug or placebo. One patient showed a marginal increase 
in eye movements 10 minutes after injection of 3,4-DAP 
but in the other 11 there was no change in either 
degree of limitation of eye movements, degree of ptosis 
or jaw opening. Maximal inspiratory pressures were 
recorded in one patient who was intubated and 
ventilated. No changes were noted after either active 
drug or placebo.
Side effects
At the end of each test, the patient was asked 
about any symptoms occurring following injection of 
"the drug". Several patients reported transient 
discomfort along the site of the vein and all of these 
had been given active drug. Three patients reported 
perioral and peripheral paraesthesia around 5 minutes 
after injection, and several patients reported 
flushing, increased salivation and increased sweating. 
In 2 patients this was visible to the investigator. All 
3 patients had been given active drug. No symptoms were 
reported from patients given placebo. One patient
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needed to pass urine within minutes of receiving 3,4- 
DAP on two occasions. This did not occur on the 
occasion when she was given placebo. Widespread 
fasciculation was seen in one male patient, 
predominantly involving deltoids, pectoral muscles and 
gastocnemii. No EGG changes were detected after 
administration of the drug except for an increase in 
heart rate which was attributed to the administration 
of atropine.
3. The effect of edrophonium and 3,4-diaminopyridine 
in combination.
Table 5.5 shows the mean and median increases in CMAP 
amplitude after administration of 10 mg 3,4-DAP and 
1Omg edrophonium. Controls quoted for comparison are 
the patients given saline in the second section of the 
trial. The percentage changes in CMAP amplitude 
measured in patients given the combination of 3,4-DAP 
and edrophonium are shown in Figure 5.19.
 5.5 : Mean and median changes in CMAP amplitude
after 3 ,4-DAP and edrophonium. (n=10/6)
3,4-DAP/Edro PLACEBO p value*
T5 4.6% (4) -0.8% (0) 0.13
T10 10.2% (5) -3.7% (-4) 0.05
T15 19.3% (9) -3.3% (-3,5) 0.002
T20 16.8% (13) -3.6% (-3) 0.013
T30 17.6% (13) -4.7% (-5.5) 0.002
T45 15.9% (13) -3.8% (-4) 0.04
T60 16.7%
T90 15.5%
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Fig, 6,19 Sequential CMAP amplitude measurements after 
10mg 3,4-DAP followed by 10mg edrophonium at 7 minutes (n = 10).
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Fig 5,20 Sequential grip strength measurements after 
lOmg 3,4-DAP followed by 10mg edrophonium at 7 minutes.
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Table 5.6 shows the mean and median changes in 
grip strength after administration of 1Omg 3,4-DAP and 
1Omg edrophonium. Figure 5.20 shows the results of 
sequential grip strength recordings in the 9 patients.
Table 5.6 : Changes in grip ...strength af ter 3 , 4-pAP and
.9 .P .h .P .n .ium  (n=9~/6)
3,4 DAP/Edro. PLACEBO p value
T5 5.5% (1) -0.8%(0) 0.94
T10 33.8% (22.5) -3.7%(-4) 0.01
T1 5 38.8% (27.5) -3.3%(-3.5) 0.01
T20 39.5% (22.5) -3.6%(-3) 0.01
T30 28.5% (21.5) -5.1%(-7) 0.04
T45 20% (10) -3,7%(-3.5) 0.03
T60 18%
T90 8%
'' p values calculated using unpaired t-test.
The calculated mean values in table 5.6 excludes 
one set of grip strength readings from a patient who 
showed a profound increase in grip strength from a very 
low initial average of 1.3 dynes to a maximum average 
of 7.7 dynes, an increase of over 400% after receiving
3,4-DAP and edrophonium. Whilst this increase appeared 
real, it would clearly bias the numerical values of the 
averaged data dramatically. A second dose of both drugs 
in the same patient also produced an impressive 
increase but to a lesser degree, from an initial 
average of 4 dynes to a maximum of 9.7 dynes. The 
results of CMAP and grip strength measurements made 
after doses of 3,4- DAP and edrophonium 27 and 46 hours 
after envenoming in this patient are shown in Figure 
5.21 and Figure 5.22. These were the largest percentage 
responses seen in any patient.
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Fig 5.21 Sequential measurements of CMAP amplitude and muscle grip strength in patient S3693 after lOmg 3,4-DAP and edrophonium at 7 minutes.Study performed 27 hours after envenoming, clinical stage IV.
AMPLITUDE (MV) GRIP STRENGTH (dynes)6
5
4
3
2
1 -- AM PL.48 
MGS48
0 9070 80605030 40201
TIME POST DOSE (mins)
Fig 5.22 Similar recordings In same patient 46 hours after envenoming
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Table 5.7 shows a comparison of the responses to a 
combination of 3,4-DAP and edrophonium and to 3,4-DAP 
alone from the studies reported above.
Table 5.7 : Mean chang e in grip strength and CMAP
amplitude after 3j4-DAP with and without edrophonium
GRIP STRENGTH AMPLITUDE
DAP/Edro 3,4-DAP P DAP/Edro 3,4-DAP P
T5 5.5% 5 . 5% 0 . 74 5.1% 3.2% 0.65
T1 0 33.8% 10.6% 0.06 10.2% 5.4% 0.6
T1 5 38.8% 12.1% 0.02 19.3% 6.7% 0.3
T30 28.5% 13.1% 0.28 17.6% 6.0% 0.29
T45 20.3% 10.6% 0.2 15.9% 2.1% 0.07
The combination of 3,4-DAP and edrophonium 
produced a measurable increase in both CMAP and muscle 
grip strength in the majority of patients to whom they 
were given. There was a correlation between the two 
responses, demonstrated in Figures 5.19 and 5.20. This 
response was significantly different from the responses 
seen in the saline control group at all times after T5. 
The size of the increases in both amplitude and grip 
strength in those patients who showed the biggest 
response was greater than in those who received 3,4-DAP 
alone. However when the two groups were specifically 
compared and ranked, there was only a significant 
difference in the grip strength responses at T15. In 
the majority of the study group, the maximal response 
in both variables was at around 10-20 minutes after the 
injection of the 3,4-DAP (8-13 minutes after the 
injection of edrophonium). One patient showed a very 
marginal improvement in eye movements from 10-30 
minutes after the injection of the drug. Another
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patient showed an improvement in the degree of ptosis 
from grade 3 to grade 2 between 10 and 45 minutes after 
the drug. Both of these patients showed an impressive 
increase in grip strength and GMAP amplitude at the 
same time. One other patient showed a convincing 
improvement in mouth opening, from a maximum inter­
incisor distance of 22mm initially to a peak of 31mm 
corresponding with the maximal grip strength 
improvement (20-25 minutes). No other patient showed 
greater than a 3mm variation in mouth opening at any 
time. Maximal inspiratory pressures recorded in one 
intubated patient appeared to show a minor improvement 
around 20 minutes. Repetitive stimulation tests were 
performed on 5 of the 10 patients. Stimuli were given 
every 5 minutes at 125% threshold at a frequency of 3 
Hz. There were minor variations between recordings but 
no trend emerged to show a significant change in the 
décrémentai response.
Side effects
There was a marked increase in oral secretions 
in 6 of the 10 tests requiring additional suction of 
the endotracheal tube or pharynx. Six patients felt hot 
and had a visible increase in sweating between 5 and 10 
minutes after the 3,4-DAP. Five patients complained of 
pain along the vein proximal to the injection site. One 
patient complained of perioral paraesthesia after each 
of three injections of the drug. Fasciculation was seen 
in 5 patients most obviously in deltoids, pectorals and 
gastrocnemii, but also involving other muscle groups. 
One patient needed to pass urine within minutes of the 
injection, another catheterised patient showed a marked 
increase in urine production soon after the active 
drugs were given.
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The patients included in the various intervention 
studies described in this chapter were studied at 
various clinical stages and at various periods of time 
post envenoming. The rate of progression of 
neurotoxicity varied considerably between patients. 
Figure 5.23 and Figure 5.24 show the maximal increases 
in amplitude recorded in each patient given an active 
drug and the time post envenoming (5.23) and the 
clinical stage at the time (5.24).
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Fig 6.23 showing the maximal recorded amplitude increase with each 
intervention and the time post envenoming at which study performed.
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Fig 5.24 showing the maximal recorded amplitude increase with 
each intervention plotted against clinical stage.
See appendix 3 for clinical staging.
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CHAPTER 6 - THE EPIDEMIOLOGY OF TAIPAN BITE 
1. Who gets bitten? When, where and why?
i.Incidence and mortality rates
Incidence rates of snakebite are calculated 
in different ways by different authors and it is 
difficult to compare the results of studies, both 
within Papua New Guinea and between different areas of 
the tropics. This study distinguishes between incidence 
rates of definitive envenoming and incidence of 
reported snakebite. Envenoming is defined as the 
presence of one or more unequivocal signs of systemic 
envenoming witnessed by the study team, including 
lymphadenitis, prolonged clotting, bleeding and 
neurotoxicity. The estimated incidence of envenoming 
and mortality rates for Central Province (55 and 
3.2/100,000) are underestimates of the true figures 
because they do not account for envenomed patients who 
were managed at health centres without referral to Port 
Moresby General Hospital (PMGH), or who died before or 
during referral. There were at least 8 patients who 
died before arrival at PMGH during the study period. If 
these patients are included in the calculation, the 
estimated rural mortality rate is almost doubled to 
6.1/100,000/year. By comparison, the mortality rate for 
snake bite deaths in the whole of Sri Lanka between 
1975 and 1979 was 5.3/100,0009 6 and in Myanmar was 
greater than 3.3/100,000/year in 198597.
All patients with suspected snakebite in the 
urban area of National Capital District (NCD) are 
referred to PMGH so the mortality and incidence figures 
(0.5 and 9.8/100,000/year respectively) are likely to 
be more reliable than those quoted for Central
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Province. These values are lower than those calculated 
by Currie (2.1 and 21.8/100,000)90 and lower than the 
calculated urban rate of envenoming found by Campbell 
(30/100,000)19 and Lalloo (15.5/100,000)%. The trend 
towards a fall in the number of reported snake bites in 
NCD over the past 30 years is almost certainly 
explained by the increased urbanisation of NCD and the 
disappearance of habitat. The estimated incidence rates 
quoted for all reported snake bites (envenomed and non­
envenomed) in the year May 1991-May 1992 are likely to 
be reasonably accurate for urban NCD but significant 
underestimates for Central Province. Relatively few 
non-envenomed patients are referred to Port Moresby 
from distant health centres and none of the patients 
managed at health centres alone are counted in the 
estimates. An analysis of health centre records 
suggested that the actual total number of bites from 
Central Province reported to the medical services 
between May 1991 and May 1992 was in the order of 200, 
an incidence of 140/100,000.
Figure 3.1 shows that there were also 
marked differences in the number of bites from 
different geographical areas of rural Central Province. 
No attempt has been made to estimate more localised 
incidence figures from these areas because there is 
insufficient information on variables such as local 
population numbers, population movements and locally 
reported bites to be able to calculate such figures 
with any accuracy.
ii. Biting species and area of bite
The areas where the 117 patients in this series 
were bitten are shown in Figure 3.1. With the exception 
of a single bite from the western edge of the Sogeri 
plateau (1100 feet above sea level), all the bites were
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from the low lying coastal belt of Central Province. 
Slater saw a live taipan at 8ogerii% and it is 
interesting to note the presence of a confirmed bite 
from this area in this series. It is clear that the 
Papuan taipan is by far the most important venomous 
species in Central Province and this may well have 
changed since the studies of Campbell in the early 
1960's when he believed the Papuan black snake to be 
the most common venomous snake in the area%7. Currie et 
al. drew attention to the fact that taipan bites had 
become much more common^o.^s and this is borne out by 
the findings of this study. During the two year study 
period, taipan bites accounted for 90% of all envenomed 
patients in whom a definitive diagnosis of biting 
species was made and a similar proportion of envenomed 
patients in whom venom antigen was detected. Papuan 
black bites are now extremely rare amongst snake bite 
admissions to PMGH, causing no definitive bites and 
only one "probable" bite, during the two years of the 
study. Because of the difficulty in establishing 
definitive diagnoses in earlier studies it is 
impossible to say with certainty to what extent the 
relative frequencies of bites by different species have 
changed, but the evidence certainly suggests that they 
have. In Campbell’s paper on patients envenomed by the 
Papuan black snake, only one of the 13 snakes 
responsible was definitively identified^?. His 
assertion that the characteristic red back of the 
taipan was sufficiently distinctive to be identified 
and described by the victim was not borne out by this 
series (see below).
One possible explanation for the apparent rarity 
of the Papuan black snake is that the decline in 
numbers is associated with the introduction of the cane 
toad {Bufo marinus) to Central Province in the 1940's. 
The toad was initially introduced to Queensland from
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South America in an attempt at biological control of 
the Grey Cane beetle whose larvae damaged the sugar 
cane crop. The toad secretes toxins from its neck 
glands which are toxic to snakes. Papuan black snakes 
and death adders both feed on amphibians whilst taipans 
do not9 9 and it may be that the decline in numbers of 
the former may have created an expanded ecological 
niche for the latter. The herpetofauna of Queensland 
appears to have changed significantly over the past 40 
years for the same reason^^. Four freshly killed 
specimens of Pseudechis papuanus were identified during 
the course of this study, two from Vaifa'a in the west 
of the province, one from Moreguina in the east and one 
from Wasur in eastern Irian Jaya. It is interesting 
that these are areas where the cane toad is currently 
either rare or absent. Whether this is coincidence or 
supporting evidence for the cane toad theory is open to 
conjecture. Other environmental changes such as 
deforestation and changes in population distribution 
may also have influenced the distribution of snake 
populations.
The Papuan black snake continues to have great 
mythological and cultural significance among the 
Mekeoioo, M o t u ^ 6 1 , 1 0 2 ^^d other coastal groups of 
Central Province. Taipans are usually dark in colour 
and both it and the whipsnake {Demansia spp,) are 
commonly mis-identifled as the Papuan black snake. Only 
one patient out of 117 in this series confidently 
identified the snake that bit him as a taipan. The 
majority of patients described a long black or brown 
snake and identified this as a Papuan black snake. 
Thirteen patients who noticed red colouration in the 
snake still believed that they had been bitten by a 
Papuan black. Even dead taipans, shown to groups of 
both rural and urban dwellers, were frequently mis- 
identif ied as Papuan black snakes. Some communities in
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Papua New Guinea and Irian Jaya make no distinction 
between the two species, either regarding them all as 
black snakes or as different sexes of the same snake, a 
belief reported from Western Provinceios and also 
related to me in two villages in south-eastern Irian 
Jaya. For the health worker treating the victim of a 
bite, the distinction between the two species is 
important and a patient's description of the biting 
snake as a Papuan black must be regarded with caution 
when selecting antivenom.
The use of immunoassays to identify 
retrospectively biting species allows a more rational 
approach to the use of antivenom than has previously 
been possible. At the time of writing, the Papua New 
Guinea Department of Health continues to buy black 
snake antivenom for distribution throughout Central 
Province (91 vials were purchased between January 1991 
and the end of March 1993, at a total cost of £36,832). 
From the results of this study, black snake antivenom 
appears to have no therapeutic role in the treatment of 
snakebite in Papua New Guinea. There is no evidence 
that black snake antivenom is of any value in the 
treatment of bites by other elapid snakes. The use of 
black snake antivenom may prevent patients receiving 
appropriate antivenom with potentially detrimental 
consequences. The misconception about the perceived 
over-riding importance of Pseudechis papuanus is likely 
to persist for some time despite attempts at education 
of health staff. If polyvalent antivenom, which 
contains both taipan and black snake antivenom, is 
always used in cases of suspected Papuan black bite 
instead of black snake antivenom, that misconception 
will be less dangerous. The simplest way to achieve 
this would be to stop distributing black snake 
antivenom and this recommendation will be made to the 
Papua New Guinea Department of Healthi64.
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iii. Age and sex of victim
There was a preponderance of male patients 
bitten in this series (64%), very similar to the figure 
of 62% found by Currie in his nationwide study of 
envenoming between 1987 and 19899 0. Campbell found a 
male to female ratio of 4:1 in the 1 960'si 9. Currie 
suggested that the proportional increase in the numbers 
of females bitten has been due to the change in the 
demography of patients admitted to PMGH, from a 
predominantly urban population, with male predominance, 
to a predominantly rural one with much less marked 
differences between the sexes. Males still seem to be 
at greater risk in both populations. The most obvious 
explanation for the greater frequency of bites in males 
is that it reflects the greater exposure of the male 
population to snake ridden areas, but there may be 
other factors. Some high risk activities such as 
hunting are almost exclusively male activities but 
others such as gardening and collecting wood are 
predominantly done by women. 46% of the women were 
bitten in the garden compared with only 16% of the men. 
Gardening is usually a collective activity for women 
and children and it may be that snakes are more likely 
to be disturbed and to flee from a noisy group than 
from a lone male walking through the bush. Snakes are 
more likely to be seen on well worn paths and in 
cultivated gardens than on overgrown bush tracks. Males 
may be more likely to display bravado when they see a 
snake and by attempting to kill or capture it, expose 
themselves to an increased risk of being bitten. At 
least 2 of the males in this series were bitten 
avoidably, whilst attempting to kill the snake. This 
study suggests that a combination of differential 
exposure and behavioural factors are relevant.
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The age distribution of patients was similar to 
that found by Currie^o, 24% of the patients were under 
the age of 15 compared with a figure of 25.9% in 
Currie's study. Over 80% of bites occured in patients 
between the ages of 11 and 45 during what might be 
considered as their independent, active and productive 
years. Currie found that the femalermale ratio 
increased in rural patients aged 30 years old and over, 
a result which he attributed to older women spending a 
greater proportion of their time working in the 
gardens. This was not borne out by the results of this 
study which, if anything, showed the opposite.
iv. Month and time of bite
Few Melanesians in rural areas wear watches so 
the times of bites given by patients must be regarded 
as loose approximations. Despite this, two reliable 
observations can be made, first that few bites occur 
outside daylight hours and those that do occur soon 
after nightfall; secondly, that the majority of bites 
occur in the middle of the day. The two factors which 
influence the distribution of the bite times are the 
activity of the human population and the activity of 
the snakes themselves. Taipans are typically diurnal 
and c r e p u s c u l a r  12 - 19 .  in this series, only 4.5% of 
bites occurred during the hours of darkness and all of 
these were just after dusk. In Madang Province, where 
the two major venomous land snakes (Micropechis ikaheka 
and Acanthopis spp) are more active at night, Hudson 
reported 33% of bites occurring after n i g h t f a l 1 1 65 . The 
majority of taipan bites occurred while the victim was 
engaged in activities related to subsistence farming. 
These included: working in a vegetable garden (a 
"garden" is typically a piece of cleared land which may 
be some distance from the village and often surrounded
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by uncleared bush); en route to or from a garden; 
collecting wood; hunting or even urinating in long 
grass. The majority of these are daytime activities. It 
is no surprise that the incidence of bites in the rural 
population was considerably higher than that of the 
semi-urban population of NCD, and appears to reflect 
the degree to which a given population is involved in 
"at risk" activities.
Rainfall may influence the number of patients 
bitten by snakes by affecting both human and snake 
behaviour. After rain, subsistence farmers work in 
their gardens while during long, dry spells they may do 
relatively little. The movement and activity of both 
snakes and the prey upon which they are feeding are 
also likely to be influenced by the availability of 
water sources, which could either increase or decrease 
their proximity to humans. There is a distinct wet 
season in Central Province, typically between December 
and March. Bell commented that taipans appear to be 
most active at the beginning of this periodios. The 
data shown graphically in Figure 3:4 suggests that 
there was little seasonal variation in numbers of bites 
during the two years of the study. Although there 
appear to be more taipan bites in the second year of 
the study, the total number of clinically envenomed 
patients was very similar. This suggests that this 
trend is due to a higher pick-up rate in venom antigen 
testing, perhaps due to better technique with taking 
swabs and aspirates or with the assay. There is some 
suggestion that periods of exceptionally high rainfall 
at any time of year were followed by higher bite rates. 
In 1992 however, after several exceptionally dry 
months, the incidence of all bites began to climb 
despite the continuing absence of rain. It is possible 
to hypothesize that this reflects the increasing 
necessity for snakes to proximate to human populations
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to find food and water. Although an anecdotal and 
unsubstantiated observation, we noticed that a heavy 
rainfall after a dry spell was commonly associated with 
the admission of several envenomed patients within a 
few hours. It seems likely that rain did cause an 
increase in the number of bites for the two reasons 
given above, but that there was little difference 
overall between wet and dry seasons. It is unclear 
whether other facets of snake behaviour which may be 
seasonal, such as breeding habits, have a significant 
influence on movement, feeding and the incidence of 
human bites.
V. Circumstances of the bite
The vast majority of victims of taipan bite 
are bitten below the knee whilst walking or working in 
long grass or an overgrown garden. Almost all victims 
were unshod, those who were wearing shoes were bitten 
above rather than through them. These observations are 
not surprising and were the same as the conclusions 
reached by Campbell^s and C u r r i e ^ o .  Although envenoming 
by an Australian taipan has been described which 
occurred following the penetration of fangs through a 
boots 1, it is probable that if the rural population of 
Central Province were supplied with, and wore, calf 
length boots in which to work, the number of 
envenomings would fall dramatically. Whilst this is an 
impractical proposition for the majority of the 
population, it would not be unreasonable to expect 
employers to supply boots to employees facing extensive 
exposure, such as those working on rubber plantations, 
coconut plantations and cattle ranches for example.
The vast majority of bites resulted from the 
victim inadvertently disturbing the snake at close 
quarters with one case where a patient was bitten after
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attempting to pick up the snake. This is consistent 
with Slater's description of the Papuan taipan as "a 
shy and retiring snake, preferring flight when 
encountered but if interfered with, defending itself 
readily"12. Twelve of the 51 patients in whom the 
number of bite site puncture wounds could be clearly 
distinguished, had more than two. It is impossible to 
say whether these wounds represent multiple bites. 
Campbell pointed out that some apparent "fang marks" 
may be wounds caused by the snake's palatine teeth or 
teeth of the lower jawis. There was no apparent 
association between the number of puncture wounds at 
the bite site in this series and the level of venom 
antigen subsequently detected in serum, swab or 
aspirate.
2. What happens after a bite?
i. Pre-hospital treatment
The delay which many patients experienced before 
arrival at a health centre and the further delay which 
occured at the health centre and during transfer to 
PMGH emphasises the importance of first aid measures.
In the bush, potentially harmful practices are still 
widespread. Tourniquets were used by nearly a third of 
the patients in this series, made from a variety of 
materials including grass, rope, pieces of rubber and 
cloth. The majority of these were not arterial 
tourniquets and did little damage but one 10 year old 
boy was seen during the study period who lost the use 
of a leg due to prolonged ischaemic injury (Plate 
3.2)95. Nineteen patients had incisions made around the 
site of the bite, usually with a razor blade, stone or 
piece of glass. Several patients with venom induced 
coagulopathy had prolonged bleeding from these cuts
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requiring treatment with pressure bandages after 
admission to hospital. Eight patients were admitted to 
hospital with pressure bandages applied to delay 
absorption of venom. Seven of these were referred from 
a health centre (6 referred by the same person), one 
patient had the bandage applied by a companion at the 
time of the bite. The majority of health centres did 
not apply pressure bandages, perhaps on the assumption 
that having given antivenom, there is no benefit in 
doing so. It might be argued that for patients who face 
a protracted journey to hospital, a pressure bandage 
should be applied whether or not antivenom has been 
given, in an attempt to continue to delay the 
absorption of venom. The value of pressure bandages in 
delaying the absorption of venom is still open to 
debate but the consensus seems to be to encourage their 
use at p r e s e n t  1 6 ?■1 69_ Por patients bitten in the rural 
tropics, where any increase in the "safety period" for 
a patient to reach hospital may be life saving, 1 
believe that there is a good rationale for continuing 
their use. Clearly further efforts need to be made to 
disseminate this message in Papua.
Only 20 of the 52 patients who presented 
initially to a health centre were given antivenom 
before referral to PMGH. The health centres frequently 
did not have antivenom in stock and this was why so few 
received it. Three of the 20 patients who were treated 
were given inappropriate antivenom. All were given 
black snake antivenom, an error which can be prevented 
by further education of health centre staff and by 
halting the supply of black snake antivenom. It is 
recommended that promethazine and adrenaline should be 
administered with a n t i v e n o m ^ ? . 88  ^ but this was not 
always done. The necessity of prophylactic adrenaline 
may be questionediio but at present, health centres 
administering antivenom should follow the guidelines
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issued in the standard treatment books which advocates 
its use8?.88. Several patients were admitted heavily 
sedated after inappropriately high doses of 
promethazine, a potentially dangerous situation in the 
presence of compromised gag reflexes and pharyngeal 
pooling of secretions 111. The recommended doses, 
accounting for body weight, should be adhered to.
ii. First point of contact
Slightly fewer than 50% of patients presented 
initially to a health centre before referral to PMGH 
and the majority of these were seen at one of only four 
health centres. The median time of arrival after the 
bite was slightly longer in patients presenting 
directly to hospital (2.75 hours) than it was in 
patients who presented at a health centre (2 hours). 
More significantly, the median time of arrival at PMGH 
of patients who had been seen initially at a health 
centre was 7.5 hours. It is believed that the earlier 
that antivenom is given, the greater the benefit the 
patient receives from it and the evidence from this 
study (see Chapter 7) suggests that antivenom is of 
maximum value if received within 4 hours of envenoming. 
It may not always be possible for all health centres in 
Central Province to stock antivenom, because of the 
cost of the drug and the necessity for a reliable cold 
chain. The four centres who see the majority of the 
patients however, (Bereina, Vaifa'a, Kwikila and 
Kupiano) clearly must have appropriate antivenom in 
stock at all times. These health centres should be 
targeted to improve early management of victims in 
their area and could be encouraged to exchange 
information with the hospital. This should include 
informing each health centre of the details of species 
biting in their catchment area, of the appropriate
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antivenoms to use and which patients to refer to Port 
Moresbyi12 . Simplification of antivenom prescribing 
policies will make this easier to achievei°^. Staff at 
all health centres should be encouraged to utilise 
existing radio links with PMGH to discuss the 
management of patients about whom any uncertainty 
exists.
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CHAPTER 7 “ CLINICAL ASPECTS OF TAIPAN ENVENOMING 
AND ANTIVENOM TREATMENT
1.Inclusion criteria
Admission to this study was on the basis of 
unequivocal clinical evidence of envenoming 
subsequently confirmed to be due to a taipan bite by 
the detection of irrefutable levels of taipan venom 
antigen. Levels of venom antigen in serum are very 
labile and were influenced by prior administration of 
antivenom and the time elapsed since envenoming. There 
was no clear association between levels of antigen 
detected and clinical outcome. Some patients had 
relatively high circulating levels of taipan venom 
antigen in their blood without clinical signs of 
envenoming including 15 of the clinically non-envenomed 
patients who had levels of serum venom antigen 
>18ng/ml. One possible explanation for the lack of 
correlation between the level of venom antigen and 
clinical signs of envenoming is that the main antigenic 
component of the venom is not one of the most 
clinically significant toxins. A second factor which 
may be relevant is that it is bound rather than 
circulating toxin which produces many of the clinical 
effects. The detection of venom at the bite site does 
not necessarily imply systemic envenoming, a factor of 
considerable importance for those using venom detection 
kits.
The main aim of the criteria used for inclusion 
of patients in this study was to guarantee unequivocal 
clinical envenoming by a taipan. Some background 
activity was detected in immunoassays in the serum of 
control subjects. This is taken into account with the 
cut-off levels chosen at greater than two standard 
deviations from the control mean to exclude false
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positives. Background activity is less likely to be a 
problem with swabs, aspirates and urine samples. Lower 
concentrations of venom antigen could probably be 
safely regarded as significant in these specimens, but 
in the absence of adequate control data to prove this, 
18ng/ml was used as a cut-off for all samples. The use 
of stringent defining criteria is likely to have 
produced an underestimate of the total number of taipan 
bites admitted to PMGH during the two years of the 
study but guarantees that those patients studied were 
bitten by taipans.
2. Clinical course of envenoming
i. Early symptoms and signs
The clinical findings of this series of 
taipan bites are consistent with the findings of Currie 
et al. and of those reported e l s e w h e r e i  - %>119 . Currie 
also identified his taipan bites on the basis of 
antigen detection in serum, bite site swab, aspirate or 
urine sample. He used an assay cut-off venom antigen 
level of 5ng/mli. A higher cut-off level has been used 
in this series based on findings in the control series 
(details above), Lymph node pain was present in 95% of 
envenomed patients seen by Currie, abdominal pain was 
reported by 80%, vomiting by 60% and headache by 75%. 
Clinical bleeding and/or prolonged clotting was seen in 
44% of patients and neurotoxicity in 81%. The main 
difference from Currie's series is that a higher 
proportion of envenomed patients had prolonged clotting 
(78% v.44%). It is interesting to note that the median 
time of onset of neurotoxic signs in both series was 
6.5 hours after envenoming, considerably later than 
that described by Senanayake et. al in their discussion 
of other elapid n e u r o t o x i n s i i 4 , i i s .  This emphasises the
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need to observe patients who claim to have been bitten 
by a snake, for a minimum of 12 hours before dismissing 
the possibility of envenoming.
17.6% of patients in this series collapsed within 
minutes of the bite, a similar proportion to the 24% 
reported by Currie. The mechanism of collapse is not 
clear. Fourteen out of 18 patients appeared to have 
recovered full consciousness by the time of admission 
to hospital with no indication of the cause of 
collapse, 3 others had evidence of cerebral insult and 
one evidence of a fundal haemorrhage. Possible 
explanations for the collapse include: vasovagal 
attacks, hypotension secondary to the effects of 
vasoactive components of venom or released endogenous 
mediators or seizures secondary to cerebral bleeding or 
thrombosis. Grand mal seizures were witnessed in one 
patient in this series and have been described 
following envenoming by other elapidsii&. It is quite 
possible that all three mechanisms might occur. In June 
1993, after the end of this series, a 14 year old boy 
was admitted to PMGH who had a cerebrovascular accident 
involving the middle cerebral artery which occurred 
within minutes of a taipan bitei1?. This may have been 
a thrombotic episode secondary to the action of the 
venom procoagulants or it may have been a spontaneous 
bleed.
Headache was a common and early feature of 
taipan envenoming in this series and has been described 
as a feature of envenoming by many Australasian 
elapidsiiG. The mechanism of the headache is intriguing 
and unexplained. The nature of the headache, the speed 
of onset and relatively short duration, suggest that 
the pathogenesis is related to a circulating venom 
component, perhaps through a direct or indirect 
vasoactive effect. The release of endogenous vasoactive 
substances by venom components has been described in
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association with other v e n o m s 11^ but whether taipan 
venom produces similar effects is unknown.
Limitation of jaw opening has been described by- 
several authors in association with taipan b i t e % > 1 9 , 3 i . 
Typically the jaw rests in a closed position and there 
is considerable resistance to passive opening. The 
explanation for this consistent finding is unclear. It 
is possible that it reflects an imbalance between the 
opposing actions of the masseter and pterygoid muscles. 
Alternatively, weakness in the lateral pterygoids may 
prevent protraction of the mandible which is necessary 
before depression. The temporo-mandibular is a 
ginglymo-arthrodial joint and opening involves both 
gliding and hinge movements. In support of this 
explanation, the jaw of affected patients can be opened 
much more easily if the mandible is first pulled 
anteriorly. Concentric needle studies of the masseter 
in 3 patients with limitation of mouth opening showed 
minimal sporadic fibrillation potentials and positive 
sharp waves but no evidence of myokymia or other 
regular electrical activity as one might expect to see 
in trismus. It seems most likely that the inability of 
envenomed patients to open their mouth is due to muscle 
weakness rather than increased muscle activity.
The mechanism of the bradycardia and 
electrocardiographic abnormalities seen in many 
envenomed patients is not clear. EGG abnormalities have 
been described following envenoming by an eastern brown 
snake and have been observed after experimental 
envenoming of d o g s 1 1 9,i2 o  ^ It is possible that the 
abnormalities may be due to the local effects of 
intravascular coagulation and microthrombi compromising 
the coronary circulation. Taipan venom is known to 
contain a selective calcium channel blocker, 
taicatoxin, which may act selectively on cardiac 
conducting tissue. It is intriguing that
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electrocardiographic abnormalities were common in this 
series of taipan bites but have rarely been described 
with other elapids whose venoms also contain powerful 
prothrombin activators. The electrocardiographic 
abnormalities which were observed were transient and 
there was no evidence of persisting cardiac damage in 
any of the patients.
In patients with clinically evident 
fasciculation, concentric needle EMG studies of 
involved muscles showed fasciculation potentials, 
fibrillation potentials and positive sharp waves. No 
repetitive discharges were seen although myokymia has 
been reported in association with a bite by the timber 
rattle snakei%i and repetitive discharges from damaged 
endplates have been described in association with B- 
bungarotoxini22. Occasional fibrillation potentials and 
positive sharp waves were also seen when concentric 
needle studies were done on other muscles in envenomed 
patients. Abnormal impulse generation occurring 
somewhere in the terminal arborisation might result in 
propagation of an action potential throughout the motor 
unit and produce the clinical fasciculation seen. Toxin 
induced damage of the nerve terminal itself could 
result in fibrillation potentials and positive sharp 
waves but does not explain why clinically apparent 
fasciculation should occur. On the other hand, it is 
difficult to reconcile extensive pre-terminal axonal 
damage with the observations that conduction velocities 
remain normal and that the architecture of motor units 
in recovering patients appeared relatively normal. An 
alternative possibility is that the abnormal muscle 
activity results from the effect of a toxin which 
alters the electrical stability of the resting muscle 
membrane. Non-depolarising muscle relaxants might help 
to clarify whether the mechanism of fasciculation is of 
neural or muscle origin. Neuromuscular blocking agents
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were not used routinely in patients in this study, but 
fasciculation was not seen in 2 patients who received 
pancuronium. The presence of fasciculation or 
vermicular movement is a sign that should be looked for 
specifically in patients envenomed by other snakes with 
neurotoxic venoms and the mechanism requires further 
study.
ii. Progression of neurotoxicity
The progression of neurotoxicity, from ptosis, 
to external ophthalmoplegia, bulbar paralysis, 
respiratory paralysis and ultimately peripheral 
paralysis, has been described by several 
a u t h o r s  1 > % > 1 9 , 1 1 3 . vitro observations have shown
that the speed of onset of neuromuscular block in nerve 
muscle preparations, is enhanced by repetitive 
stimulation of the nerve^s. The distribution of muscle 
involvement seen with both pre-and post-synaptic elapid 
neurotoxins is similar to that seen in myasthenia 
gravis. In myasthénies, weakness typically becomes 
apparent after prolonged use of a muscle. It is 
possible that the sequence of progression of muscle 
involvement in victims of taipan bite similarly 
reflects usage. An alternative explanation is that the 
muscles that are affected first by circulating toxins 
are those with the smallest motor units and lowest 
"safety factor" for neuromuscular transmission. The 
extrinsic eye muscles are known to have innervation 
ratios as low as 3 :1 1%9 and this may make them more 
susceptible to the effects of neurotoxins than for 
example limb muscles with ratios of perhaps 1 2 0 :1 i% ^ _
The progression of recovery from neurotoxicity is 
the reverse of the onset, with the first signs of 
improvement occurring in extraocular muscles. Although 
there was considerable variation between patients.
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discussed further below, a "typical" seriously 
envenomed stage V patient could be weaned from the 
ventilator by the 4th or 5th hospital day and could be 
discharged home around day 7-8. At the time of 
discharge, eye movements appeared normal to the 
observer but patients frequently complained of diplopia 
at the extremes of gaze. Full recovery of peripheral 
muscle power took around 2-3 weeks by which time vision 
was normal. The time course of full recovery suggests 
that re-innervation is occurring at the nerve 
terminals. Concentric needle EMG studies performed at 
follow up showed essentially normal motor unit 
architecture. This suggests that the toxin damage is 
localised to the nerve terminals and that the terminal 
arborisation is relatively unaffected.
iii. Autonomic function
Adequate testing of the autonomic system was 
not achieved in significantly envenomed patients. 
Several of the most useful tests such as response to 
sustained grip, Valsalva or 60 degree tilt were not 
possible. The limited studies which were performed 
suggest that baroreceptor reflexes function normally in 
envenomed patients and the responses were similar to 
those recorded in controls. Postural hypotension was 
not seen, suggesting normal function of sympathetic 
constrictor fibres. The response to intravenous 
atropine was comparable to that reported in normal 
subjects by Ewingi%s suggesting that the vagal supply 
to the heart is unaffected by envenoming. The pupil 
reflexes were normal in all patients and resting pupil 
size was unremarkable suggesting no action of venom on 
either sympathetic or parasympathetic fibres 
controlling pupillary size. Ciliospinal reflex pathways 
were also intact.
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iv. Complications
The management of patients requiring 
intubation and ventilation is difficult where both 
facilities and expertise are limited. One young child 
died as a result of a respiratory arrest during an 
emergency intubation and it is possible that in 
different circumstances this death might have been 
avoided. It is imperative that the impending need for 
intubation is appreciated as early as possible and the 
help of the most skilled person available should be 
obtained. Many of the middle-grade staff in PMGH are 
highly skilled at procedures such as intubation and 
ventilation. Advanced airway and respiratory support 
should however still be deemed a specialist area and 
the advice and help of an anaesthetist should be sought 
whenever possible. Aspiration in a small number of 
patients prior to arrival at hospital is probably 
unavoidable but several patients may have aspirated 
after admission, either as a result of unwarranted 
delay before intubation or past a deflated cuff. The 
laryngeal stridor which occurred in 4 patients 
emphasises the need for optimal management of patients 
with endotracheal tubes in situ. Tracheal mucosal 
damage may have resulted from traumatic intubation, 
from failure periodically to deflate pressure cuffs, 
from over-enthusiastic suctioning and from prolonged 
use of endotracheal tubes. Ideally endotracheal tubes 
should be changed every 48 hours. With limited 
resources this was rarely possible but this economy 
exposes patients to increased risk of infection and 
tube blockage. Airway management is probably the single 
most important aspect in the care of victims of taipan 
bite and an area where important complications and 
unnecessary deaths can be avoided by attention to 
detai1.
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V. Sequelae
A localised sensory deficit around the site 
of the bite was a common finding and persisted for 
several weeks. The absence of other sensory 
abnormalities suggests that the mechanism is local 
damage of cutaneous nerves, possibly by the action of 
phospholipases in the venom deposited locally. Other 
sequelae were rare. Recovery of motor function 
typically took 2-3 weeks in severely envenomed patients 
but complete recovery appeared to occur in all cases. 
One patient, who collapsed at the time of the bite, had 
a persistent neurological deficit after what appeared 
to have been diffuse hypoxic brain damage. One patient 
required a tracheostomy after developing tracheal 
stenosis following prolonged intubation with a rubber 
tube. This unfortunate series of events occurred when 
there were no plastic endotracheal tubes in the 
hospital and highlights the need to ensure that 
appropriate equipment is available.
3. Laboratory results
i. Biochemistry
The majority of the patients included in this 
series had evidence of muscle damage with both elevated 
creatinine kinase and aspartate transaminase levels. 
Clinical evidence of significant systemic myotoxicity 
was not seen however. Taipoxin and crude taipan venom 
have both been shown to be myotoxic when applied to 
skeletal muscle^^ and there are reports of myotoxicity 
following a bite by the Australian t a i p a n ^ & . 1 1 &. 
Myoglobinuria has been reported following a bite by the 
Papuan taipan^. It appears that the myotoxic effect of 
circulating venom is not usually clinically
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significant. Myoglobinuria is only visible at 
concentrations approaching 1 m g / m l 2 6 , i 2 7 and was not 
detected visually in any patients included in this 
series. It was witnessed however in one boy with 
ischaemic muscle damage secondary to prolonged use of a 
tourniquet, reported e l s e w h e r e ^ T h e  creatinine kinase 
level in this boy was greater than 10,000 IU/1. 
Typically, symptomatic rhabdomyolysis is associated 
with creatinine kinase levels of this o r d e r ' ' 2 6 which 
were not seen in patients in this series.
Renal impairment has been described in 
association with envenoming following bites by several 
elapid species including the Australian taipan'' ' ^  . 
Several mechanisms have been proposed for renal 
impairment in snakebite including a direct toxic effect 
of venom, hypotension, the deposition of microvascular 
thrombi and a toxic effect of constituents released 
following extensive muscle damage. A high proportion of 
the patients in this series had proteinuria and 
granular casts in their urine. None of the patients 
with impaired renal function had hypotension, 
hypovolaemia or evidence of significant myotoxicity. It 
seems most likely that the abnormalities in renal 
function which were seen were caused either by a direct 
toxic effect of circulating venom or by deposition of 
micro-emboli in the renal vascular bed. Significant 
renal tubular damage was seen in one boy with ischaemic 
muscle damage following the use of a tourniquet^^. In 
addition to the toxic effect of myoglobin itself, 
release of potassium and other metabolites from damaged 
muscle cells may produce both renal and cardiac 
toxicityi28. Whether an effect of the toxin or of first 
aid measures, if significant muscle damage has occurred 
active measures may be required to limit the 
consequences^5. Adequate hydration is a simple and 
important first s t e p  2 9 , 1 3 0 ^
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ii. Haematology
42.5% of patients had an admission white cell 
count above the normal range for PMGH (4-12x10^/1).
This was due to neutrophilia in all cases in which a 
differential count was performed and appears to be a 
reaction to envenoming. This was reported by Campbell 
and has also been described in association with 
envenoming by the Australian taipan'* ^ 1 1 3 2 ^ The
increase in white cell count does not depend on 
administration of antivenom. Neutrophilia was not seen 
in snakebite victims without signs of systemic 
envenoming. The absence of significant local effects of 
the venom suggest that local release of inflammatory 
mediators is unlikely to be the cause but it may be 
that cytokines are released in response to circulating 
venom. In turn, they may stimulate the release of 
marginated white cells. Lymphocytopenia has been 
described in association with envenoming by the 
Australian taipan'* ^ 3, In this series, lymphopenia 
(absolute count <1.0 xIO^/l) was seen in 11 out of 66 
patients who had differential white counts, but in only 
one patient was the count below 0.5 xlO^/1. The gross 
sphero-echinocytic transformation described by Arthur^s 
was not seen in any patients but increased red cell 
crenation was seen in 28/66 admission films. Arthur 
postulated that the change in morphology was due to a 
direct effect of venom phospholipases on red cell 
membranes and it is possible that the increased 
crenation seen in this series was due to the same 
mechanism, operating to a lesser degree.
Mean and median haemoglobin levels fell 
marginally in envenomed patients by 1.3g/dl below 
admission levels. The nadir was usually reached on day 
2 or 3. This is probably explained predominantly by the 
effects of haemodilution in patients treated with
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intravenous fluids. There was no evidence of 
significant haemolysis and overt blood loss from 
bleeding sites was usually trivial. Sutherland found 
little evidence of haemolysis in monkeys given taipan 
venom'* 21. Mean and median platelet counts also fell by 
18 x1Q9/l and 20 xIO^/l respectively. There was no 
association between admission levels or changes in 
haematological parameters and the presence of 
coagulopathy or severe neurotoxicity. This is somewhat 
surprising. One might have anticipated that platelet 
levels might have fallen more significantly in patients 
with coagulopathy of sufficient severity to be 
clinically evident. At least two mechanisms may 
contribute to the fall in platelet count :- 
thrombocytopenia is common in d e f i b r i n a t i o n * 2 4 and 
taipan venom is known to cause agglutination of 
platelets in vitro^^. Thrombocytopenia has been 
described in association with envenoming by the 
Australian t a i p a n * 25,
H i .  Haemostasis
The 20 minute whole blood clotting test (WBGT) is 
a simple and sensitive indicator of envenoming. It does 
not help to distinguish between the various elapid 
species in Central Province which cause coagulopathy, 
but an abnormal test excludes a bite by a death adder, 
the species responsible for the majority of non-taipan 
bites2. Prolongation of clotting was an early sign, 
occurring as soon as 30 minutes after the bite in 2 
patients, and was present by the time of admission in 
all patients in whom it was to occur. Lalloo 
demonstrated a close correlation between an abnormal 
WBCT and a fibrinogen level below normal limits^. The 
main mechanism of coagulopathy in taipan envenoming is 
the action of a potent prothrombin activator. This
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produces a significant fall in levels of fibrinogen, 
and a reduction in levels of other clotting factors 
including factors II,V ,VIII,,IX,XI and XII. The 
mechanisms of the action of the venom on the clotting 
system are discussed in detail by Lalloo2.*36.
iv. Venom detection kits
The VDKs, used with bite site swabs as 
recommended by the manufacturers, detected venom 
antigen in 37 out of the 42 clinically envenomed 
patients in which they were used (88%). Laboratory 
enzyme immunoassay (EIA) detected venom antigen in 33 
of these swabs. It is possible that the lesser 
sensitivity of the laboratory assay may be due to the 
effects of prolonged storage of the swabs and the use 
of a second diluent prior to analysis. Only 1 swab was 
positive on laboratory assay but negative on VDK, in 
which venom antigen was detected at 2ng/ml, below the 
manufacturer’s claimed lower limit of sensitivity. In 
all patients in which venom antigen was detected on 
both VDK and laboratory immunoassay, the type of venom 
detected correlated.
VDKs currently cost £104 for a three test kit. Their 
potential value in Papua New Guinea is to allow the 
confident use of appropriate monovalent antivenom by 
identifying the biting species. This could help 
diminish the administration of inappropriate antivenom, 
decrease the frequency of side effects which may be 
more common with polyvalent antivenoms with a higher 
protein c o n t e n t * 2 7,i38 and potentially produce 
financial savings. The current cost of a vial of 
monovalent taipan antivenom is £545 compared with £594 
for a vial of polyvalent. It would be ideal to use VDKs 
in all patients admitted to PMGH with signs of systemic 
envenoming but the cost of this is not clearly
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justified. 90% of patients admitted to PMGH have been 
bitten by taipans and the majority of these have non­
clotting blood at admission. The presence of non­
clotting blood has a high predictive value (0.96) for 
taipan bite and it seems reasonable and pragmatic to 
give all patients with non-clotting blood monovalent 
taipan antivenom. Each year one or 2 patients who have 
been bitten by a Papuan black or eastern brown snake 
may be given inappropriate antivenom but retrospective 
analysis of admissions between 1990 and 1993 suggests 
that these patients have not had adverse clinical 
outcomes. The most useful potential role of VDKs in 
PMGH appears to be to help to discriminate between 
patients bitten by a taipan who do not have non­
clotting blood (22.1% in this series) and patients who 
have been bitten by a death adder, A positive VDK does 
not necessarily imply systemic envenoming and their use 
is not indicated unless this is suspected. The use of 
VDKs is discussed more fully e l s e w h e r e *
4. Antivenom treatment
i. Type of antivenom
Polyvalent antivenom is used more commonly than 
monovalent antivenom by both health centre and hospital 
staff. It has the advantage that it covers most of the 
possible local venomous snakes and consequently there 
is no need to make a specific diagnosis of the biting 
species. The disadvantages of this policy are that 
polyvalent antivenom is considerably more expensive 
than monovalent antivenom and that there may be a 
higher risk of antivenom r e a c t i o n s  * 2 7 , i 3 8 _  The 
patient’s description of the biting snake is usually of 
little value in the identification of the biting 
species (see chapter 3) but the presence of non­
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clotting blood is a useful discriminant. In 96% of 
snakebite cases with non-clotting blood, where a 
definitive species diagnosis was made by immunoassay, a 
taipan was incriminated, and, as discussed above, a 
case can be made for giving all patients with non­
clotting blood taipan antivenom. Papuan black bites are 
now extremely rare. There are no clear distinguishing 
clinical features of Papuan black e n v e n o m i n g  * 2 9  and 
there seems to be little argument for continuing the 
purchase and use of monovalent black snake antivenom.
ii. Antivenom reaction prophylaxis
Early antivenom reactions were seen or reported 
in 10.8% of patients given antivenom, considerably 
higher than the 4.8% reported by Sutherland in a review 
of returned reports of antivenom use from around 
A u s t r a l i a * 2 8 ,  a review of all patients given
antivenom at PMGH between 1990 and early 1993, early 
reactions were seen in 6 of 134 patients, a rate of 
4.5%**0. It is interesting to note that 4 early 
reactions were seen in the space of a month at the end 
of this study (3 in patients who received polyvalent 
and 1 who received taipan antivenom) and it is 
conceivable that this was associated with the use of a 
new batch of antivenom which arrived just prior to 
this. The numbers in this series are too small to 
confirm or refute the suggestion that antivenom 
reactions may be more common after polyvalent 
antivenom. Late "serum sickness" antivenom reactions 
appear to be most common in patients who have received 
multiple doses of antivenom. The absence of any late 
reactions amongst the 48% of patients who attended for 
follow up may be due to the fact that few patients in 
this series received more than one vial of antivenom. 
Unlike doses of antivenom the doses of drugs used for
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the prophylaxis or treatment of antivenom reactions 
should be calculated on the basis of body weight. This 
point did not appear to be universally understood 
amongst health staff. One child was seen whose 
condition had been exacerbated by an excessively high 
and sedating dose of promethazine given with antivenom 
at a health centre. This was exceptional, but 
highlights the point that drugs which may sedate, 
should be used judiciously, in patients such as this 
one, who have impaired gag reflexes***.
The question of whether prophylaxis for 
antivenom reactions should consist of an antihistamine 
used alone or in combination with adrenaline, as 
recommended by Sutherland*40,1 4 1  ^ is not answered by 
this study. While there were no serious adverse 
reactions in the course of this series, there is 
clearly a potential risk of anaphylaxis. The 
prophylactic use of at least an antihistamine should be 
recommended in all patients and all health workers who 
are giving antivenom must have the knowledge, drugs and 
equipment to treat an anaphylactic reaction.
5. The efficacy of antivenom
Antivenom has been an integral and established 
part of the therapy for Australasian taipan bite since 
1957 and yet there are few published data assessing its 
efficacy. There is only a single published report of a 
patient who survived without antivenom treatment after 
being envenomed by an Australian taipan^* but this 
cannot be used as evidence of the efficacy of the drug. 
Fourteen patients in this study made a full recovery 
after significant envenoming by the Papuan taipan 
despite not receiving antivenom. At all times during 
the course of this study patients were treated with 
antivenom in accordance with the treatment regimes
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recommended by the Papua New Guinea Department of 
Health27,88, For economic and logistic reasons 
however, there were times during the study when there 
was no antivenom available presenting an important 
opportunity to evaluate its role. As Campbell pointed 
out, there are innumerable factors which make analysis 
of antivenom therapy extremely difficult, for example 
no two patients can be assumed to have received or 
absorbed the same quantity of venom and we know little 
about the extent of variation of venom constituents 
between taipans. Nonetheless, there is some information 
in this study which allows some critical assessment of 
the following generally accepted principles:
1. antivenom is significantly beneficial to a
patients outcome.
2. antivenom is most beneficial if given soon after
envenoming.
In addition, if there is an optimal time at which to 
give antivenom, is there a time beyond which antivenom 
is of no value? Is the single vial of antivenom given 
to most patients in Papua New Guinea enough? Should 
Sutherland's assertion that "on first principles..it is 
never too late to administer antivenom, except when the 
patient is d e a d " *42 be applied in Papua New Guinea 
where antivenom supplies are finite and exhaustible?
i.Antivenom and survival
Table 4.10 shows that mortality was higher in the 
group of patients not receiving appropriate antivenom. 
Of the 2 deaths in this group, one was a 3 year old boy 
treated with black snake antivenom, who died following 
a respiratory arrest during a delayed intubation. His 
clinical course to that time had been unremarkable and 
the death can be attributed to delay rather than 
absence of correct antivenom. The second death was that
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of a 15 year old girl (SI 892) who was admitted when 
there was no antivenom available, had prolonged 
neuromuscular paralysis and could not be weaned from 
the ventilator. She developed pneumonia in the second 
week of her admission, became septicaemia and 
ultimately died. The protracted clinical course, and 
consequent complications, appear to be attributable to 
the absence of antivenom although there were other 
factors which may have contributed, including 
malnutrition, hypomagnesaemia, ventilator dependency 
and relatively low body weight. There were avoidable 
delays in commencing parenteral nutrition and in 
performing a tracheostomy, both of which may have 
exacerbated the situation. The possibility that this 
death occurred due to failure to receive antivenom is a 
powerful indication to adopt Sutherland's maxim quoted 
above but does not remove the need for a dispassionate 
appraisal of the use of a limited resource.
ii. Antivenom, intubation and ventilation
Surprisingly, the proportion of patients 
requiring intubation and ventilation was higher in the 
group of patients receiving antivenom than in the 
heterogeneous group who did not, although this did not 
reach statistical significance. There are significant 
sources of bias amongst what is a small number of 
patients in the no-antivenom group. Nine of the 16 
patients who did not receive antivenom presented to 
hospital more than 20 hours after the bite. Four of 
these patients were not given antivenom because they 
only had mild neurotoxic signs but 4 others did require 
intubation and ventilation suggesting that the group 
was not solely selected from mild cases. It is possible 
that the 4 patients who received black snake antivenom 
in error, and the patient who received death adder
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antivenom, may have received some therapeutic benefit 
from these medications although several investigators 
have demonstrated little if any cross protection 
between a n t i v e n o m s 4o « 1^ . The other 7 patients failed to 
receive antivenom solely because of lack of supplies. 
The mean length of hospital admission was not 
significantly different between the two groups.
The mean duration of intubation and 
ventilation in patients not receiving appropriate 
antivenom was longer than for those receiving it 
although this was not statistically significant. This 
is due to the very prolonged ventilation of patient 
S1892 (see above) and the small numbers in the group. 
The median duration of intubation was comparable to the 
group who received antivenom. The start of recovery and 
the completion of resolution of ophthalmoplegia in the 
group of patients not receiving antivenom appears to 
have been as quick as in those patients who were given 
antivenom later than 3 hours after the bite. Recovery 
of peripheral power (Fig.4.1) occurred at a similar 
rate in antivenom and no-antivenom patients. There was 
considerable variation in the rate of recovery of grip 
strength, with one patient in each group in Fig 4.1 
particularly slow:- the slowest of whom was a patient 
who did not receive antivenom. It is impossible to know 
whether this patient would have recovered faster had he 
received antivenom.
H i .  Antivenom, coagulopathy and bleeding
In this study, when bleeding manifestations 
occurred, they did so soon after envenoming.
Significant bleeding after hospital admission was rare 
in both groups and was not influenced by administration 
of antivenom. The time after envenoming at which 
previously incoagulable blood began to clot appeared to
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be shorter in patients receiving antivenom but numbers 
in the non-antivenom group were too small to assess the 
significance of this observation. Only one of 9 
patients admitted greater than 20 hours after 
envenoming in the no-antivenom group still had non­
clotting blood. The recovery of fibrinogen levels and 
normalisation of prothrombin time occurred at a similar 
rate in a single patient with severe coagulopathy who 
did not receive antivenom as in 8 patients who did%.
iv. Time of antivenom and outcome
The mean and median length of hospital admission 
was significantly shorter in patients who received 
antivenom fewer than 4 hours after envenoming (p<0.002) 
than it was in patients who received antivenom later 
than this. There was little variation in either 
variable when compared with various times of receiving 
antivenom greater than 4 hours after envenoming 
(Fig.4.2). This observation suggests a significant 
beneficial effect of early antivenom. Patients who 
received antivenom more than 4 hours after envenoming 
were significantly more likely to require intubation 
than those who received antivenom less than 4 hours 
after envenoming (p<0.001, RR 2.04, 95% confidence 
limits 1.3-3.23). The proportion of patients who did 
not develop neurotoxicity of sufficient severity to 
require intubation was highest in those given antivenom 
fewer than 2 hours after envenoming. The period of time 
to complete resolution of eye signs was significantly 
shorter in the group of patients given antivenom within 
4 hours of envenoming (p<0.0001), the scatter plot.
Fig.4.5 also shows this trend. The time to onset of 
neuroresolution was not significantly different between 
the two groups. It has been demonstrated in vitro that 
the effect of bound taipoxin persists even after a
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nerve muscle preparation has been washed and moved to a 
toxin free bath®*. This situation may be analogous to 
the situation where a patient is given antivenom after 
the majority of the toxin has already bound. It 
emphasises the potential importance of first aid 
measures such as the use of pressure bandages which may 
delay the absorption of v e n o m * 4 3 , 1 4 4 ,
The mean and median lengths of intubation were 
shorter in the small group of patients given antivenom 
between 2 and 4 hours after the bite than in those 
given antivenom before 2 hours although this trend did 
not reach statistical significance (p<0.09). It is 
relatively consistent amongst the other groups 
(Fig.4.3). This observation may be an artefact created 
by the small numbers in both groups, but it is 
conceivable that it reflects an optimal window in which 
to give antivenom. It is possible that the neutralising 
capacity of antivenom given too early may be limited by 
clearance from the circulation before the majority of 
venom has been absorbed from the depot deposited by the 
snake. There was however no significant difference 
between the time to onset or completion of 
neuroresolution between the 0-2 and 2-4 hour groups.
Too few patients were given two vials of antivenom 
to make much assessment of the possible benefit of 
larger volumes of the drug. The median time of 
administration of the first vial in those who received 
2 was 5.25 hours (mean 7 hours). There is no evidence 
to suggest that these patients received any benefit 
from receiving a second vial of antivenom at this late 
stage.
V. Antivenom treatment - summary and conclusions
It is impossible to prove the significance of 
the relationship between time of antivenom and clinical
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outcome shown in this small series, but the absence of 
a clear benefit of antivenom given more than 4 hours 
after envenoming has important implications. There is 
no evidence that antivenom had any effect in lessening 
established neurotoxicity and to be effective probably 
must neutralise circulating neurotoxin before it 
becomes bound to the presynaptic membrane. In the 
majority of patients, even those who received antivenom 
early, appropriate antivenom at best only partly 
achieved this. There is limited evidence to suggest 
that antivenom promotes faster recovery from 
coagulopathy but the absence of significant bleeding 
episodes in any patients after the first few hours 
after envenoming, suggests that this may only be of 
limited clinical value
The best chance of producing maximal benefit with 
antivenom appears to be to give it within 4 hours of 
envenoming. Seventy five per cent of patients arrived 
at a health centre or the hospital early enough for 
this to have been possible. It is impossible to say 
from this study whether a higher volume of antivenom 
given this early would produce a greater benefit and 
this question still needs to be answered. Campbell 
described two cases of taipan bite treated with 
multiple doses of antivenom, in one patient there was 
no reversal, in the other no development of 
neurotoxicity*45, Sutherland treated two envenomed 
laboratory monkeys with 11 times the required in vitro 
quantity of taipan antivenom. One monkey made a slow 
recovery whilst the other died*44, a simple randomised 
trial could be devised in PMGH to assess the 
comparative benefits more than 1 vial of antivenom but 
large numbers of patients would be required to overcome 
the confounding variations between patients. The 
expense at present would be prohibitive.
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The overriding message from this analysis is that 
the current antivenom treatment in Central Province 
fails to achieve its objective in the majority of 
patients. Most patients who die from taipan bite in 
Papua New Guinea do so because of respiratory failure 
or because of a complication associated with managing 
respiratory failure. There is no evidence to suggest 
that a single vial of antivenom prevents this if it is 
given more than 4 hours after envenoming but limited 
evidence that it does so if given earlier. Only 30% of 
the 106 patients in this series were given antivenom 
before 4 hours, but this could have been achieved in 
75%. It is possible that delaying absorption of venom 
from the bite site, by the use of pressure bandages, 
may increase the period within which antivenom is most 
useful.
The taipan antivenom used in Papua New Guinea is 
made using Australian taipan venom. Papuan taipan venom 
(O.s.canni) is known to have a lower LD50 in mice than
0.s . scutellatus and there also appear to be differences 
in its protein composition^o. Antivenom made using 
0,s. canni venom might be more effective for treating 
envenoming due to a bite by the Papuan taipan. There is 
scope to develop subunit antivenoms more specifically 
directed against particular venom components. It is 
likely, however, that even a specific anti-taipoxin 
antivenom would be of little value once the toxin has 
bound to the presynaptic membrane, and this binding 
time is probably what is reflected by the apparent 
watershed around 4 hours. Improving management in the 
immediate future depends on delaying the absorption of 
venom and by increasing the proportion of patients who 
are treated early. In practical terms this means that 
envenomed patients must be treated with the appropriate 
antivenom immediately after reaching the health centre 
or hospital - an obvious statement, but a message that
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CHAPTER 8 - ELECTROPHYSIOLOGICAL STUDIES
1. The effects of envenoming
i. Control data
The control data for sensory and motor 
conduction studies in ulnar and median nerves are 
similar to those quoted in Caucasian p a t i e n t s * 2 4 ^  
suggesting that the range of normal values in 
Melanesians is comparable. There were, however, minor 
differences. The mean amplitude of compound muscle 
action potentials (CMAP) recorded following stimulation 
of both median and ulnar nerves, were of greater 
amplitude in the Melanesian series although the 
standard deviations of the distributions were almost 
identical. There was also some variation between the 
two series in the size of the sensory amplitudes 
recorded. In particular, ulnar sensory amplitudes were 
generally lower in the Melanesian series. The majority 
of the Melanesian control group were rural dwellers and 
subsistence farmers. It is possible that there might be 
significant physical differences, for example in skin 
thickness (and hence resistance) or recurrent minor 
trauma to peripheral sensory nerves, between this 
predominantly rural group, and a Caucasian control 
group. Both might significantly influence the 
amplitudes of the sensory potentials. The most likely 
explanation for these differences however, is inter- 
observer variation in technique.
ii. Motor and sensory studies in envenomed patients
CMAP amplitudes were dramatically and 
unequivocally reduced in envenomed patients with 
clinical evidence of neurotoxicity. Amplitudes
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typically reached their nadir at around 24 hours after 
the time of envenoming and were usually 10-20% of the 
admission values (when the majority were stage 1 or 2) 
in patients who required ventilation. Smaller 
reductions were seen in patients with less severe 
clinical neurotoxicity. Motor nerve conduction 
velocities in envenomed patients were comparable to 
those found in the control series. Sequential 
measurements of motor conduction velocities showed 
little variation throughout the clinical course of 
neurotoxicity. The changes in motor amplitudes are 
consistent with profound neuromuscular blockade. The 
normal conduction velocity results suggests that the 
effect of the venom is localised to the synapse, with 
no evidence of any effect on the peripheral nerve 
itself. This is in keeping with the experimental 
evidence that suggests that the predominant effect of 
taipoxin is localised to the neuromuscular 
junction's,49,146,147, The F wave responses in the 
envenomed patients in which they could be recorded 
(impossible where CMAP amplitudes were very markedly 
reduced) were not significantly different from those 
obtained in controls considered as a group and when 
matched for age and height. This suggests that the 
integrity of the motor nerves from anterior horn cell 
to neuromuscular junction is preserved and that 
conduction is normal. There was no significant 
difference between the mean stimulus threshold in 
envenomed and non-envenomed patients.
Mean sensory conduction velocities were 
marginally slower at the peak of neurotoxicity than at 
admission or discharge but the difference was not 
significant. The lowest values in the series correlated 
with the lowest recorded skin temperatures in patients 
with decreased peripheral perfusion, and can probably 
be explained as a temperature effect. Sensory
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amplitudes were lower in envenomed patients than in 
controls (P<0.01). There was definite clinical evidence 
of local sensory neuropathy around the site of the bite 
but no evidence of abnormal sensation elsewhere. Loss 
of taste and smell has been described following 
envenoming by the Australian taipan2i>34 but was not 
detected or reported in any patients in this series.
The local neuropathy around the bite site appears to be 
a direct toxic effect of venom on superficial cutaneous 
nerves. The findings of minor sensory abnormalities on 
electrophysiological studies raise the possibility that 
some sensory fibres are affected by circulating venom 
components. There are however several potential sources 
of error in recording low amplitude sensory potentials. 
Extrinsic factors such as variation in skin temperature 
and minor degrees of oedema which was occasionally seen 
in hypostatic limbs in paralysed patients could have 
influenced the amplitude of sensory nerve action 
potentials. Sequential recordings in some patients 
showed considerable variation in the size of the 
sensory amplitudes although the values were lower at 
peak neurotoxicity than at admission or following 
recovery. These studies suggest, but do not prove, that 
sensory amplitudes are diminished in severely envenomed 
patients; more tightly controlled studies are required 
to clarify this. If sensory conduction is impaired by 
taipan venom, the effect is a minor one.
Sequential grip strength readings showed a rapid 
decline and slow recovery phase in envenomed patients. 
The sequential studies shown in Fig 5.1-5.7 demonstrate 
a close correlation between the changes in CMAP 
amplitude and grip strength. The rapid decline in CMAP 
and grip strength mirrors the clinical deterioration of 
the patient and the values of both are approaching 
their nadir at the time that the patient required 
intubation. The administration of antivenom to the
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patient in Fig 5.6 and Fig. 5.7, 6.5 hours after 
envenoming, at which time the only clinical evidence of 
neurotoxicity was an equivocal diminution in lateral 
eye movements, did not prevent the deterioration. This 
suggests one of two things; either that the neurotoxins 
were already irreversibly bound to the presynaptic 
membrane at this time or that the volume of antivenom 
given failed to neutralise circulating neurotoxin. If 
the former is the case, there is a considerable delay 
between binding of the neurotoxin and maximal 
inhibitory effect on transmitter release. In vitro work 
on the effect of taipoxin suggests that the rate of 
onset of the effect of taipoxin is influenced by the 
rate of firing of the motor neurone and a delay has 
been recorded between binding and b l o c k a d e ^ 3,45, %t may
be that that the period of maximal therapeutic 
opportunity for using antivenom is considerably earlier 
than suggested by the onset of clinical signs of 
neurotoxicity, a hypothesis supported by the clinical 
outcome of patients given antivenom at different times, 
discussed in chapter 7.
The recovery in CMAP amplitudes is slow and 
mirrors clinical recovery. The length of time for the 
amplitudes to regain maximal values varied between 
patients but was typically of the order of two to three 
weeks. Muscle grip strength readings also reached their 
maximum at about the same time. Ultrastructural 
studies of the effect of taipoxin on the nerve terminal 
in vitro demonstrate clear morphological changes^s and 
it appears that the effect of the toxin is 
irreversible. The time taken for full recovery probably 
reflects the time taken for resprouting of nerve 
terminals, which may take some weeks. Complete recovery 
from the myotoxic effects of taipan venom in vitro, 
also took around 3 weeksS4, although clinically, direct 
myotoxicity appears to be of much less significance.
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H i .  Repetitive nerve stimulation studies
The décrémentai responses on repetitive nerve 
stimulation (RNS) are indicative of a deficiency in 
synaptic transmission but do not distinguish between a 
pre-synaptic and post-synaptic problem. Both pre- and 
post-synaptic neurotoxins are known to occur in taipan 
venom4 2 although the predominant effect on 
neuromuscular transmission is believed to be pre­
synaptic. The findings of low CMAP amplitudes and 
décrémentai responses at both low and high frequency 
seen in envenomed patients, are similar to those seen 
in myasthenia gravis. The classic RNS appearance of 
pre-synaptic dysfunction is seen in the Lambert Eaton 
myasthenic syndrome (LEMS) where a low initial CMAP 
amplitude is followed by a décrémentai response at low 
frequency stimulation, but an incremental response at 
high frequency repetitive stimulation (HRS).
Stimulation at higher frequencies in envenomed patients 
in this study, produced more profound décrémentai 
responses but no incremental responses were seen. In 
LEMS, two patterns of response are seen following HRS, 
either an immediate incremental response or an initial 
décrémentai response which is then followed by an 
i n c r e m e n t * 4 8 ,  OL suggests that the latter pattern may 
reflect pre-synaptic block of a more severe degree. In 
botulism, the size of the incremental response to HRS 
is inversely proportional to the severity of the
n e u r o t o x i c i t y * 4 8 , 1 4 9 ,  The clinical severity of the
neurotoxicity in patients envenomed following a taipan 
bite is significantly more extreme than that usually 
seen in LEMS. Although the clinical consequences share 
some common features, the mechanism of presynaptic 
block is entirely different. It would therefore be 
simplistic to expect a similar "LEMS-type" response to
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HRS. No incremental responses were seen in any 
envenomed patient in this series.
After a short burst of high frequency 
stimulation, the proportional increase in amplitude of 
the CMAP recorded in envenomed patients was 
significantly greater than that seen in controls. In 
the controls with normal neuromuscular function, the 
end plate potential (EPF) is already exceeded for each 
muscle fibre and an increase in acetylcholine (ACh) 
makes little difference to the size of the CMAP. In 
envenomed patients however, the diminished ACh release 
produces low amplitude EPPs which may be sub-threshold. 
It may be that the marked initial increase in the 
amplitude of the CMAP following tetanic stimulation 
results from the proportionate increase in the quantal 
release of ACh*2 0 , Kamenskaya and Thesleff, however, 
failed to demonstrate post tetanic facilitation in 
envenomed preparations in vitro^^ , The proportional 
increase in post-tetanic CMAP, recorded in envenomed 
patients probably reflects increased quantal release 
from unaffected nerve terminals rather than any effect 
overcoming the toxin inhibition of transmitter release. 
The décrémentai response seen at low frequency 
repetitive stimulation (LFRS) was significantly 
increased following tetanic stimulation or exercise 
(Fig 5.10). Initial post-tetanic facilitation, which 
often lasted for up to 30 minutes, was followed by a 
period of post-tetanic exhaustion in which the 
amplitude of the recorded CMAP was less than that of 
the pre-tetanic CMAP. Repetitive high frequency 
stimulation of envenomed in vitro preparations caused a 
rapid decline in EPP amplitude, and the in vivo 
observations may reflect this. The rate of onset of 
neuromuscular block in envenomed in vitro preparations 
was accelerated by stimulation of the n e r v e ^ s ,  j n  the 
clinical setting, this is reflected by the use of a
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muscle and this may be a factor in the progression of 
muscle involvement in envenoming.
iv. Concentric needle electromyography
The observation of reduced recruitment patterns 
is consistent with significant neuromuscular blockade 
and is not unexpected. Recruitment patterns gradually 
recovered over 2-3 weeks after envenoming in keeping 
with clinical recovery. Motor unit morphology appeared 
relatively normal during this recovery phase suggesting 
that the toxin damage may be restricted to the nerve 
terminals, if more proximal damage had occurred, 
extensive resprouting might have been expected to 
produce more eccentric re-innervation. Considerable 
spontaneous electrical activity was seen in several 
muscle groups. The observation of irregular 
fibrillation potentials and positive sharp waves may be 
due to spontaneous erratic transmitter release from 
damaged nerve terminals. However, both abnormalities 
also occur in association with axonal damage and the 
electrophysiological findings do not distinguish the 
s o u r c e * 24, An alternative and perhaps more plausible 
explanation for the spontaneous activity is that it 
represents the effect of a toxin acting on the muscle 
membrane itself and perhaps altering the resting 
membrane potential.
V. Single fibre studies
It was not possible to do single fibre 
electromyography on any patients included in this 
series although studies were done subsequently on four 
patients envenomed following a taipan bite. The results 
of these studies are presented elsewhere*%*.
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vi. Summary of abnormalities
In summary, the main electrophysiological 
abnormalities found in patients envenomed following a 
taipan bite are :
1. reduced CMAP at rest.
2. décrémentai response on low frequency repetitive
stimulation.
3. décrémentai response on high frequency repetitive
stimulation.
4. post-tetanic and post-exercise facilitation.
5. post-tetanic exhaustion.
Oh describes similar findings in antibiotic induced 
myasthenic syndrome and in procainamide induced 
p a r a l y s i s * 4 8 ,  in both of these, there are pre- and 
post- synaptic mechanisms affecting synaptic function.
It is possible that both pre- and post- synaptic 
neurotoxins play a significant role in the paralysis 
which follows a taipan bite but the absence of a 
clinical response to antivenom or pharmacological 
interventions suggests that the predominant effect is 
pre-synaptic.
2. Intervention studies
i. The effect of edrophonium and 3,4 diaminopyridine
The results of the studies on the effect 
of edrophonium and 3,4-DAP detailed above, suggest that 
both produce a small electrophysiological response and 
that 3,4- DAP produces a small physiological response 
in envenomed patients with profound neurotoxicity. The 
two drugs appear to have a synergistic effect although 
there is insufficient data to prove unequivocally that
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the response to both drugs is significantly greater 
than that to 3,4-DAP alone (Table 5.7). A response was 
measurable by an increase in CMAP amplitude together 
with an increase in muscle grip strength but was not 
normally accompanied by a change in respiratory 
function, the degree of ophthalmoplegia, ptosis or 
restriction of jaw opening. Neither effect was dramatic 
and there was no evidence of a difference in the degree 
of the response at different stages of neurotoxicity or 
at different time intervals after envenoming (Fig 5.23 
and 5.24). It seems likely that the increase in 
amplitude of the CMAP produced by the drugs is in 
proportion to the existing diminution of transmitter 
release. This suggests that the main effect of the 
drugs is on relatively unaffected nerve terminals with 
little effect on transmitter release already inhibited 
by toxin. Unfortunately the response one might expect 
in a non-envenomed patient is not known. 3,4-DAP 
appears to produce a greater increase in the amplitude 
of the CMAP than edrophonium. This is probably due to 
the different mechanisms of action. 3,4- DAP augments 
release of acetylchloline. Edrophonium increases the 
bioavailability of existing acetylcholine but does not 
affect release. Logically, the effect of the two drugs 
on the facilitation of neuromuscular transmission might 
be expected to be additive and this appears to be the 
case.
There is some evidence that there are isolated 
"responders" who show a more pronounced response to the 
drugs. The patient whose studies are shown in Figures 
5.21 and 5.22, was a 16 year old girl who did not 
receive antivenom until 7 hours after envenoming by 
which time she had complete ophthalmoplegia and 
weakness of her bulbar muscles. She was intubated 13 
hours after the bite but did not require ventilation 
and was discharged after 6 days. Taipan venom antigen
1 42
was detected in a bite site swab and an admission serum 
sample. The explanation as to why this patient showed a 
more marked response to the combination of 3,4-DAP and 
edrophonium is obscure, with no apparent link to the 
stage of neurotoxicity, to the period of time which had 
elapsed since envenoming or to the time of receiving 
antivenom. It is conceivable that the proportions of 
pre- and post-synaptic toxins in venom from different 
taipans may vary, or that there may be intrinsic 
differences in neurophysiological architecture between 
patients which affect resilience to neurotoxins but 
these and other possible explanations are purely 
speculative.
ii. Dosage and timing
A variety of stages of clinical neurotoxicity 
were chosen for the trials of the drugs in an attempt 
to find a period of maximal effect. No differences in 
response were apparent. In the absence of a clear 
beneficial clinical effect I did not believe that it 
was justifiable to give repeated courses of drugs to 
any patients, the maximum number of doses received by 
any one patient was 4. The doses of edrophonium and 
3,4-DAP used in the study are the standard doses used 
in the "tensilon" test and in the treatment of Lambert 
Eaton syndrome respectively. Higher intravenous doses 
of 3,4-DAP have occasionally been given in LEMS^z but 
were not attempted in this study. In addition to the 
frequent occurrence of minor side effects at the doses 
used, the potential proconvulsant effect of high doses 
of aminopyridines was considered a reason for 
circumspection, especially in view of limited clinical 
data that envenoming by the Australian taipan may on 
occasions itself cause convulsions**&.
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H i .  Side effects
Side effects of the drugs given were seen in 
several patients and are detailed in the results 
section. The unwanted muscarinic effects of increasing 
cholinergic activity after 3,4-DAP are a potential 
problem, in particular the stimulation of oral and 
pharyngeal secretions. In the regulated setting of the 
intensive care unit, it was easy to use pharyngeal 
suction to prevent aspiration. Clearly in a rural 
setting, or in transit, a patient with an impaired gag 
reflex and with diminished pharyngeal muscle activity 
could be compromised. Premedication with atropine 
helped to minimise the problem of excess secretion, but 
did not abolish it. Transient local thrombophlebitis 
was seen in several patients and dilution of the 
intravenous preparation of 3,4-DAP preparation to a 
minimum volume of 10ml is essential. As a precaution, a 
minimum of 100ml of a crystalloid solution was run 
through the intravenous cannula after the 3,4-DAP was 
given. This may have helped to prevent any persisting 
problems.
iv. Study Design
There are significant limitations and potential 
sources of error in the design of these studies. It is 
conceivable that bias, for example in interpreting eye 
movements, could have been introduced because of the 
difficulty experienced in maintaining true "blinding" 
in all cases. Patients who had noticeably increased 
secretions after an injection had clearly received 
active drug. The analysis is based predominantly on 
hand grip and CMAP, the most objective of the tests. 
Obtaining reliable readings of CMAP depended on 
religious attention to detail with technique, in
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particular with fixation of electrodes, but with 
cooperative patients this did not prove unduly 
difficult. I attempted to maximise the objectivity of 
assessments of eye movements and degrees of ptosis by 
measuring the change in proportion of iris covered and 
by measuring the maximum angle of lateral gaze from the 
midline with the head facing directly forward. 
Typically, however, eye movements could not be 
sustained and precision was difficult. This is a 
potential source of erroneous observations and did not 
prove a sensitive test for detecting minor changes.
Ideally, one would wish to measure the effect 
of the pharmacological interventions on respiratory 
function. This did not prove possible. Patients with 
neurotoxicity who were not intubated, usually had some 
weakness of facial muscles and limited jaw opening and 
were unable to form a tight seal around the mouthpiece 
of a vitalograph or spirometer. Patients who were 
intubated +/~ ventilated, did not tolerate repeated 
measurements of their maximal inspiratory pressure and 
the few readings obtained were very variable even in 
control patients. For these reasons, sequential 
assessment of respiratory function did not prove 
satisfactory.
V. Concluding remarks
There is insufficient evidence from 
these studies to advocate the use of 
anticholinesterases or 3,4-DAP in the management of 
patients with neurotoxicity secondary to taipan venom. 
The presence of a measurable response does however 
suggest that there may be value in looking more closely 
at the effect of higher doses of these drugs on in 
vitro preparations poisoned with taipoxin. There is 
also scope to look more closely at the effects of these
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drugs on preparations poisoned with other neurotoxins 
and their potential value as adjuncts in the management 
of neurotoxic snakebite should not be discarded 
completely. Anticholinesterases have been shown to be 
of value both as a diagnostic aid and as therapy for 
patients bitten by snakes with post-synaptic 
n e u r o t o x i n s 2 3 , 6  7 , 6  8 , 6  9 , 8 5  ^ Their effect in patients 
bitten by snakes with pre-synaptic neurotoxins appears 
to be much less dramatic. The absence of a response to 
edrophonium may be diagnostically useful. The absence 
of a coagulopathy does not itself distinguish patients 
who have been bitten by a death adder and those who 
have been bitten by other species. If a clinician sees 
a clear improvement in eye signs of neurotoxicity 
following a dose of edrophonium, he or she may give 
monovalent death adder antivenom with a degree of 
confidence.
These studies demonstrate that simple 
electrophysiological measurements provide a 
reproducible and well tolerated means of monitoring 
neurotoxicity at the bedside. The objectivity and 
repeatability of the measurements provides a means of 
assessing interventions in neurotoxicity. The need for 
an effective intervention remains.
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CHAPTER 9
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS
There appears to have been a significant change in 
the distribution of venomous snakes in Central 
Province during the past 30 years. The Papuan taipan 
is now the major species causing snakebite morbidity 
and mortality in Central Province, PNG. Over 99% of 
these bites occurred at altitudes of less than 300 
metres. The predominance of taipan bites is not 
universally recognised amongst health staff and has 
significant implications for antivenom treatment.
2. Patients can rarely describe distinguishing features 
of the snake that bit them. In some areas the Papuan 
black snake and taipan are not recognised as 
separate species. This frequently leads to mis- 
identification of the biting snake and in some cases 
subsequent use of incorrect antivenom which is 
avoidable.
3. Papuan black snakes are now extremely rare in 
Central Province and appear to be limited to the 
extreme west and east. Distinguishing clinically 
between a taipan bite and a black snake bite is 
impossible and if a black snake bite is suspected, 
polyvalent antivenom should be given. The role of 
black snake antivenom in PNG is now extremely 
limited and the health department should stop 
purchasing it,
4. Over 95% of taipan bites occurred during daylight 
hours. There was no evidence of significant seasonal 
trends or associations with rainfall during the two
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years of this study.
5. The majority of victims of taipan bite are bitten on 
the lower limb below the knee whilst walking in 
overgrown bush. Provision of calf length boots to 
workers at particularly high risk, such as 
plantation and cattle ranch workers, would provide 
significant protection and be feasible.
6 . Tourniquets and local incisions are still widely 
used as first aid treatment throughout Central 
Province with occasional disastrous results. Further 
efforts at education about safe first aid measures 
are necessary.
7. Delay in referral is the most significant avoidable 
factor in mortality from snakebite and could be 
reduced by further education of health centre staff 
and better use of existing communication, in 
particular, radio links. Health centre staff should 
be encouraged to use pressure bandages to delay 
absorption of venom, even in patients who have been 
given antivenom. This may increase the safe period 
for envenomed patients to get to hospital before the 
onset of life-threatening neurotoxicity.
8 . The majority of patients bitten by a taipan have 
non-clotting blood at admission to hospital. Over 
97% of snakebite victims admitted to PMGH in the 
past two and a half years with coagulopathy, where 
the species was identified, had been bitten by a 
taipan. The predictive value of non-clotting blood 
for taipan bite is so high that it would be 
reasonable to give monovalent taipan antivenom to 
all such patients.
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9. There are important differences between the clinical 
features of patients bitten by the Papuan and 
Australian taipans, notably, spontaneous systemic 
bleeding is significantly more common in victims of 
the Papuan subspecies. It also appears that the 
response of Papuan victims to antivenom is less 
favourable than that of Australian victims. The 
pattern of neurotoxicity appears to be similar in 
envenoming by both species.
10. No evidence of autonomic dysfunction was found in 
any envenomed patients. Sensory abnormalities were 
limited to an area local to the bite site.
11. Current antivenom treatment did not reverse and in 
many cases failed to inhibit the progression of 
neurotoxicity. Antivenom appeared to speed the 
resolution of coagulopathy but this did not appear 
to be of great clinical significance. There is a 
need for improved antivenom, either specific to the 
Papuan subspecies or a subunit antivenom.
12. Antivenom was of maximal benefit if given within 4 
hours of envenoming. The proportion of patients who 
receive antivenom in this time span could be 
significantly increased by maintaining antivenom 
supplies to four health centres, Veifa'a, Kwikila, 
Kupiano and Bereina, and further education of the 
health staff working there. Over 75% of envenomed 
patients in this series could have been given 
antivenom within 4 hours of envenoming.
13. There was no difference between monovalent taipan 
and polyvalent antivenom either in efficacy or in 
the incidence of side effects. The optimal volume 
of antivenom required to treat the victim of a
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taipan bite remains unknown.
14. Early antivenom reactions occurred in 7% of all 
patients given antivenom despite the use of 
prophylaxis. All reactions were mild and not life 
threatening. No late antivenom reactions were seen, 
possibly because no patients received more than two 
vials of antivenom. The optimal prophylaxis to 
prevent antivenom reactions is unknown but all 
patients should be given at least a parenteral 
antihistamine. All staff giving antivenom must know 
how to treat an anaphylactic reaction and have the 
requisite drugs and equipment.
15. Most morbidity and mortality in snake bite victims 
in hospital was associated with difficulties with 
intubation and the management of ventilated 
patients. Many of these problems were avoidable.
16. Venom detection kits proved a sensitive means of 
detecting venom in bite site swabs. They should be 
used on selected patients at admission to help 
distinguish biting species. There are potential 
benefits both in terms of better use of antivenom 
and by producing financial savings. The 
discriminatory value of VDKs is potentially most 
useful in identifying the biting species in 
patients who do not have a coagulopathy.
17. Envenomed patients had markedly reduced evoked CMAP 
amplitudes, normal motor conduction velocities and 
normal F wave responses. The decline and recovery 
of CMAP amplitudes correlated closely with the 
clinical stage of neurotoxicity including 
measurements of peripheral grip strength.
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18. Repetitive nerve stimulation studies showed 
décrémentai responses in envenomed patients 
consistent with abnormal synaptic transmission. 
Transient post-tetanic and post-exercise 
facilitation occured followed by post-tetanic 
exhaustion.
19. Sensory nerve action potentials were reduced in 
envenomed patients. Sensory nerve conduction 
velocities were also marginally reduced. Clinical 
sensory abnormalities were restricted to the area 
of the bite site.
20. Spontaneous electrical activity was frequently 
detectable in the form of positive sharp waves, 
fibrillation potentials and fasciculation 
potentials in the muscles of envenomed patients. 
Clinically evident fasciculation was visible in 
some patients, most notable in gastocnemii and 
deltoid muscles. This may reflect spontaneous 
transmitter release or a direct action of a toxin 
on the muscle membrane.
21. Edrophonium and 3,4-DAP both produced an 
electrophysiological response in envenomed patients 
suggesting a minor improvement in neuromuscular 
transmission. The effect was maximal when the two 
drugs were used in combination. The improvement in 
peripheral strength was minor and not sufficient to 
be clinically useful.
22. Both edrophonium and 3,4-DAP produced a significant 
increase in oral secretions in envenomed patients 
which was diminished but not abolished by atropine. 
Caution must be exercised if these drugs are used 
in patients with compromised pharyngeal musculature
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who are at risk of aspiration.
Campbell and Young wrote in 1961 "..we believe that 
with modern treatment, the elapine snake victim should 
not die if he lives long enough to reach a hospital"
In 1994, with the improvements in communications, 
transport and rural health facilities of the past 30 
years, victims of elapine snake bite in Central 
Province should not die.
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APPENDIX 1
Proforma for clinically envenomed patients
SNAKEBITE STUDY
First Name Surname...
Age ....
Village
3. Study Number... Hospital Number
5. Sex (m/f)
7, Sub-province8. Province ....
9. Address in NCD
10. Date of bite / /12. Date of admission / /14. Date seen / /
16.Date of discharge/death
17. Area of Province where bitten.18. Pre-hospital treatment details
Description of snake. Circumstances of bite
11. Time of bite.......13. Time of arrival in hospital15. Time seen...........
Vegetation............Distance from water...
SYMPTOMS
19. Part of body bitten...............20. Pain around bite.  ................ (Y/N)21 Pain in limb.........   (Y/N)22. Pain in lymph nodes............... (Y/N)23. Headache........................... (Y/N)24. Abdominal pain.................... (Y/N)25. Vomiting. .  ........................(Y/N)26. Collapse........................... (Y/N)27. Bleeding........................... (Y/N)From where................
28 . Ptosis............................. (Y/N)29. Double vision..................... (Y/N)30. Dysphagia...................  (Y/N)31. Dysarthria.........................(Y/N)32. Limb weakness..................... (Y/N)33. Respiratory symptoms..............(Y/N)34. Drowsiness.........................(Y/N)35. Muscle pain........................(Y/N)36. Passing urine..................... (Y/N)
37. Previous history of snakebite....(Y/N)
38. Other significant medical condition(Y/N)
Time of onset Progression
When..........
What treatment
SIGNS Datetime
39. Local swelling40. Local tenderness41. Lvmgh nodes42. Tender nodes ■43. Muscle tenderness
44. Bleeding gums45. Nose bleed46. Haemootvsis/emesis47. Bleeding bite site48. Other bleeding
49. Abdo tenderness50. Liver (cm)51. Sgleen (cm)52. Lungs53. Heart54. Conscious (grade)55. Fundi (Findings)
56. Ptosis (+ - ++++)57. Ud gaze (N/dec/abs )58. Down gaze (" " " )59. Lateral gaze(" " )60. Puoil size (mm)61. Interdental dist(mm)62 Slurred soeech63. Facial weakness64 Lat i aw movement65 Passive iaw ooenin g6 6 Tongue protrusion
■k *
67. Resoiratorv pattern68. Peak flow69. Gag (Y/N)70. Cough reflex71. Pooling secretions
72. Grip (grade)73. Moving limbs74. Reflexes (+/++++)75, Intubated (Y/N)76. Ventilated (-/A/T) ■k77. Pulse78 . BP
* a/t auto/triggered ** N/shallow/diaphr/ven
Patient name..................  Study number. .
76, Exact site of bite......................77. Drawing of bite......  78, Inter-fang distance cm
79. Snake available (Y/N)LengthDescription
Extra Clinical information 
Date Time
Patient name.................
TREATMENT
80. Antivenom given...... (Y/N)
Type given....
81. Second ampoule given.(Y/N)
82. Intubated............ (Y/N)
83. Ventilated........... (Y/N)
84. FFP given............ (Y/N)
Study number
Time commenced... Time completed...
Time commenced.... Time completed....
DateTime
Date extubated Time extubated
Date commenced Time commenced
Date discontinued Time discontinued
Number of units At what times
Drugs given with -polyvalent
85 .
86 .87 .
88 . 89 .
Promethazine Adrenaline Hydrocortisone Tet toxoid Procillin
Other drugs
mgmgmgmlml
IM/IVSC/IMIM/IVIMIM
atatatatat
am/pm am/pm am/pm am/pm am/pm
Drug Dose Route Freguencv Commenced Ended
IV fluids ; - Vol in 1st 24 hrs... Urine : - Vol in 1st 24 hrsVol in 2nd 24 hrs... Vol in 2nd 24 hrsVol in 3rd 24 hrs. . . Vol in 3rd 24 hrs
LABORATORY INVESTIGATIONS- Snakebite Patient name.... Study number..
Date
Time
Clottingtime
WBC
RBC
Hb
HCTMCVMCHMCHC
DifPlat
Glucose
Na
K
HCO^
Cl
Urea
Creat
AST (ALT)
Bil (Dir)
ALP
Prot
Alb
CK
LDH
UrineAnalysis
Patient name.... Study number...
ADM 6 12 18 24 36 48 72 96 DIS
DateTime
TEST
Exam + + + + + + + +
EDTA FBC,Plat + + + 4- +
Citrate + + + + + + +
Serum (Ag, clotting. + + + + + + + + + +
FDP + + +
BTG +
(only if non-clotting)
+ +
Hep plasma (Hb, Myo) + + + + + + +
Lab for U/E,CK,AST -p + + + + +
TNF + + +
Wound t Aspirate/swab
Urine Ag +
Urine Stix myoglobin + + + + +
SUMMARY
1. Systemic symptoms............................. (Y/N)2. Local signs of envenoming.....................(Y/N)3. Neurotoxic signs...............................(Y/N)4. Prolonged blood clotting............;......... (Y/N)5. Clinical bleeding..............................(Y/N)6. Signs of myotoxicity.  ........................ (Y/N)
7. Neurotoxicity development post antivenom........ (Y/N)8. Neurotoxicity deterioration post antivenom......(Y/N)9. Need for intubation.............................. (Y/N)10.Need for ventilation............................. (Y/N)11 Survived......................................... (Y/N)12. Referral from other centre......................(Y/N)13. Length of stay in hospital... ............ days
From time of bite :-
14 . Time to arrival in hospital...... hrs15 Time to symptoms of envenoming.... hrs16 . Time to neurotoxic symptoms...... hrs17 . Time to clinical bleeding........ hrs
18 . Time to onset of incoaguable blood hrs19 . Time to observed neurotoxicity.... - hrs20 . Time to pea^ of neurotoxicity.... ■ hrs21 . Time to intubation................ hrs22 . Time to giving of antivenom...... hrs23 . Time to resolution of neurotoxicity hrs
Following antivenom:-
24 . Time to normal clotting time...... hrs25 . Time to commence neuroresolution.., hrs26 . Time to neurotoxicity resolution.., hrs27. Length of time intubated........... hrs28. Length of time ventilated.......... hrs
Complications
29. Antivenom reaction........(Y/N)30. Local tissue damage.......(Y/N)31. Local infection........... (Y/N)32. Renal impairment.  ......(Y/N)33. Pneumonia.................. (Y/N)34. Serum sickness............ (Y/N)3 5 . Other...................... (Y/N)
SNAKEBITE - Follow up
1. First name2, Surname... 3 . Study number Date......
4. Number of days since admission5. Specific complaints
6. Episodes of fever......... (Y/N)7. Intercurrent medical problems.(Y/N)
8. Temp Oral.. 10, B/P Sitting C 9. Pulse Weight /minkg
1112131415
16171819
20 21 22
Bite site...........Regional lymph nodesAuscultation........Liver...............Spleen.............. cms below costal margin cms below costal margin
Eye movements....................................Fundi.............................................Limb Tone................................. Increased/Decreased/NormalReflexes.................................. Increased/Decreased/Normal
Other Signs
Stored
Serum XHep XCitrate XUrine X
WCC Na ASTHb K BilPlatelets HC03 ALPCl ProtClotting Urea AlbCreat CK
Urine
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APPENDIX 2
Proforma for clinically non-envenomed patients
SNAKEBITE STUDY (non envenomed)
First Name Surname...
Age......
Village.....
Address in NCD
Date of bite Date seen
Study Number 
Sex (m/f)
Sub-province Province
/ / / /
Time of bite. Time seen....
Description of snake........Circumstances of bite.......
Area of Province where bitten Any pre-hospital treatment...
SYMPTOMS
Part of body bitten..........
Local symptoms Systemic symptoms Symptoms of bleeding Neurotoxic symptoms
SIGNS
Description of bite
Local swelling/signsLymphadenopathyNeurological signsEvidence of clotting disturbance
Previous history of snakebite....(Y/N) Other significant medical condition(Y/N)
EDTASerumFDPCK only SwabAspirateHbWCCPlat
X
X
X
X
X
X
Time
Clotting time
Na ASTK BilCl ALPHC03 ProtUrea AlbCreat CKLDH
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APPENDIX 3
Neurotoxicity grading scale
A simple grading system was used in order to 
compare patients. This was necessary because the time 
course and rate of progression of envenoming varied 
extensively. The sequence of progression of 
neurotoxicity was similar in patients who developed 
signs, with involvement of external ocular muscles, 
bulbar and respiratory muscles, in that order.
Comparative assessment of peripheral muscle weakness 
between patients was more subjective and therefore not 
included in the grading. This system, although crude, 
proved workable. The suffix "A" was used to denote 
patients of grade 2-4 who were deteriorating, "B" to 
denote those who were recovering. All the patients 
included in the intervention studies were during the 
deteriorating phase or stage 5.
Grade 1 Envenomed but no neurotoxicity
Grade 2 Ptosis +/- partial opthamoplegia
Grade 3 Complete opthalmoplegia
Grade 4 Pooling of secretions requiring
intubation or intubated but not
ventilated
Grade 5 Ventilated
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APPENDIX 4
Hospital snakebite observation chart
SNAKE BITE OBSERVATION
NAME NUMBER DATE
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